{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.1-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.1", "sentence": "MINIPRESS (prazosin hydrochloride) capsule", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.1.e.0"}, "arg2": {"span": [[11, 33]], "type": "Biomedical_Entity", "mmcui": "C0700578", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2", "sentence": "MINIPRESS (prazosin hydrochloride), a quinazoline derivative, is the first of a new chemical class of antihypertensives.", "arg1": {"span": [[11, 33]], "type": "Biomedical_Entity", "mmcui": "C0700578", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.1"}, "arg2": {"span": [[102, 119]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2", "sentence": "MINIPRESS (prazosin hydrochloride), a quinazoline derivative, is the first of a new chemical class of antihypertensives.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.2"}, "arg2": {"span": [[102, 119]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2", "sentence": "MINIPRESS (prazosin hydrochloride), a quinazoline derivative, is the first of a new chemical class of antihypertensives.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.2"}, "arg2": {"span": [[11, 33]], "type": "Biomedical_Entity", "mmcui": "C0700578", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.2.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4", "sentence": "MINIPRESS is contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.1"}, "arg2": {"span": [[105, 122]], "type": "Biomedical_Entity", "mmcui": "C1968272", "rxcui": 4691, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4", "sentence": "MINIPRESS is contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients.", "arg1": {"span": [[81, 89]], "type": "Biomedical_Entity", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.2"}, "arg2": {"span": [[105, 122]], "type": "Biomedical_Entity", "mmcui": "C1968272", "rxcui": 4691, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4", "sentence": "MINIPRESS is contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.1"}, "arg2": {"span": [[81, 89]], "type": "Biomedical_Entity", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.4.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.6-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.6", "sentence": "As with all alpha-blockers, MINIPRESS may cause syncope with sudden loss of consciousness. ", "arg1": {"span": [[12, 26]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.6.e.0"}, "arg2": {"span": [[28, 37]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.6.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.9-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.9", "sentence": "occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of MINIPRESS. ", "arg1": {"span": [[112, 133]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.9.e.0"}, "arg2": {"span": [[185, 194]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.9.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.11-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.11", "sentence": "Clinical trials conducted during the investigational phase of this drug suggest that syncopal episodes can be minimized by limiting the initial dose of the drug to 1 mg, by subsequently increasing the dosage slowly, and by introducing any additional antihypertensive drugs into the patient's regimen with caution (see DOSAGE AND ADMINISTRATION). ", "arg1": {"span": [[37, 71]], "type": "Biomedical_Entity", "mmcui": "C0013230", "rxcui": 691721, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.11.e.0"}, "arg2": {"span": [[250, 272]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.11.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.12-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.12", "sentence": "Hypotension may develop in patients given MINIPRESS who are also receiving a beta-blocker such as propranolol.", "arg1": {"span": [[42, 51]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.12.e.2"}, "arg2": {"span": [[77, 89]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.12.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.25-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.25", "sentence": "There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery.", "arg1": {"span": [[41, 49]], "type": "Biomedical_Entity", "mmcui": "C0723457", "rxcui": 220037, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.25.e.0"}, "arg2": {"span": [[50, 65]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.25.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.32-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.32", "sentence": "While taking MINIPRESS, be careful in the amount of alcohol you drink. ", "arg1": {"span": [[13, 22]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.32.e.1"}, "arg2": {"span": [[52, 59]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.32.e.0"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[132, 150]], "type": "Biomedical_Entity", "mmcui": "C0007158", "rxcui": 1025351, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.0"}, "arg2": {"span": [[165, 172]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.2"}, "arg2": {"span": [[132, 150]], "type": "Biomedical_Entity", "mmcui": "C0007158", "rxcui": 1025351, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[132, 150]], "type": "Biomedical_Entity", "mmcui": "C0007158", "rxcui": 1025351, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.0"}, "arg2": {"span": [[151, 160]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-3", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.2"}, "arg2": {"span": [[165, 172]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-4", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[151, 160]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.3"}, "arg2": {"span": [[165, 172]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36-5", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36", "sentence": "MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides digitalis and digoxin; ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.2"}, "arg2": {"span": [[151, 160]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.36.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[50, 58]], "type": "Biomedical_Entity", "mmcui": "C0012010", "rxcui": 3322, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.1"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0031412", "rxcui": 8134, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[32, 48]], "type": "Biomedical_Entity", "mmcui": "C0008188", "rxcui": 203173, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.2"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0031412", "rxcui": 8134, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[4, 17]], "type": "Biomedical_Entity", "mmcui": "C0040614", "rxcui": 10692, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.3"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0031412", "rxcui": 8134, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-3", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0036557", "rxcui": 9634, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.4"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0031412", "rxcui": 8134, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-4", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[32, 48]], "type": "Biomedical_Entity", "mmcui": "C0008188", "rxcui": 203173, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.2"}, "arg2": {"span": [[50, 58]], "type": "Biomedical_Entity", "mmcui": "C0012010", "rxcui": 3322, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-5", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[4, 17]], "type": "Biomedical_Entity", "mmcui": "C0040614", "rxcui": 10692, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.3"}, "arg2": {"span": [[50, 58]], "type": "Biomedical_Entity", "mmcui": "C0012010", "rxcui": 3322, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-6", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0036557", "rxcui": 9634, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.4"}, "arg2": {"span": [[50, 58]], "type": "Biomedical_Entity", "mmcui": "C0012010", "rxcui": 3322, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-7", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[4, 17]], "type": "Biomedical_Entity", "mmcui": "C0040614", "rxcui": 10692, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.3"}, "arg2": {"span": [[32, 48]], "type": "Biomedical_Entity", "mmcui": "C0008188", "rxcui": 203173, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-8", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0036557", "rxcui": 9634, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.4"}, "arg2": {"span": [[32, 48]], "type": "Biomedical_Entity", "mmcui": "C0008188", "rxcui": 203173, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38-9", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38", "sentence": "(3) tranquilizers and sedatives chlordiazepoxide, diazepam, and phenobarbital; ", "arg1": {"span": [[4, 17]], "type": "Biomedical_Entity", "mmcui": "C0040614", "rxcui": 10692, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.3"}, "arg2": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0036557", "rxcui": 9634, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.38.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39", "sentence": "(4) antigout allopurinol, colchicine, and probenecid; ", "arg1": {"span": [[13, 24]], "type": "Biomedical_Entity", "mmcui": "C0002144", "rxcui": 519, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.0"}, "arg2": {"span": [[26, 36]], "type": "Biomedical_Entity", "mmcui": "C0009262", "rxcui": 2683, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39", "sentence": "(4) antigout allopurinol, colchicine, and probenecid; ", "arg1": {"span": [[13, 24]], "type": "Biomedical_Entity", "mmcui": "C0002144", "rxcui": 519, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.0"}, "arg2": {"span": [[42, 52]], "type": "Biomedical_Entity", "mmcui": "C0033209", "rxcui": 8698, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39", "sentence": "(4) antigout allopurinol, colchicine, and probenecid; ", "arg1": {"span": [[26, 36]], "type": "Biomedical_Entity", "mmcui": "C0009262", "rxcui": 2683, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.1"}, "arg2": {"span": [[42, 52]], "type": "Biomedical_Entity", "mmcui": "C0033209", "rxcui": 8698, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[4, 19]], "type": "Biomedical_Entity", "mmcui": "C0003195", "rxcui": 883, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.0"}, "arg2": {"span": [[34, 45]], "type": "Biomedical_Entity", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[4, 19]], "type": "Biomedical_Entity", "mmcui": "C0003195", "rxcui": 883, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.0"}, "arg2": {"span": [[74, 83]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[4, 19]], "type": "Biomedical_Entity", "mmcui": "C0003195", "rxcui": 883, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.0"}, "arg2": {"span": [[20, 32]], "type": "Biomedical_Entity", "mmcui": "C0033216", "rxcui": 155056, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-3", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[34, 45]], "type": "Biomedical_Entity", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.1"}, "arg2": {"span": [[74, 83]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-4", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[20, 32]], "type": "Biomedical_Entity", "mmcui": "C0033216", "rxcui": 155056, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.3"}, "arg2": {"span": [[34, 45]], "type": "Biomedical_Entity", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40-5", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40", "sentence": "(5) antiarrhythmics procainamide, propranolol (see WARNINGS however), and quinidine; ", "arg1": {"span": [[20, 32]], "type": "Biomedical_Entity", "mmcui": "C0033216", "rxcui": 155056, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.3"}, "arg2": {"span": [[74, 83]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.40.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42", "sentence": "Addition of a diuretic or other antihypertensive agent to MINIPRESS has been shown to cause an additive hypotensive effect. ", "arg1": {"span": [[32, 54]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.2"}, "arg2": {"span": [[58, 67]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42", "sentence": "Addition of a diuretic or other antihypertensive agent to MINIPRESS has been shown to cause an additive hypotensive effect. ", "arg1": {"span": [[14, 22]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.1"}, "arg2": {"span": [[58, 67]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42", "sentence": "Addition of a diuretic or other antihypertensive agent to MINIPRESS has been shown to cause an additive hypotensive effect. ", "arg1": {"span": [[14, 22]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.1"}, "arg2": {"span": [[32, 54]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.42.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.43-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.43", "sentence": "This effect can be minimized by reducing the MINIPRESS dose to 1 to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating MINIPRESS based on clinical response.", "arg1": {"span": [[45, 54]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.43.e.3"}, "arg2": {"span": [[118, 140]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.43.e.0"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.44-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.44", "sentence": "Concomitant administration of MINIPRESS with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION).", "arg1": {"span": [[30, 39]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.44.e.0"}, "arg2": {"span": [[47, 84]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.44.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.46-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.46", "sentence": "In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. ", "arg1": {"span": [[54, 62]], "type": "Biomedical_Entity", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.46.e.0"}, "arg2": {"span": [[156, 170]], "type": "Biomedical_Entity", "mmcui": "C0028351", "rxcui": 7508, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.46.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.57-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.57", "sentence": "In view of the testicular changes observed in animals, 105 patients on long term MINIPRESS therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. ", "arg1": {"span": [[81, 90]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.57.e.0"}, "arg2": {"span": [[118, 132]], "type": "Biomedical_Entity", "mmcui": "C0000167", "rxcui": 21, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.57.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.64-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.64", "sentence": "The use of prazosin and a beta-blocker for the control of severe hypertension in 44 pregnant women revealed no drug-related fetal abnormalities or adverse effects. ", "arg1": {"span": [[11, 19]], "type": "Biomedical_Entity", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.64.e.1"}, "arg2": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.64.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.66-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.66", "sentence": "Prazosin has also been used alone or in combination with other hypotensive agents in severe hypertension of pregnancy by other investigators. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.66.e.0"}, "arg2": {"span": [[63, 81]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.66.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86", "sentence": "When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out.", "arg1": {"span": [[14, 22]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.1"}, "arg2": {"span": [[32, 54]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86-1", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86", "sentence": "When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out.", "arg1": {"span": [[32, 54]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.0"}, "arg2": {"span": [[68, 77]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86-2", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86", "sentence": "When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out.", "arg1": {"span": [[14, 22]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.1"}, "arg2": {"span": [[68, 77]], "type": "Biomedical_Entity", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.86.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.87-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.87", "sentence": "Concomitant administration of MINIPRESS with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; ", "arg1": {"span": [[30, 39]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.87.e.0"}, "arg2": {"span": [[47, 62]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.87.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.88-0", "sentence_id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.88", "sentence": "therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking MINIPRESS.", "arg1": {"span": [[11, 34]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.88.e.2"}, "arg2": {"span": [[93, 102]], "type": "Drug", "mmcui": "C0242447", "rxcui": 71515, "id": "Dailymed.36c4da56-502e-4da1-acf7-8e81ee453dcc.s.88.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1", "sentence": "Drug Label for drug brand Nitroglycerin In Dextrose, containing Nitroglycerin.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.2"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1", "sentence": "Drug Label for drug brand Nitroglycerin In Dextrose, containing Nitroglycerin.", "arg1": {"span": [[43, 51]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.3"}, "arg2": {"span": [[64, 77]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1", "sentence": "Drug Label for drug brand Nitroglycerin In Dextrose, containing Nitroglycerin.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.2"}, "arg2": {"span": [[26, 39]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1-3", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1", "sentence": "Drug Label for drug brand Nitroglycerin In Dextrose, containing Nitroglycerin.", "arg1": {"span": [[26, 39]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.1"}, "arg2": {"span": [[43, 51]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1-4", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1", "sentence": "Drug Label for drug brand Nitroglycerin In Dextrose, containing Nitroglycerin.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.2"}, "arg2": {"span": [[43, 51]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.1.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6", "sentence": "Dextrose (Dextrose Hydrous, USP) is D-glucose monohydrate, a hexose sugar whose structural formula is", "arg1": {"span": [[38, 45]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.0"}, "arg2": {"span": [[68, 73]], "type": "Biomedical_Entity", "mmcui": "C0242209", "rxcui": 71470, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6", "sentence": "Dextrose (Dextrose Hydrous, USP) is D-glucose monohydrate, a hexose sugar whose structural formula is", "arg1": {"span": [[10, 18]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.1"}, "arg2": {"span": [[68, 73]], "type": "Biomedical_Entity", "mmcui": "C0242209", "rxcui": 71470, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6", "sentence": "Dextrose (Dextrose Hydrous, USP) is D-glucose monohydrate, a hexose sugar whose structural formula is", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.3"}, "arg2": {"span": [[68, 73]], "type": "Biomedical_Entity", "mmcui": "C0242209", "rxcui": 71470, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.6.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8", "sentence": "Nitroglycerin in 5% Dextrose Injection is a sterile, nonpyrogenic solution of nitroglycerin and dextrose in water for injection. ", "arg1": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.0"}, "arg2": {"span": [[96, 113]], "type": "Biomedical_Entity", "mmcui": "C0719841", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8", "sentence": "Nitroglycerin in 5% Dextrose Injection is a sterile, nonpyrogenic solution of nitroglycerin and dextrose in water for injection. ", "arg1": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.0"}, "arg2": {"span": [[78, 91]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8", "sentence": "Nitroglycerin in 5% Dextrose Injection is a sterile, nonpyrogenic solution of nitroglycerin and dextrose in water for injection. ", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.3"}, "arg2": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8-3", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8", "sentence": "Nitroglycerin in 5% Dextrose Injection is a sterile, nonpyrogenic solution of nitroglycerin and dextrose in water for injection. ", "arg1": {"span": [[78, 91]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.2"}, "arg2": {"span": [[96, 113]], "type": "Biomedical_Entity", "mmcui": "C0719841", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8-4", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8", "sentence": "Nitroglycerin in 5% Dextrose Injection is a sterile, nonpyrogenic solution of nitroglycerin and dextrose in water for injection. ", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.3"}, "arg2": {"span": [[96, 113]], "type": "Biomedical_Entity", "mmcui": "C0719841", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12", "sentence": "Although dry nitroglycerin is explosive, nitroglycerin in 5% dextrose is not.", "arg1": {"span": [[13, 26]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12.e.0"}, "arg2": {"span": [[58, 69]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12", "sentence": "Although dry nitroglycerin is explosive, nitroglycerin in 5% dextrose is not.", "arg1": {"span": [[41, 54]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12.e.2"}, "arg2": {"span": [[58, 69]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.12.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.18-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.18", "sentence": "Nitroglycerin in 5% Dextrose Injection is contraindicated in patients who are allergic to it.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.18.e.0"}, "arg2": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.18.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21", "sentence": "Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.", "arg1": {"span": [[21, 29]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21.e.1"}, "arg2": {"span": [[95, 99]], "type": "Biomedical_Entity", "mmcui": "C1095906", "rxcui": 1323308, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21", "sentence": "Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.", "arg1": {"span": [[21, 29]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21.e.1"}, "arg2": {"span": [[87, 91]], "type": "Biomedical_Entity", "mmcui": "C1095906", "rxcui": 1323308, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.21.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.23-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.23", "sentence": "Amplification of the vasodilatory effects of Nitroglycerin by sildenafil can result in severe hypotension. ", "arg1": {"span": [[45, 58]], "type": "Drug", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.23.e.0"}, "arg2": {"span": [[62, 72]], "type": "Drug", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.23.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.28-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.28", "sentence": "The delivered fraction of the solution's original nitroglycerin content has been 20-60% in published studies using PVC tubing, the fraction varies with time during a single infusion, and no simple correction factor can be used. ", "arg1": {"span": [[4, 13]], "type": "Biomedical_Entity", "mmcui": "C1874964", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.28.e.1"}, "arg2": {"span": [[50, 63]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.28.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.35-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.35", "sentence": "The intravenous administration of solutions may cause fluid overloading resulting in dilution of serum electrolyte concentrations, overhydration and congested states of pulmonary edema. ", "arg1": {"span": [[103, 114]], "type": "Biomedical_Entity", "mmcui": "C3536863", "rxcui": 3793, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.35.e.1"}, "arg2": {"span": [[149, 158]], "type": "Biomedical_Entity", "mmcui": "C0700150", "rxcui": 1096425, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.35.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.37-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.37", "sentence": "The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration of the injections.", "arg1": {"span": [[36, 45]], "type": "Biomedical_Entity", "mmcui": "C0700150", "rxcui": 1096425, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.37.e.1"}, "arg2": {"span": [[121, 132]], "type": "Biomedical_Entity", "mmcui": "C0013832", "rxcui": 3793, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.37.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.0"}, "arg2": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.0"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C1874964", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.0"}, "arg2": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-3", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.1"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C1874964", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-4", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.1"}, "arg2": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49-5", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.3"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C1874964", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.51-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.51", "sentence": "Nitroglycerin in 5% Dextrose Injection should be administered only via an infusion pump that can maintain a constant infusion rate.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.51.e.0"}, "arg2": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.51.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.52-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.52", "sentence": "Intracoronary injection of Nitroglycerin in 5% Dextrose Injection has not been studied.", "arg1": {"span": [[27, 40]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.52.e.0"}, "arg2": {"span": [[44, 55]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.52.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54", "sentence": "Because of the propylene glycol content of intravenous nitroglycerin, serum triglyceride assays that rely on glycerol oxidase may give falsely elevated results in patients receiving this medication.", "arg1": {"span": [[15, 31]], "type": "Biomedical_Entity", "mmcui": "C0072225", "rxcui": 1314239, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.0"}, "arg2": {"span": [[109, 117]], "type": "Biomedical_Entity", "mmcui": "C0017861", "rxcui": 4910, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54", "sentence": "Because of the propylene glycol content of intravenous nitroglycerin, serum triglyceride assays that rely on glycerol oxidase may give falsely elevated results in patients receiving this medication.", "arg1": {"span": [[15, 31]], "type": "Biomedical_Entity", "mmcui": "C0072225", "rxcui": 1314239, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.0"}, "arg2": {"span": [[55, 68]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54", "sentence": "Because of the propylene glycol content of intravenous nitroglycerin, serum triglyceride assays that rely on glycerol oxidase may give falsely elevated results in patients receiving this medication.", "arg1": {"span": [[55, 68]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.2"}, "arg2": {"span": [[109, 117]], "type": "Biomedical_Entity", "mmcui": "C0017861", "rxcui": 4910, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.54.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.55-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.55", "sentence": "The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.", "arg1": {"span": [[28, 41]], "type": "Drug", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.55.e.1"}, "arg2": {"span": [[78, 90]], "type": "Drug_Class", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.55.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.56-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.56", "sentence": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "arg1": {"span": [[66, 90]], "type": "Drug_Class", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.56.e.2"}, "arg2": {"span": [[95, 111]], "type": "Drug_Class", "rxcui": 1427579, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.56.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.57-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.57", "sentence": "Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. ", "arg1": {"span": [[0, 25]], "type": "Drug", "mmcui": "C0017887", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.57.e.0"}, "arg2": {"span": [[98, 105]], "type": "Drug", "mmcui": "C0019134", "rxcui": 5224, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.57.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.58-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.58", "sentence": "In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.", "arg1": {"span": [[22, 47]], "type": "Drug", "mmcui": "C0017887", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.58.e.0"}, "arg2": {"span": [[61, 68]], "type": "Drug", "mmcui": "C0019134", "rxcui": 5224, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.58.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.59-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.59", "sentence": "Administration of Nitroglycerin in 5% Dextrose Injection through the same infusion set as blood can result in pseudoagglutination and hemolysis. ", "arg1": {"span": [[18, 31]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.59.e.1"}, "arg2": {"span": [[35, 46]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.59.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60", "sentence": "More generally, Nitroglycerin in 5% Dextrose Injection should not be mixed with any other medication of any kind.", "arg1": {"span": [[33, 44]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.0"}, "arg2": {"span": [[84, 100]], "type": "Biomedical_Entity", "mmcui": "C1115771", "rxcui": 1429329, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60", "sentence": "More generally, Nitroglycerin in 5% Dextrose Injection should not be mixed with any other medication of any kind.", "arg1": {"span": [[16, 29]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.2"}, "arg2": {"span": [[33, 44]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60", "sentence": "More generally, Nitroglycerin in 5% Dextrose Injection should not be mixed with any other medication of any kind.", "arg1": {"span": [[16, 29]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.2"}, "arg2": {"span": [[84, 100]], "type": "Biomedical_Entity", "mmcui": "C1115771", "rxcui": 1429329, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.60.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.87-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.87", "sentence": "Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. ", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.87.e.1"}, "arg2": {"span": [[17, 28]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.87.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.0"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C0308779", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-1", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.0"}, "arg2": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-2", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[24, 37]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.0"}, "arg2": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-3", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.2"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C0308779", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-4", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.3"}, "arg2": {"span": [[177, 186]], "type": "Biomedical_Entity", "mmcui": "C0308779", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96-5", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96", "sentence": "Lower concentrations of Nitroglycerin in 5% Dextrose Injection increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.2"}, "arg2": {"span": [[86, 95]], "type": "Biomedical_Entity", "mmcui": "C2939802", "rxcui": 317175, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.96.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.99-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.99", "sentence": "Using nonabsorptive tubing, the initial adult dosage of Nitroglycerin in 5% Dextrose Injection should be 5 mcg/min. ", "arg1": {"span": [[56, 69]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.99.e.0"}, "arg2": {"span": [[73, 84]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.99.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.105-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.105", "sentence": "If this precaution is not taken, then depending upon the tubing, pump, and flow rate used, it might be several hours before nitroglycerin is delivered at the desired rate.", "arg1": {"span": [[124, 137]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.105.e.0"}, "arg2": {"span": [[141, 150]], "type": "Biomedical_Entity", "mmcui": "C0308779", "rxcui": 693491, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.105.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.107-0", "sentence_id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.107", "sentence": "Do not add supplementary medication to Nitroglycerin in 5% Dextrose Injection.", "arg1": {"span": [[39, 52]], "type": "Biomedical_Entity", "mmcui": "C0017887", "rxcui": 4917, "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.107.e.0"}, "arg2": {"span": [[56, 67]], "type": "Biomedical_Entity", "mmcui": "C0985452", "rxcui": "NA", "id": "Dailymed.457a026c-ebce-4701-9deb-2d7652759a99.s.107.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.1"}, "arg2": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.0"}, "arg2": {"span": [[80, 99]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.0"}, "arg2": {"span": [[51, 75]], "type": "Biomedical_Entity", "mmcui": "C0770917", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-3", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.1"}, "arg2": {"span": [[80, 99]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-4", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.1"}, "arg2": {"span": [[51, 75]], "type": "Biomedical_Entity", "mmcui": "C0770917", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1-5", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1", "sentence": "Drug Label for drug brand Lotensin HCT, containing benazepril hydrochloride and hydrochlorothiazide.", "arg1": {"span": [[51, 75]], "type": "Biomedical_Entity", "mmcui": "C0770917", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.3"}, "arg2": {"span": [[80, 99]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[0, 12]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.1"}, "arg2": {"span": [[100, 113]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[100, 113]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.0"}, "arg2": {"span": [[151, 162]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[100, 113]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.0"}, "arg2": {"span": [[118, 137]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-3", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[75, 85]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.4"}, "arg2": {"span": [[100, 113]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-4", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[0, 12]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.1"}, "arg2": {"span": [[151, 162]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-5", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[0, 12]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.1"}, "arg2": {"span": [[118, 137]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-6", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[0, 12]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.1"}, "arg2": {"span": [[75, 85]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-7", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[118, 137]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.3"}, "arg2": {"span": [[151, 162]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-8", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[75, 85]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.4"}, "arg2": {"span": [[151, 162]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8-9", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8", "sentence": "Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. ", "arg1": {"span": [[75, 85]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.4"}, "arg2": {"span": [[118, 137]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.8.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.10-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.10", "sentence": "Lotensin HCT is also contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.", "arg1": {"span": [[0, 12]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.10.e.0"}, "arg2": {"span": [[103, 116]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.10.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11", "sentence": "Do not co-administer aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes.", "arg1": {"span": [[21, 30]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11.e.2"}, "arg2": {"span": [[36, 65]], "type": "Drug_Class", "mmcui": "C0521942", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11", "sentence": "Do not co-administer aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes.", "arg1": {"span": [[21, 30]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11.e.2"}, "arg2": {"span": [[67, 81]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.11.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14", "sentence": "Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including benazepril) may be subject to a variety of adverse reactions, some of them serious.", "arg1": {"span": [[167, 181]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14.e.0"}, "arg2": {"span": [[193, 203]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14", "sentence": "Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including benazepril) may be subject to a variety of adverse reactions, some of them serious.", "arg1": {"span": [[19, 59]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 6162, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14.e.1"}, "arg2": {"span": [[193, 203]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.14.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.23-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.23", "sentence": "The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. ", "arg1": {"span": [[129, 137]], "type": "Biomedical_Entity", "mmcui": "C0723457", "rxcui": 220037, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.23.e.0"}, "arg2": {"span": [[142, 155]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.23.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.25-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.25", "sentence": "Anaphylactoid Reactions During Desensitization: Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. ", "arg1": {"span": [[101, 118]], "type": "Substance", "mmcui": "C1290000", "rxcui": 390053, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.25.e.0"}, "arg2": {"span": [[135, 149]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.25.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.32-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.32", "sentence": "Like other ACE inhibitors, benazepril has been only rarely associated with hypotension in uncomplicated hypertensive patients. ", "arg1": {"span": [[11, 25]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.32.e.1"}, "arg2": {"span": [[27, 37]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.32.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.35-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.35", "sentence": "Lotensin HCT should be used cautiously in patients receiving concomitant therapy with other antihypertensives. ", "arg1": {"span": [[0, 12]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.35.e.1"}, "arg2": {"span": [[92, 109]], "type": "Drug_Class", "mmcui": "C0350167", "rxcui": 968, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.35.e.0"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36", "sentence": "The thiazide component of Lotensin HCT may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. ", "arg1": {"span": [[4, 38]], "type": "Drug", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36.e.0"}, "arg2": {"span": [[74, 96]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.37-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.37", "sentence": "The antihypertensive effects of the thiazide component may also be enhanced in the postsympathectomy patient.", "arg1": {"span": [[4, 20]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.37.e.1"}, "arg2": {"span": [[36, 44]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.37.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39", "sentence": "In such patients, Lotensin HCT therapy should be started under close medical supervision, they should be followed closely for the first 2 weeks of treatment and whenever the dose of benazepril or diuretic is increased.", "arg1": {"span": [[18, 30]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.0"}, "arg2": {"span": [[182, 192]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39", "sentence": "In such patients, Lotensin HCT therapy should be started under close medical supervision, they should be followed closely for the first 2 weeks of treatment and whenever the dose of benazepril or diuretic is increased.", "arg1": {"span": [[18, 30]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.0"}, "arg2": {"span": [[196, 204]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39", "sentence": "In such patients, Lotensin HCT therapy should be started under close medical supervision, they should be followed closely for the first 2 weeks of treatment and whenever the dose of benazepril or diuretic is increased.", "arg1": {"span": [[182, 192]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.1"}, "arg2": {"span": [[196, 204]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.44-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.44", "sentence": "Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. ", "arg1": {"span": [[102, 113]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.44.e.1"}, "arg2": {"span": [[128, 137]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.44.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.45-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.45", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute of acute renal failure on Lotensin HCT. ", "arg1": {"span": [[78, 89]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.45.e.0"}, "arg2": {"span": [[291, 303]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.45.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.47-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.47", "sentence": "In a small study of hypertensive patients with unilateral or bilateral renal artery stenosis, treatment with benazepril was associated with increases in blood urea nitrogen and serum creatinine, these increases were reversible upon discontinuation of benazepril therapy, concomitant diuretic therapy, or both.", "arg1": {"span": [[109, 119]], "type": "Drug", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.47.e.1"}, "arg2": {"span": [[283, 291]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.47.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.49-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.49", "sentence": "Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients (incidence probably less than once per 10,000 exposures) but more frequently (incidence possibly as great as once per 1000 exposures) in patients with renal impairment, especially those who also have collagen-vascular diseases such as systemic lupus erythematosus or scleroderma. ", "arg1": {"span": [[8, 47]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 6162, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.49.e.0"}, "arg2": {"span": [[49, 58]], "type": "Biomedical_Entity", "mmcui": "C0006938", "rxcui": 1998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.49.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59", "sentence": "Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. ", "arg1": {"span": [[75, 91]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59.e.0"}, "arg2": {"span": [[168, 179]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59", "sentence": "Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. ", "arg1": {"span": [[168, 179]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59.e.2"}, "arg2": {"span": [[198, 221]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.59.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.70-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.70", "sentence": "When hydrochlorothiazide was orally administered without benazepril to pregnant mice and rats during their respective periods of major organogenesis, at doses up to 3000 and 1000 mg/kg/day respectively, there was no evidence of harm to the fetus. ", "arg1": {"span": [[5, 24]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.70.e.0"}, "arg2": {"span": [[57, 67]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.70.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.71-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.71", "sentence": "Similarly, no teratogenic effects of benazepril were seen in studies of pregnant rats, mice, and rabbits, on a mg/kg basis, the doses used in these studies were 300 times (in rats), 90 times (in mice), and more than 3 times (in rabbits) the maximum recommended human dose.", "arg1": {"span": [[37, 47]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.71.e.1"}, "arg2": {"span": [[117, 122]], "type": "Biomedical_Entity", "mmcui": "C1874451", "rxcui": 1046801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.71.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72", "sentence": "Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.1"}, "arg2": {"span": [[121, 140]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72", "sentence": "Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. ", "arg1": {"span": [[121, 140]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.0"}, "arg2": {"span": [[153, 162]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72", "sentence": "Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.1"}, "arg2": {"span": [[153, 162]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.72.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.84-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.84", "sentence": "Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. ", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.84.e.1"}, "arg2": {"span": [[23, 34]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.84.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93", "sentence": "In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.", "arg1": {"span": [[22, 34]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.1"}, "arg2": {"span": [[325, 344]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93", "sentence": "In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.", "arg1": {"span": [[236, 245]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.2"}, "arg2": {"span": [[325, 344]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93", "sentence": "In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.", "arg1": {"span": [[64, 73]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.3"}, "arg2": {"span": [[325, 344]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93-3", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93", "sentence": "In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.", "arg1": {"span": [[22, 34]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.1"}, "arg2": {"span": [[236, 245]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93-4", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93", "sentence": "In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.", "arg1": {"span": [[22, 34]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.1"}, "arg2": {"span": [[64, 73]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.93.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.100-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.100", "sentence": "Hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.100.e.0"}, "arg2": {"span": [[30, 37]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.100.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102", "sentence": "Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102.e.1"}, "arg2": {"span": [[83, 90]], "type": "Biomedical_Entity", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102", "sentence": "Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102.e.1"}, "arg2": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.102.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106", "sentence": "Surgery/Anesthesia: In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. ", "arg1": {"span": [[61, 71]], "type": "Biomedical_Entity", "mmcui": "C0002932", "rxcui": 239756, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.1"}, "arg2": {"span": [[136, 150]], "type": "Biomedical_Entity", "mmcui": "C0003009", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106", "sentence": "Surgery/Anesthesia: In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. ", "arg1": {"span": [[8, 18]], "type": "Biomedical_Entity", "mmcui": "C0002932", "rxcui": 239756, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.2"}, "arg2": {"span": [[136, 150]], "type": "Biomedical_Entity", "mmcui": "C0003009", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106", "sentence": "Surgery/Anesthesia: In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. ", "arg1": {"span": [[110, 120]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.3"}, "arg2": {"span": [[136, 150]], "type": "Biomedical_Entity", "mmcui": "C0003009", "rxcui": 839, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106-3", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106", "sentence": "Surgery/Anesthesia: In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. ", "arg1": {"span": [[61, 71]], "type": "Biomedical_Entity", "mmcui": "C0002932", "rxcui": 239756, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.1"}, "arg2": {"span": [[110, 120]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106-4", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106", "sentence": "Surgery/Anesthesia: In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. ", "arg1": {"span": [[8, 18]], "type": "Biomedical_Entity", "mmcui": "C0002932", "rxcui": 239756, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.2"}, "arg2": {"span": [[110, 120]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.106.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117", "sentence": "Hyperkalemia: A patient receiving Lotensin HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.", "arg1": {"span": [[34, 46]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.0"}, "arg2": {"span": [[73, 94]], "type": "Drug_Class", "mmcui": "C0304475", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117", "sentence": "Hyperkalemia: A patient receiving Lotensin HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.", "arg1": {"span": [[34, 46]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.0"}, "arg2": {"span": [[98, 135]], "type": "Substance", "mmcui": "C0784217", "rxcui": 9547, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117", "sentence": "Hyperkalemia: A patient receiving Lotensin HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.", "arg1": {"span": [[73, 94]], "type": "Drug_Class", "mmcui": "C0304475", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.3"}, "arg2": {"span": [[98, 135]], "type": "Substance", "mmcui": "C0784217", "rxcui": 9547, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.117.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.120-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.120", "sentence": "The hydrochlorothiazide component of Lotensin HCT may decrease serum PBI levels without signs of thyroid disturbance.", "arg1": {"span": [[4, 23]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.120.e.1"}, "arg2": {"span": [[37, 49]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.120.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.123-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.123", "sentence": "Interactions Common for Both Benazepril and Hydrochlorothiazide", "arg1": {"span": [[29, 39]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.123.e.0"}, "arg2": {"span": [[44, 63]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.123.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124", "sentence": "Potassium Supplements and Potassium-Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. ", "arg1": {"span": [[26, 53]], "type": "Drug_Class", "mmcui": "C0304490", "rxcui": 1437061, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.2"}, "arg2": {"span": [[76, 88]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124", "sentence": "Potassium Supplements and Potassium-Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. ", "arg1": {"span": [[0, 21]], "type": "Drug_Class", "mmcui": "C0304475", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.1"}, "arg2": {"span": [[76, 88]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124", "sentence": "Potassium Supplements and Potassium-Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. ", "arg1": {"span": [[0, 21]], "type": "Drug_Class", "mmcui": "C0304475", "rxcui": 8588, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.1"}, "arg2": {"span": [[26, 53]], "type": "Drug_Class", "mmcui": "C0304490", "rxcui": 1437061, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.124.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126", "sentence": "Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. ", "arg1": {"span": [[28, 35]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.2"}, "arg2": {"span": [[50, 59]], "type": "Drug_Class", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126", "sentence": "Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. ", "arg1": {"span": [[50, 59]], "type": "Drug_Class", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.3"}, "arg2": {"span": [[85, 92]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127", "sentence": "Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "arg1": {"span": [[16, 23]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.2"}, "arg2": {"span": [[105, 119]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.6"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127", "sentence": "Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "arg1": {"span": [[47, 54]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.3"}, "arg2": {"span": [[105, 119]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.6"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.128-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.128", "sentence": "Monitor lithium levels when used concomitantly with Lotensin HCT.", "arg1": {"span": [[8, 15]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.128.e.2"}, "arg2": {"span": [[52, 64]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.128.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.130-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.130", "sentence": "Closely monitor blood pressure, renal function and electrolytes in patients on Lotensin HCT and other agents that block the RAS.", "arg1": {"span": [[79, 91]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.130.e.2"}, "arg2": {"span": [[102, 127]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 126263, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.130.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.131-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.131", "sentence": "Do not co-administer aliskiren with Lotensin HCT in patients with diabetes. ", "arg1": {"span": [[21, 30]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.131.e.2"}, "arg2": {"span": [[36, 48]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.131.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.132-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.132", "sentence": "Avoid use of aliskiren with Lotensin HCT in patients with renal impairment (GFR 60 ml/min).", "arg1": {"span": [[13, 22]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.132.e.2"}, "arg2": {"span": [[28, 40]], "type": "Drug", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.132.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.135-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.135", "sentence": "Monitor renal function periodically in patients receiving benazepril and NSAID therapy.", "arg1": {"span": [[58, 68]], "type": "Drug", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.135.e.2"}, "arg2": {"span": [[73, 78]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.135.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136", "sentence": "The antihypertensive effect of benazepril and hydrochlorothiazide may be attenuated by NSAIDs.", "arg1": {"span": [[31, 41]], "type": "Drug", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136.e.3"}, "arg2": {"span": [[87, 93]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136", "sentence": "The antihypertensive effect of benazepril and hydrochlorothiazide may be attenuated by NSAIDs.", "arg1": {"span": [[46, 65]], "type": "Drug", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136.e.4"}, "arg2": {"span": [[87, 93]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.136.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.139-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.139", "sentence": "Other ACE inhibitors have had less than additive effects with beta-adrenergic blockers, presumably because drugs of both classes lower blood pressure by inhibiting parts of the renin-angiotensin system.", "arg1": {"span": [[6, 20]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.139.e.0"}, "arg2": {"span": [[62, 86]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.139.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140", "sentence": "Interaction studies with warfarin and acenocoumarol have failed to identify any clinically important effects of benazepril on the serum concentrations or clinical effects of these anticoagulants.", "arg1": {"span": [[25, 33]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.0"}, "arg2": {"span": [[38, 51]], "type": "Biomedical_Entity", "mmcui": "C0000956", "rxcui": 154, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140", "sentence": "Interaction studies with warfarin and acenocoumarol have failed to identify any clinically important effects of benazepril on the serum concentrations or clinical effects of these anticoagulants.", "arg1": {"span": [[25, 33]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.0"}, "arg2": {"span": [[112, 122]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140", "sentence": "Interaction studies with warfarin and acenocoumarol have failed to identify any clinically important effects of benazepril on the serum concentrations or clinical effects of these anticoagulants.", "arg1": {"span": [[38, 51]], "type": "Biomedical_Entity", "mmcui": "C0000956", "rxcui": 154, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.1"}, "arg2": {"span": [[112, 122]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.140.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.143-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.143", "sentence": "Ion exchange resins: Stagger the dosage of hydrochlorothiazide and ion exchange resins such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins. ", "arg1": {"span": [[43, 62]], "type": "Drug", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.143.e.2"}, "arg2": {"span": [[67, 86]], "type": "Drug_Class", "mmcui": "C0022014", "rxcui": 1239134, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.143.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144", "sentence": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.", "arg1": {"span": [[23, 37]], "type": "Drug", "mmcui": "C0008402", "rxcui": 2447, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144.e.0"}, "arg2": {"span": [[41, 58]], "type": "Drug_Class", "mmcui": "C0009279", "rxcui": 104485, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145", "sentence": "Digitalis glycosides: Thiazide-induced hypokalemia or hypomagnesemia may predispose the patients to digoxin toxicity", "arg1": {"span": [[22, 30]], "type": "Drug_Class", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145.e.3"}, "arg2": {"span": [[100, 107]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150", "sentence": "Conversely, pro-kinetic drugs may decrease the bioavailability of thiazide diuretics.", "arg1": {"span": [[12, 29]], "type": "Drug_Class", "mmcui": "C0013227", "rxcui": 992037, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150.e.0"}, "arg2": {"span": [[66, 84]], "type": "Drug_Class", "mmcui": "C0012802", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150.e.3"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.151-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.151", "sentence": "Cyclosporin: Concomitant treatment with diuretics may increase the risk of hyperuricaemia and gout-type complications.", "arg1": {"span": [[0, 11]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.151.e.1"}, "arg2": {"span": [[40, 49]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.151.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[66, 84]], "type": "Drug_Class", "mmcui": "C0012802", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.0"}, "arg2": {"span": [[116, 125]], "type": "Drug_Class", "mmcui": "C0027415", "rxcui": 992359, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[66, 84]], "type": "Drug_Class", "mmcui": "C0012802", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.0"}, "arg2": {"span": [[99, 111]], "type": "Drug_Class", "mmcui": "C0004745", "rxcui": 1437144, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[66, 84]], "type": "Drug_Class", "mmcui": "C0012802", "rxcui": 141801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.0"}, "arg2": {"span": [[90, 97]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-3", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[99, 111]], "type": "Drug_Class", "mmcui": "C0004745", "rxcui": 1437144, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.2"}, "arg2": {"span": [[116, 125]], "type": "Drug_Class", "mmcui": "C0027415", "rxcui": 992359, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-4", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[90, 97]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.1"}, "arg2": {"span": [[116, 125]], "type": "Drug_Class", "mmcui": "C0027415", "rxcui": 992359, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152-5", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152", "sentence": "Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.", "arg1": {"span": [[90, 97]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.1"}, "arg2": {"span": [[99, 111]], "type": "Drug_Class", "mmcui": "C0004745", "rxcui": 1437144, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.152.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153", "sentence": "Pressor amines: Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline but the clinical significance of this effect is not sufficient to preclude their use.", "arg1": {"span": [[16, 35]], "type": "Drug", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153.e.0"}, "arg2": {"span": [[63, 77]], "type": "Drug_Class", "mmcui": "C0237795", "rxcui": 203344, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153.e.3"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.159-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.159", "sentence": "At doses of 50-500 mg/kg/day (6-61 times the maximum recommended dose on a body-surface-area basis), benazepril had no adverse effect on the reproductive performance of male and female rats.", "arg1": {"span": [[93, 98]], "type": "Biomedical_Entity", "mmcui": "C1874451", "rxcui": 1046801, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.159.e.1"}, "arg2": {"span": [[101, 111]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.159.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.166-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.166", "sentence": "There are no human fertility data for hydrochlorothiazide. ", "arg1": {"span": [[10, 33]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.166.e.1"}, "arg2": {"span": [[38, 57]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.166.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.167-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.167", "sentence": "In animal studies, benazepril and hydrochlorothiazide alone or in combination had no effect on fertility and conception (see Non-Clinical Safety Data).", "arg1": {"span": [[19, 29]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.167.e.1"}, "arg2": {"span": [[34, 53]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.167.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172", "sentence": "Because of the potential for serious adverse reactions in nursing infants from hydrochlorothiazide and the unknown effects of benazepril in infants, a decision should be made whether to discontinue nursing or to discontinue Lotensin HCT, taking into account the importance of the drug to the mother.", "arg1": {"span": [[79, 98]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.0"}, "arg2": {"span": [[224, 236]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172-1", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172", "sentence": "Because of the potential for serious adverse reactions in nursing infants from hydrochlorothiazide and the unknown effects of benazepril in infants, a decision should be made whether to discontinue nursing or to discontinue Lotensin HCT, taking into account the importance of the drug to the mother.", "arg1": {"span": [[79, 98]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.0"}, "arg2": {"span": [[126, 136]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172-2", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172", "sentence": "Because of the potential for serious adverse reactions in nursing infants from hydrochlorothiazide and the unknown effects of benazepril in infants, a decision should be made whether to discontinue nursing or to discontinue Lotensin HCT, taking into account the importance of the drug to the mother.", "arg1": {"span": [[126, 136]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.2"}, "arg2": {"span": [[224, 236]], "type": "Biomedical_Entity", "mmcui": "C0721437", "rxcui": 218088, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.172.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.181-0", "sentence_id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.181", "sentence": "Benazepril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, there are occasional reports of benefit from these maneuvers with another ACE inhibitor, but experience is limited.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0053091", "rxcui": 18867, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.181.e.0"}, "arg2": {"span": [[189, 202]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.181.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1", "sentence": "Drug Label for drug brand ADCIRCA, containing Tadalafil.", "arg1": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.1"}, "arg2": {"span": [[46, 55]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1", "sentence": "Drug Label for drug brand ADCIRCA, containing Tadalafil.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.2"}, "arg2": {"span": [[46, 55]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1", "sentence": "Drug Label for drug brand ADCIRCA, containing Tadalafil.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.2"}, "arg2": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4", "sentence": "<item>History of known serious hypersensitivity reaction to ADCIRCA or CIALIS (4.2)", "arg1": {"span": [[60, 67]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.1"}, "arg2": {"span": [[71, 77]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6", "sentence": "Do not use ADCIRCA in patients who are using any form of organic nitrate, either regularly or intermittently. ", "arg1": {"span": [[11, 18]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.2"}, "arg2": {"span": [[57, 72]], "type": "Drug_Class", "rxcui": 1427579, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7", "sentence": "ADCIRCA potentiates the hypotensive effect of nitrates. ", "arg1": {"span": [[0, 7]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.3"}, "arg2": {"span": [[46, 54]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8", "sentence": "This potentiation is thought to result from the combined effects of nitrates and ADCIRCA on the nitric oxide/cGMP pathway see Clinical Pharmacology (12.2).", "arg1": {"span": [[81, 88]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.1"}, "arg2": {"span": [[96, 108]], "type": "Biomedical_Entity", "mmcui": "C0028128", "rxcui": 1311391, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10", "sentence": "ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.0"}, "arg2": {"span": [[80, 89]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10", "sentence": "ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.0"}, "arg2": {"span": [[102, 108]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10", "sentence": "ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). ", "arg1": {"span": [[80, 89]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1"}, "arg2": {"span": [[102, 108]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10-3", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10", "sentence": "ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). ", "arg1": {"span": [[80, 89]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1"}, "arg2": {"span": [[91, 98]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10-4", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10", "sentence": "ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). ", "arg1": {"span": [[91, 98]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.3"}, "arg2": {"span": [[102, 108]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16", "sentence": "<item>Concomitant alpha-blockers or alcohol: Note additive blood pressure-lowering effects. ", "arg1": {"span": [[18, 32]], "type": "Drug_Class", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.2"}, "arg2": {"span": [[36, 43]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20", "sentence": "<item>Other concomitant potent CYP3A inhibitors: Avoid use with ADCIRCA. ", "arg1": {"span": [[24, 47]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.0"}, "arg2": {"span": [[64, 71]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22", "sentence": "<item>Potent Inducers of CYP3A: Avoid use of ADCIRCA in patients chronically taking potent inducers of CYP3A (e.g., rifampin). ", "arg1": {"span": [[45, 52]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.2"}, "arg2": {"span": [[84, 108]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28", "sentence": "<item>Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. ", "arg1": {"span": [[50, 56]], "type": "Drug", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.2"}, "arg2": {"span": [[66, 81]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33", "sentence": "Discuss with patients the appropriate action to take in the event that they experience anginal chest pain requiring nitroglycerin following intake of ADCIRCA. ", "arg1": {"span": [[116, 129]], "type": "Biomedical_Entity", "mmcui": "C0885378", "rxcui": 4917, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.1"}, "arg2": {"span": [[150, 157]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34", "sentence": "At least 48 hours should elapse after the last dose of ADCIRCA before taking nitrates. ", "arg1": {"span": [[55, 62]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.0"}, "arg2": {"span": [[77, 85]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35", "sentence": "If a patient has taken ADCIRCA within 48 hours, administer nitrates under close medical supervision with appropriate hemodynamic monitoring. ", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.0"}, "arg2": {"span": [[59, 67]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37", "sentence": "PDE5 inhibitors, including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.0"}, "arg2": {"span": [[27, 36]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39", "sentence": "Patients with severely impaired autonomic control of blood pressure or with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) may be particularly sensitive to the actions of vasodilators, including PDE5 inhibitors.", "arg1": {"span": [[233, 245]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.0"}, "arg2": {"span": [[257, 272]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41", "sentence": "Since there are no clinical data on administration of ADCIRCA to patients with veno-occlusive disease, administration of ADCIRCA to such patients is not recommended. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.1"}, "arg2": {"span": [[121, 128]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41", "sentence": "Since there are no clinical data on administration of ADCIRCA to patients with veno-occlusive disease, administration of ADCIRCA to such patients is not recommended. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.1"}, "arg2": {"span": [[54, 61]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51", "sentence": "Use with Alpha Blockers and Antihypertensives", "arg1": {"span": [[9, 23]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.1"}, "arg2": {"span": [[28, 45]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1"}, "arg2": {"span": [[77, 89]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2"}, "arg2": {"span": [[77, 89]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3"}, "arg2": {"span": [[77, 89]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-3", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1"}, "arg2": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-4", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3"}, "arg2": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52-5", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3"}, "arg2": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55", "sentence": "Safety of combined use of PDE5 inhibitors and alpha blockers may be affected by other variables, including intravascular volume depletion and use of other antihypertensive drugs see Drug Interactions (7.1).", "arg1": {"span": [[26, 41]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.0"}, "arg2": {"span": [[46, 60]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55", "sentence": "Safety of combined use of PDE5 inhibitors and alpha blockers may be affected by other variables, including intravascular volume depletion and use of other antihypertensive drugs see Drug Interactions (7.1).", "arg1": {"span": [[26, 41]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.0"}, "arg2": {"span": [[155, 177]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55", "sentence": "Safety of combined use of PDE5 inhibitors and alpha blockers may be affected by other variables, including intravascular volume depletion and use of other antihypertensive drugs see Drug Interactions (7.1).", "arg1": {"span": [[46, 60]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.1"}, "arg2": {"span": [[155, 177]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57", "sentence": "Both alcohol and tadalafil are mild vasodilators. ", "arg1": {"span": [[17, 26]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.0"}, "arg2": {"span": [[36, 48]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60", "sentence": "Co-administration of ADCIRCA in Patients on Ritonavir", "arg1": {"span": [[21, 28]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.1"}, "arg2": {"span": [[44, 53]], "type": "Biomedical_Entity", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61", "sentence": "In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. ", "arg1": {"span": [[22, 31]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.3"}, "arg2": {"span": [[61, 68]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63", "sentence": "Co-administration of Ritonavir in Patients on ADCIRCA", "arg1": {"span": [[21, 30]], "type": "Biomedical_Entity", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.1"}, "arg2": {"span": [[46, 53]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64", "sentence": "Avoid use of ADCIRCA during the initiation of ritonavir. ", "arg1": {"span": [[13, 20]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.3"}, "arg2": {"span": [[46, 55]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65", "sentence": "Stop ADCIRCA at least 24 hours prior to starting ritonavir. ", "arg1": {"span": [[5, 12]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.2"}, "arg2": {"span": [[49, 58]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66", "sentence": "After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. ", "arg1": {"span": [[52, 61]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.2"}, "arg2": {"span": [[70, 77]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70", "sentence": "In patients taking potent inhibitors of CYP3A such as ketoconazole and itraconazole, avoid use of ADCIRCA see Drug Interactions (7.2) and Clinical Pharmacology (12.3).", "arg1": {"span": [[19, 45]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3"}, "arg2": {"span": [[98, 105]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72", "sentence": "For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of ADCIRCA see Drug Interactions (7.2) and Clinical Pharmacology (12.3).", "arg1": {"span": [[32, 56]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.0"}, "arg2": {"span": [[89, 96]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78", "sentence": "Avoid use of ADCIRCA because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis see Dosage and Administration (2.2) and Clinical Pharmacology (12.3).", "arg1": {"span": [[13, 20]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.0"}, "arg2": {"span": [[42, 51]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89", "sentence": "Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators such as PDE5 inhibitors see Adverse Reactions (6.2).", "arg1": {"span": [[208, 220]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.1"}, "arg2": {"span": [[229, 244]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93", "sentence": "These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including ADCIRCA. ", "arg1": {"span": [[126, 141]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.1"}, "arg2": {"span": [[153, 160]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96", "sentence": "Tadalafil is also marketed as CIALIS. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.1"}, "arg2": {"span": [[30, 36]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97", "sentence": "The safety and efficacy of taking ADCIRCA together with CIALIS or other PDE5 inhibitors have not been studied. ", "arg1": {"span": [[34, 41]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.0"}, "arg2": {"span": [[72, 87]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97", "sentence": "The safety and efficacy of taking ADCIRCA together with CIALIS or other PDE5 inhibitors have not been studied. ", "arg1": {"span": [[34, 41]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.0"}, "arg2": {"span": [[56, 62]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97", "sentence": "The safety and efficacy of taking ADCIRCA together with CIALIS or other PDE5 inhibitors have not been studied. ", "arg1": {"span": [[56, 62]], "type": "Biomedical_Entity", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.2"}, "arg2": {"span": [[72, 87]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98", "sentence": "Inform patients taking ADCIRCA not to take CIALIS or other PDE5 inhibitors.", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2"}, "arg2": {"span": [[43, 49]], "type": "Drug", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98", "sentence": "Inform patients taking ADCIRCA not to take CIALIS or other PDE5 inhibitors.", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2"}, "arg2": {"span": [[59, 74]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98", "sentence": "Inform patients taking ADCIRCA not to take CIALIS or other PDE5 inhibitors.", "arg1": {"span": [[43, 49]], "type": "Drug", "mmcui": "C0967376", "rxcui": 303263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3"}, "arg2": {"span": [[59, 74]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106", "sentence": "When administered in combination with aspirin, tadalafil 20 mg did not prolong bleeding time, relative to aspirin alone. ", "arg1": {"span": [[47, 62]], "type": "Biomedical_Entity", "mmcui": "C1321753", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.2"}, "arg2": {"span": [[106, 113]], "type": "Biomedical_Entity", "mmcui": "C0004057", "rxcui": 1191, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106", "sentence": "When administered in combination with aspirin, tadalafil 20 mg did not prolong bleeding time, relative to aspirin alone. ", "arg1": {"span": [[38, 45]], "type": "Biomedical_Entity", "mmcui": "C0004057", "rxcui": 1191, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.1"}, "arg2": {"span": [[47, 62]], "type": "Biomedical_Entity", "mmcui": "C1321753", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112", "sentence": "Do not use ADCIRCA in patients who are using any form of organic nitrate see Contraindications (4.1). ", "arg1": {"span": [[11, 18]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.2"}, "arg2": {"span": [[57, 72]], "type": "Drug_Class", "rxcui": 1427579, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113", "sentence": "In clinical pharmacology studies ADCIRCA potentiated the hypotensive effect of nitrates see Clinical Pharmacology (12.2). ", "arg1": {"span": [[33, 40]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.2"}, "arg2": {"span": [[79, 87]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114", "sentence": "In a patient who has taken ADCIRCA, where nitrate administration is deemed medically necessary in a life threatening situation, at least 48 hours should elapse after the last dose of ADCIRCA before nitrate administration is considered. ", "arg1": {"span": [[183, 190]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.2"}, "arg2": {"span": [[198, 205]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1"}, "arg2": {"span": [[82, 94]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2"}, "arg2": {"span": [[82, 94]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3"}, "arg2": {"span": [[82, 94]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-3", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2"}, "arg2": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-4", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1"}, "arg2": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117-5", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117", "sentence": "PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2"}, "arg2": {"span": [[40, 72]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": "NA", "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[101, 110]], "type": "Biomedical_Entity", "mmcui": "C0051150", "rxcui": 46043, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1"}, "arg2": {"span": [[114, 124]], "type": "Biomedical_Entity", "mmcui": "C0257343", "rxcui": 77492, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[90, 99]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2"}, "arg2": {"span": [[114, 124]], "type": "Biomedical_Entity", "mmcui": "C0257343", "rxcui": 77492, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[75, 84]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3"}, "arg2": {"span": [[114, 124]], "type": "Biomedical_Entity", "mmcui": "C0257343", "rxcui": 77492, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-3", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[90, 99]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2"}, "arg2": {"span": [[101, 110]], "type": "Biomedical_Entity", "mmcui": "C0051150", "rxcui": 46043, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-4", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[75, 84]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3"}, "arg2": {"span": [[101, 110]], "type": "Biomedical_Entity", "mmcui": "C0051150", "rxcui": 46043, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119-5", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119", "sentence": "Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2).", "arg1": {"span": [[75, 84]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3"}, "arg2": {"span": [[90, 99]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121", "sentence": "PDE5 inhibitors, including ADCIRCA, are mild systemic vasodilators. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.1"}, "arg2": {"span": [[54, 66]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121", "sentence": "PDE5 inhibitors, including ADCIRCA, are mild systemic vasodilators. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.2"}, "arg2": {"span": [[54, 66]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121", "sentence": "PDE5 inhibitors, including ADCIRCA, are mild systemic vasodilators. ", "arg1": {"span": [[0, 15]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.2"}, "arg2": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125", "sentence": "Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. ", "arg1": {"span": [[30, 44]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1"}, "arg2": {"span": [[58, 70]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125", "sentence": "Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. ", "arg1": {"span": [[17, 26]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.2"}, "arg2": {"span": [[58, 70]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125-2", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125", "sentence": "Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. ", "arg1": {"span": [[17, 26]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.2"}, "arg2": {"span": [[30, 44]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 230032, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132", "sentence": "Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.0"}, "arg2": {"span": [[95, 104]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133", "sentence": "At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir see Dosage and Administration (2.3), Warnings and Precautions (5.2), and Clinical Pharmacology (12.3).", "arg1": {"span": [[61, 70]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.0"}, "arg2": {"span": [[103, 112]], "type": "Biomedical_Entity", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133-1", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133", "sentence": "At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir see Dosage and Administration (2.3), Warnings and Precautions (5.2), and Clinical Pharmacology (12.3).", "arg1": {"span": [[19, 28]], "type": "Biomedical_Entity", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.2"}, "arg2": {"span": [[61, 70]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136", "sentence": "For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of ADCIRCA see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3).", "arg1": {"span": [[32, 56]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.0"}, "arg2": {"span": [[89, 96]], "type": "Drug", "mmcui": "C2709986", "rxcui": 849863, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141", "sentence": "Tadalafil (10 mg and 20 mg once daily) does not potentiate the increase in bleeding time caused by aspirin see Clinical Pharmacology (12.3).", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.0"}, "arg2": {"span": [[99, 106]], "type": "Biomedical_Entity", "mmcui": "C0004057", "rxcui": 1191, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143-0", "sentence_id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143", "sentence": "Coadministration of tadalafil (40 mg once daily) for 10 days did not significantly alter digoxin pharmacokinetics in healthy subjects see Clinical Pharmacology (12.3).", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C1176316", "rxcui": 358263, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.0"}, "arg2": {"span": [[89, 96]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1-0", "sentence_id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1", "sentence": "Drug Label for drug brand NeoProfen, containing ibuprofen lysine.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.1"}, "arg2": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C1712051", "rxcui": 637194, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1-1", "sentence_id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1", "sentence": "Drug Label for drug brand NeoProfen, containing ibuprofen lysine.", "arg1": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C1712051", "rxcui": 637194, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.0"}, "arg2": {"span": [[48, 64]], "type": "Biomedical_Entity", "mmcui": "C0074814", "rxcui": 5640, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1-2", "sentence_id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1", "sentence": "Drug Label for drug brand NeoProfen, containing ibuprofen lysine.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.1"}, "arg2": {"span": [[48, 64]], "type": "Biomedical_Entity", "mmcui": "C0074814", "rxcui": 5640, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.24-0", "sentence_id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.24", "sentence": "There are no long-term evaluations of the infants treated with ibuprofen at durations greater than the 36 weeks post-conceptual age observation period. ", "arg1": {"span": [[63, 72]], "type": "Biomedical_Entity", "mmcui": "C0020740", "rxcui": 5640, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.24.e.1"}, "arg2": {"span": [[76, 85]], "type": "Biomedical_Entity", "mmcui": "C2926735", "rxcui": 1001007, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.24.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.30-0", "sentence_id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.30", "sentence": "NeoProfen, like other non-steroidal anti-inflammatory agents, can inhibit platelet aggregation. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C1712051", "rxcui": 637194, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.30.e.0"}, "arg2": {"span": [[22, 60]], "type": "Biomedical_Entity", "mmcui": "C0003211", "rxcui": 1005832, "id": "Dailymed.a4d548f5-fa96-4824-9679-dd6d12746119.s.30.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.1-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.1", "sentence": "PHOSLO (calcium acetate) capsule", "arg1": {"span": [[0, 6]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.1.e.0"}, "arg2": {"span": [[8, 23]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.2-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.2", "sentence": "PhosLo acts as a phosphate binder.  ", "arg1": {"span": [[0, 6]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.2.e.0"}, "arg2": {"span": [[17, 33]], "type": "Biomedical_Entity", "mmcui": "C2267031", "rxcui": 8208, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.2.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8", "sentence": "Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (PhosLo ).  ", "arg1": {"span": [[82, 89]], "type": "Biomedical_Entity", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.1"}, "arg2": {"span": [[118, 124]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8", "sentence": "Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (PhosLo ).  ", "arg1": {"span": [[101, 116]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.2"}, "arg2": {"span": [[118, 124]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8-2", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8", "sentence": "Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (PhosLo ).  ", "arg1": {"span": [[82, 89]], "type": "Biomedical_Entity", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.1"}, "arg2": {"span": [[101, 116]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[17, 36]], "type": "Biomedical_Entity", "mmcui": "C3540037", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.0"}, "arg2": {"span": [[62, 77]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[17, 36]], "type": "Biomedical_Entity", "mmcui": "C3540037", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.0"}, "arg2": {"span": [[106, 112]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-2", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[17, 36]], "type": "Biomedical_Entity", "mmcui": "C3540037", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.0"}, "arg2": {"span": [[48, 86]], "type": "Biomedical_Entity", "mmcui": "C0304542", "rxcui": 91254, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-3", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[62, 77]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.1"}, "arg2": {"span": [[106, 112]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-4", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[48, 86]], "type": "Biomedical_Entity", "mmcui": "C0304542", "rxcui": 91254, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.3"}, "arg2": {"span": [[62, 77]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9-5", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9", "sentence": "Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLo .", "arg1": {"span": [[48, 86]], "type": "Biomedical_Entity", "mmcui": "C0304542", "rxcui": 91254, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.3"}, "arg2": {"span": [[106, 112]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.9.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.23-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.23", "sentence": "Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg2/dL2.", "arg1": {"span": [[19, 26]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.23.e.1"}, "arg2": {"span": [[64, 67]], "type": "Biomedical_Entity", "mmcui": "C2346927", "rxcui": 315, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.23.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.27-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.27", "sentence": "The drug interaction of PhosLo  is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl and hydroxyl groups).  ", "arg1": {"span": [[24, 30]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.27.e.1"}, "arg2": {"span": [[69, 76]], "type": "Biomedical_Entity", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.27.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28", "sentence": "PhosLo  may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.", "arg1": {"span": [[0, 6]], "type": "Drug", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.0"}, "arg2": {"span": [[44, 57]], "type": "Drug_Class", "mmcui": "C1744619", "rxcui": 142446, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.1"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28", "sentence": "PhosLo  may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.", "arg1": {"span": [[0, 6]], "type": "Drug", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.0"}, "arg2": {"span": [[61, 77]], "type": "Drug_Class", "mmcui": "C0949665", "rxcui": 1427693, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.2"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29", "sentence": "There are no empirical data on avoiding drug interactions between calcium acetate or PhosLo  and most concomitant drugs.  ", "arg1": {"span": [[10, 27]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.0"}, "arg2": {"span": [[85, 91]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29", "sentence": "There are no empirical data on avoiding drug interactions between calcium acetate or PhosLo  and most concomitant drugs.  ", "arg1": {"span": [[10, 27]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.0"}, "arg2": {"span": [[66, 81]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29-2", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29", "sentence": "There are no empirical data on avoiding drug interactions between calcium acetate or PhosLo  and most concomitant drugs.  ", "arg1": {"span": [[66, 81]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.2"}, "arg2": {"span": [[85, 91]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.29.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30", "sentence": "When administering an oral medication with PhosLo  where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after PhosLo  or calcium acetate.  ", "arg1": {"span": [[238, 244]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30.e.1"}, "arg2": {"span": [[249, 264]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30", "sentence": "When administering an oral medication with PhosLo  where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after PhosLo  or calcium acetate.  ", "arg1": {"span": [[43, 49]], "type": "Biomedical_Entity", "mmcui": "C0722621", "rxcui": 219236, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30.e.2"}, "arg2": {"span": [[249, 264]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.30.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32", "sentence": "Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.", "arg1": {"span": [[16, 31]], "type": "Biomedical_Entity", "mmcui": "C0003195", "rxcui": 1436910, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.0"}, "arg2": {"span": [[84, 103]], "type": "Biomedical_Entity", "mmcui": "C0748603", "rxcui": 1023130, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32-1", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32", "sentence": "Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.", "arg1": {"span": [[16, 31]], "type": "Biomedical_Entity", "mmcui": "C0003195", "rxcui": 1436910, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.0"}, "arg2": {"span": [[198, 213]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32-2", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32", "sentence": "Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.", "arg1": {"span": [[84, 103]], "type": "Biomedical_Entity", "mmcui": "C0748603", "rxcui": 1023130, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.1"}, "arg2": {"span": [[198, 213]], "type": "Biomedical_Entity", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.32.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34-0", "sentence_id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34", "sentence": "In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets approximately 2.7 g, decreased the bioavailability of ciprofloxacin by approximately 50%.", "arg1": {"span": [[70, 93]], "type": "Drug", "mmcui": "C0717537", "rxcui": 1895, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34.e.0"}, "arg2": {"span": [[148, 161]], "type": "Drug", "mmcui": "C0008809", "rxcui": 81981, "id": "Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34.e.1"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.13-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.13", "sentence": "Tekamlo is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.13.e.0"}, "arg2": {"span": [[76, 99]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.13.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.15-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.15", "sentence": "These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. ", "arg1": {"span": [[54, 76]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.15.e.1"}, "arg2": {"span": [[132, 142]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.15.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26", "sentence": "Data from the high-dose multifactorial study see Clinical Studies (14) provide estimates of the probability of reaching a target blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy. ", "arg1": {"span": [[149, 156]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.1"}, "arg2": {"span": [[182, 192]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26", "sentence": "Data from the high-dose multifactorial study see Clinical Studies (14) provide estimates of the probability of reaching a target blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy. ", "arg1": {"span": [[169, 178]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.2"}, "arg2": {"span": [[182, 192]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26", "sentence": "Data from the high-dose multifactorial study see Clinical Studies (14) provide estimates of the probability of reaching a target blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy. ", "arg1": {"span": [[149, 156]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.1"}, "arg2": {"span": [[169, 178]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.26.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.33-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.33", "sentence": "A patient with a baseline blood pressure of 157/100 mmHg has about a 49% likelihood of achieving a goal of 140 mmHg (systolic) and 50% likelihood of achieving 90 mmHg (diastolic) on aliskiren alone, and the likelihood of achieving these goals on amlodipine alone is about 62% (systolic) and 69% (diastolic). ", "arg1": {"span": [[182, 191]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.33.e.0"}, "arg2": {"span": [[246, 256]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.33.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.1"}, "arg2": {"span": [[33, 48]], "type": "Biomedical_Entity", "mmcui": "C3537174", "rxcui": 9246, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[33, 48]], "type": "Biomedical_Entity", "mmcui": "C3537174", "rxcui": 9246, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.0"}, "arg2": {"span": [[54, 64]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[33, 48]], "type": "Biomedical_Entity", "mmcui": "C3537174", "rxcui": 9246, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.0"}, "arg2": {"span": [[68, 107]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-3", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.1"}, "arg2": {"span": [[54, 64]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-4", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.1"}, "arg2": {"span": [[68, 107]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37-5", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37", "sentence": "is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure:", "arg1": {"span": [[54, 64]], "type": "Biomedical_Entity", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.2"}, "arg2": {"span": [[68, 107]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.37.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[4, 11]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.0"}, "arg2": {"span": [[75, 94]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[4, 11]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.0"}, "arg2": {"span": [[107, 146]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[4, 11]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.0"}, "arg2": {"span": [[56, 65]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-3", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[75, 94]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.1"}, "arg2": {"span": [[107, 146]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-4", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[56, 65]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.3"}, "arg2": {"span": [[75, 94]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63-5", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63", "sentence": "Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.", "arg1": {"span": [[56, 65]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.3"}, "arg2": {"span": [[107, 146]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.63.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65", "sentence": "Switch patients receiving aliskiren and amlodipine besylate from separate tablets to a single tablet of Tekamlo containing the same component doses. ", "arg1": {"span": [[40, 59]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.0"}, "arg2": {"span": [[104, 111]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65", "sentence": "Switch patients receiving aliskiren and amlodipine besylate from separate tablets to a single tablet of Tekamlo containing the same component doses. ", "arg1": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.2"}, "arg2": {"span": [[40, 59]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65", "sentence": "Switch patients receiving aliskiren and amlodipine besylate from separate tablets to a single tablet of Tekamlo containing the same component doses. ", "arg1": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.2"}, "arg2": {"span": [[104, 111]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.65.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.67-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.67", "sentence": "Tekamlo may be administered with some other antihypertensive agents. ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.67.e.1"}, "arg2": {"span": [[44, 67]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.67.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.68-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.68", "sentence": "In diabetics, do not use in combination with angiotensin receptor blockers (ARBs) or angiotensin converting enzyme inhibitors (ACEIs) see Contraindications (4). ", "arg1": {"span": [[45, 81]], "type": "Drug_Class", "mmcui": "C0521942", "rxcui": 839, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.68.e.3"}, "arg2": {"span": [[85, 133]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 839, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.68.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69", "sentence": "Concomitant use of aliskiren with an ARB or ACEI is not recommended in patients with GFR 60 ml/min see Warnings and Precautions (5.2). ", "arg1": {"span": [[19, 28]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.0"}, "arg2": {"span": [[37, 40]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69", "sentence": "Concomitant use of aliskiren with an ARB or ACEI is not recommended in patients with GFR 60 ml/min see Warnings and Precautions (5.2). ", "arg1": {"span": [[19, 28]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.0"}, "arg2": {"span": [[44, 48]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69", "sentence": "Concomitant use of aliskiren with an ARB or ACEI is not recommended in patients with GFR 60 ml/min see Warnings and Precautions (5.2). ", "arg1": {"span": [[37, 40]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.1"}, "arg2": {"span": [[44, 48]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.69.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70", "sentence": "It is not known whether Tekamlo decreases blood pressure further when added to maximum dosages of ACE inhibitors and beta blockers see Clinical Studies (14).", "arg1": {"span": [[24, 31]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.0"}, "arg2": {"span": [[98, 112]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70", "sentence": "It is not known whether Tekamlo decreases blood pressure further when added to maximum dosages of ACE inhibitors and beta blockers see Clinical Studies (14).", "arg1": {"span": [[24, 31]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.0"}, "arg2": {"span": [[117, 130]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70", "sentence": "It is not known whether Tekamlo decreases blood pressure further when added to maximum dosages of ACE inhibitors and beta blockers see Clinical Studies (14).", "arg1": {"span": [[98, 112]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.1"}, "arg2": {"span": [[117, 130]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.70.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74", "sentence": "Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions (5.2), Clinical Studies (14.2).", "arg1": {"span": [[11, 20]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.0"}, "arg2": {"span": [[26, 30]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74", "sentence": "Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions (5.2), Clinical Studies (14.2).", "arg1": {"span": [[11, 20]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.0"}, "arg2": {"span": [[34, 39]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74", "sentence": "Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions (5.2), Clinical Studies (14.2).", "arg1": {"span": [[26, 30]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.1"}, "arg2": {"span": [[34, 39]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.74.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.76-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.76", "sentence": "Do not use with angiotensin receptor blockers (ARBs) or ACE inhibitors (ACEIs) in patients with diabetes (4)", "arg1": {"span": [[16, 52]], "type": "Drug_Class", "mmcui": "C0521942", "rxcui": 839, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.76.e.2"}, "arg2": {"span": [[56, 78]], "type": "Drug_Class", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.76.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.79-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.79", "sentence": "<item>Avoid concomitant use with ARBs or ACEI in patients with renal impairment (GFR 60 mL/min) (5.2).", "arg1": {"span": [[33, 37]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.79.e.2"}, "arg2": {"span": [[41, 45]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.79.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96", "sentence": "Avoid use of Tekamlo with ARBs or ACEIs in patients with moderate renal impairment (GFR 60 ml/min).", "arg1": {"span": [[13, 20]], "type": "Drug", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.2"}, "arg2": {"span": [[26, 30]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96", "sentence": "Avoid use of Tekamlo with ARBs or ACEIs in patients with moderate renal impairment (GFR 60 ml/min).", "arg1": {"span": [[13, 20]], "type": "Drug", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.2"}, "arg2": {"span": [[34, 39]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96", "sentence": "Avoid use of Tekamlo with ARBs or ACEIs in patients with moderate renal impairment (GFR 60 ml/min).", "arg1": {"span": [[26, 30]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.3"}, "arg2": {"span": [[34, 39]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.96.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.99-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.99", "sentence": "This may occur at any time during treatment and has occurred in patients with and without a history of angioedema with ACE inhibitors or angiotensin receptor antagonists. ", "arg1": {"span": [[119, 133]], "type": "Biomedical_Entity", "mmcui": "C0003015", "rxcui": 221294, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.99.e.0"}, "arg2": {"span": [[137, 169]], "type": "Biomedical_Entity", "mmcui": "C0815017", "rxcui": 839, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.99.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.102-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.102", "sentence": "Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. ", "arg1": {"span": [[161, 175]], "type": "Biomedical_Entity", "mmcui": "C0019590", "rxcui": 967, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.102.e.0"}, "arg2": {"span": [[180, 195]], "type": "Biomedical_Entity", "mmcui": "C0001617", "rxcui": 1427675, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.102.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.105-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.105", "sentence": "In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving renin-angiotensin-aldosterone system (RAAS) blockers. ", "arg1": {"span": [[138, 147]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.105.e.6"}, "arg2": {"span": [[205, 257]], "type": "Drug_Class", "mmcui": "C0035100", "rxcui": 9246, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.105.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[238, 242]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.1"}, "arg2": {"span": [[358, 365]], "type": "Drug", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[233, 236]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.0"}, "arg2": {"span": [[358, 365]], "type": "Drug", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[246, 285]], "type": "Drug_Class", "mmcui": "C0003209", "rxcui": 1005832, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.2"}, "arg2": {"span": [[358, 365]], "type": "Drug", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-3", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[233, 236]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.0"}, "arg2": {"span": [[238, 242]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-4", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[238, 242]], "type": "Drug_Class", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.1"}, "arg2": {"span": [[246, 285]], "type": "Drug_Class", "mmcui": "C0003209", "rxcui": 1005832, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114-5", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or non-steroidal anti-inflammatory (NSAID) therapy may be at particular risk for developing acute renal failure on Tekamlo see Contraindications (4), Warnings and Precautions (5.2), Clinical Studies (14.2). ", "arg1": {"span": [[233, 236]], "type": "Drug_Class", "rxcui": 1149617, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.0"}, "arg2": {"span": [[246, 285]], "type": "Drug_Class", "mmcui": "C0003209", "rxcui": 1005832, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.114.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116", "sentence": "When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ", "arg1": {"span": [[46, 58]], "type": "Drug", "mmcui": "C0064113", "rxcui": 28031, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.1"}, "arg2": {"span": [[88, 97]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116", "sentence": "When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ", "arg1": {"span": [[30, 42]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.0"}, "arg2": {"span": [[88, 97]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116", "sentence": "When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. ", "arg1": {"span": [[30, 42]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.0"}, "arg2": {"span": [[46, 58]], "type": "Drug", "mmcui": "C0064113", "rxcui": 28031, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117", "sentence": "Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).", "arg1": {"span": [[25, 34]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.2"}, "arg2": {"span": [[40, 52]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117", "sentence": "Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).", "arg1": {"span": [[25, 34]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.2"}, "arg2": {"span": [[56, 69]], "type": "Drug", "rxcui": 28031, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117", "sentence": "Avoid concomitant use of aliskiren with cyclosporine or intraconazole see Drug Interactions (7).", "arg1": {"span": [[40, 52]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.3"}, "arg2": {"span": [[56, 69]], "type": "Drug", "rxcui": 28031, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.117.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.119-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.119", "sentence": "Monitor serum potassium periodically in patients receiving aliskiren. ", "arg1": {"span": [[14, 23]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.119.e.1"}, "arg2": {"span": [[59, 68]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.119.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123", "sentence": "No drug interaction studies have been conducted with Tekamlo and other drugs, although studies with the individual aliskiren and amlodipine besylate components are described below.", "arg1": {"span": [[53, 60]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.0"}, "arg2": {"span": [[129, 148]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123", "sentence": "No drug interaction studies have been conducted with Tekamlo and other drugs, although studies with the individual aliskiren and amlodipine besylate components are described below.", "arg1": {"span": [[53, 60]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.0"}, "arg2": {"span": [[115, 124]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123", "sentence": "No drug interaction studies have been conducted with Tekamlo and other drugs, although studies with the individual aliskiren and amlodipine besylate components are described below.", "arg1": {"span": [[115, 124]], "type": "Biomedical_Entity", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.2"}, "arg2": {"span": [[129, 148]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.123.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.124-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.124", "sentence": "Cyclosporin e : Avoid co-administration of cyclosporine with aliskiren.", "arg1": {"span": [[43, 55]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.124.e.0"}, "arg2": {"span": [[61, 70]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.124.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.125-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.125", "sentence": "Itraconazole: Avoid co-administration of itraconazole with aliskiren see Clinical Pharmacology (12.3.", "arg1": {"span": [[41, 53]], "type": "Drug", "mmcui": "C0064113", "rxcui": 28031, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.125.e.2"}, "arg2": {"span": [[59, 68]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.125.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.128-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.128", "sentence": "Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.", "arg1": {"span": [[58, 67]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.128.e.2"}, "arg2": {"span": [[72, 77]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.128.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.129-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.129", "sentence": "The antihypertensive effect of aliskiren may be attenuated by NSAIDs.", "arg1": {"span": [[31, 40]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.129.e.0"}, "arg2": {"span": [[62, 68]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.129.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131", "sentence": "Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. ", "arg1": {"span": [[51, 61]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131.e.2"}, "arg2": {"span": [[97, 108]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.132-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.132", "sentence": "Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.", "arg1": {"span": [[18, 29]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.132.e.2"}, "arg2": {"span": [[45, 55]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.132.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.134-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.134", "sentence": "Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A4 inhibitors to determine the need for dose adjustment.", "arg1": {"span": [[51, 61]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.134.e.4"}, "arg2": {"span": [[86, 103]], "type": "Drug_Class", "rxcui": 340933, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.134.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.136-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.136", "sentence": "Blood pressure should be monitored when amlodipine is co-administered with CYP3A4 inducers.", "arg1": {"span": [[40, 50]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.136.e.2"}, "arg2": {"span": [[75, 90]], "type": "Drug_Class", "rxcui": 340933, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.136.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.140-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.140", "sentence": "<item>If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7)", "arg1": {"span": [[9, 20]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.140.e.0"}, "arg2": {"span": [[45, 55]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.140.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.1"}, "arg2": {"span": [[166, 205]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[20, 63]], "type": "Biomedical_Entity", "mmcui": "C1875984", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.2"}, "arg2": {"span": [[166, 205]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[143, 162]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.3"}, "arg2": {"span": [[166, 205]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-3", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[115, 137]], "type": "Biomedical_Entity", "mmcui": "C1950687", "rxcui": 3525, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.4"}, "arg2": {"span": [[166, 205]], "type": "Biomedical_Entity", "mmcui": "C2945601", "rxcui": 3427, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-4", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.1"}, "arg2": {"span": [[20, 63]], "type": "Biomedical_Entity", "mmcui": "C1875984", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-5", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.1"}, "arg2": {"span": [[143, 162]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-6", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.1"}, "arg2": {"span": [[115, 137]], "type": "Biomedical_Entity", "mmcui": "C1950687", "rxcui": 3525, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-7", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[20, 63]], "type": "Biomedical_Entity", "mmcui": "C1875984", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.2"}, "arg2": {"span": [[143, 162]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-8", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[20, 63]], "type": "Biomedical_Entity", "mmcui": "C1875984", "rxcui": "NA", "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.2"}, "arg2": {"span": [[115, 137]], "type": "Biomedical_Entity", "mmcui": "C1950687", "rxcui": 3525, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142-9", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142", "sentence": "Tekamlo is a single tablet for oral administration of aliskiren hemifumarate (an orally active, nonpeptide, potent direct renin inhibitor) and amlodipine besylate (a dihydropyridine calcium channel blocker).", "arg1": {"span": [[115, 137]], "type": "Biomedical_Entity", "mmcui": "C1950687", "rxcui": 3525, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.4"}, "arg2": {"span": [[143, 162]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.142.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.147-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.147", "sentence": "It is highly soluble in water, and freely soluble in methanol, ethanol and isopropanol.", "arg1": {"span": [[53, 61]], "type": "Biomedical_Entity", "mmcui": "C0001963", "rxcui": 1310568, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.147.e.1"}, "arg2": {"span": [[75, 86]], "type": "Biomedical_Entity", "mmcui": "C0022237", "rxcui": 797541, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.147.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-0", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.1"}, "arg2": {"span": [[66, 88]], "type": "Biomedical_Entity", "mmcui": "C1879678", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-1", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[66, 88]], "type": "Biomedical_Entity", "mmcui": "C1879678", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.0"}, "arg2": {"span": [[93, 112]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-2", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[66, 88]], "type": "Biomedical_Entity", "mmcui": "C1879678", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.0"}, "arg2": {"span": [[221, 242]], "type": "Biomedical_Entity", "mmcui": "C2937472", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-3", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.1"}, "arg2": {"span": [[93, 112]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-4", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2939825", "rxcui": 1372707, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.1"}, "arg2": {"span": [[221, 242]], "type": "Biomedical_Entity", "mmcui": "C2937472", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152-5", "sentence_id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152", "sentence": "Tekamlo tablets are formulated for oral administration to contain aliskiren hemifumarate and amlodipine besylate providing for the following available combinations: 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg aliskiren /amlodipine. ", "arg1": {"span": [[93, 112]], "type": "Biomedical_Entity", "mmcui": "C0354468", "rxcui": 104416, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.2"}, "arg2": {"span": [[221, 242]], "type": "Biomedical_Entity", "mmcui": "C2937472", "rxcui": 325646, "id": "Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.152.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1", "sentence": "Drug Label for drug brand SECTRAL, containing acebutolol hydrochloride.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.1"}, "arg2": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1-1", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1", "sentence": "Drug Label for drug brand SECTRAL, containing acebutolol hydrochloride.", "arg1": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.0"}, "arg2": {"span": [[46, 70]], "type": "Biomedical_Entity", "mmcui": "C0543447", "rxcui": 142130, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1-2", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1", "sentence": "Drug Label for drug brand SECTRAL, containing acebutolol hydrochloride.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.1"}, "arg2": {"span": [[46, 70]], "type": "Biomedical_Entity", "mmcui": "C0543447", "rxcui": 142130, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8", "sentence": "Although -blockers should be avoided in overt cardiac failure, Sectral can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. ", "arg1": {"span": [[164, 173]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.1"}, "arg2": {"span": [[181, 190]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8-1", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8", "sentence": "Although -blockers should be avoided in overt cardiac failure, Sectral can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. ", "arg1": {"span": [[63, 70]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.2"}, "arg2": {"span": [[181, 190]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8-2", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8", "sentence": "Although -blockers should be avoided in overt cardiac failure, Sectral can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. ", "arg1": {"span": [[63, 70]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.2"}, "arg2": {"span": [[164, 173]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.9-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.9", "sentence": "Both digitalis and Sectral impair AV conduction. ", "arg1": {"span": [[5, 14]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.9.e.0"}, "arg2": {"span": [[19, 26]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.9.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.14-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.14", "sentence": "If cardiac failure continues despite adequate digitalization and/or diuretic, Sectral therapy should be withdrawn.", "arg1": {"span": [[68, 76]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.14.e.0"}, "arg2": {"span": [[78, 85]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.14.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.20-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.20", "sentence": "If an exacerbation of angina pectoris occurs, antianginal therapy should be restarted immediately in full doses and the patient hospitalized until his condition stabilizes.", "arg1": {"span": [[46, 57]], "type": "Biomedical_Entity", "mmcui": "C1874267", "rxcui": 1447082, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.20.e.0"}, "arg2": {"span": [[147, 150]], "type": "Biomedical_Entity", "mmcui": "C0019602", "rxcui": 9434, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.20.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28", "sentence": "A bronchodilator, such as theophylline or a 2- stimulant, should be made available in advance with instructions concerning its use.", "arg1": {"span": [[2, 16]], "type": "Biomedical_Entity", "mmcui": "C0006280", "rxcui": 1779, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.0"}, "arg2": {"span": [[47, 56]], "type": "Biomedical_Entity", "mmcui": "C0002763", "rxcui": 1437130, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28-1", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28", "sentence": "A bronchodilator, such as theophylline or a 2- stimulant, should be made available in advance with instructions concerning its use.", "arg1": {"span": [[2, 16]], "type": "Biomedical_Entity", "mmcui": "C0006280", "rxcui": 1779, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.0"}, "arg2": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28-2", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28", "sentence": "A bronchodilator, such as theophylline or a 2- stimulant, should be made available in advance with instructions concerning its use.", "arg1": {"span": [[26, 38]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.2"}, "arg2": {"span": [[47, 56]], "type": "Biomedical_Entity", "mmcui": "C0002763", "rxcui": 1437130, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.28.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.31-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.31", "sentence": "-adrenergic receptor blockade impairs the ability of the heart to respond to -adrenergically mediated reflex stimuli. ", "arg1": {"span": [[21, 29]], "type": "Biomedical_Entity", "mmcui": "C3540676", "rxcui": 1423936, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.31.e.1"}, "arg2": {"span": [[93, 101]], "type": "Biomedical_Entity", "mmcui": "C0127400", "rxcui": 985488, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.31.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32", "sentence": "While this might be of benefit in preventing arrhythmic response, the risk of excessive myocardial depression during general anesthesia may be enhanced and difficulty in restarting and maintaining the heart beat has been reported with beta-blockers. ", "arg1": {"span": [[117, 135]], "type": "Biomedical_Entity", "mmcui": "C3536928", "rxcui": 4740, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.1"}, "arg2": {"span": [[235, 248]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32-1", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32", "sentence": "While this might be of benefit in preventing arrhythmic response, the risk of excessive myocardial depression during general anesthesia may be enhanced and difficulty in restarting and maintaining the heart beat has been reported with beta-blockers. ", "arg1": {"span": [[34, 44]], "type": "Biomedical_Entity", "mmcui": "C0309872", "rxcui": 1076824, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.2"}, "arg2": {"span": [[235, 248]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32-2", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32", "sentence": "While this might be of benefit in preventing arrhythmic response, the risk of excessive myocardial depression during general anesthesia may be enhanced and difficulty in restarting and maintaining the heart beat has been reported with beta-blockers. ", "arg1": {"span": [[34, 44]], "type": "Biomedical_Entity", "mmcui": "C0309872", "rxcui": 1076824, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.2"}, "arg2": {"span": [[117, 135]], "type": "Biomedical_Entity", "mmcui": "C3536928", "rxcui": 4740, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.32.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[71, 79]], "type": "Biomedical_Entity", "mmcui": "C2987634", "rxcui": 608609, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.0"}, "arg2": {"span": [[188, 201]], "type": "Biomedical_Entity", "mmcui": "C0022245", "rxcui": 82030, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-1", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[71, 79]], "type": "Biomedical_Entity", "mmcui": "C2987634", "rxcui": 608609, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.0"}, "arg2": {"span": [[174, 184]], "type": "Biomedical_Entity", "mmcui": "C0012963", "rxcui": 203121, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-2", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.3"}, "arg2": {"span": [[71, 79]], "type": "Biomedical_Entity", "mmcui": "C2987634", "rxcui": 608609, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-3", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[174, 184]], "type": "Biomedical_Entity", "mmcui": "C0012963", "rxcui": 203121, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.2"}, "arg2": {"span": [[188, 201]], "type": "Biomedical_Entity", "mmcui": "C0022245", "rxcui": 82030, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-4", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.3"}, "arg2": {"span": [[188, 201]], "type": "Biomedical_Entity", "mmcui": "C0022245", "rxcui": 82030, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34-5", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34", "sentence": "Sectral, like other -blockers, is a competitive inhibitor of -receptor agonists, and its effect on the heart can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol see OVERDOSAGE ). ", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.3"}, "arg2": {"span": [[174, 184]], "type": "Biomedical_Entity", "mmcui": "C0012963", "rxcui": 203121, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.34.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.41-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.41", "sentence": "Abrupt withdrawal of -blockade may precipitate a thyroid storm, therefore, patients suspected of developing thyrotoxicosis from whom Sectral therapy is to be withdrawn should be monitored closely.", "arg1": {"span": [[22, 30]], "type": "Biomedical_Entity", "mmcui": "C3540676", "rxcui": 1423936, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.41.e.0"}, "arg2": {"span": [[133, 140]], "type": "Biomedical_Entity", "mmcui": "C0036543", "rxcui": 9631, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.41.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.44-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.44", "sentence": "While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. ", "arg1": {"span": [[13, 26]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.44.e.1"}, "arg2": {"span": [[100, 109]], "type": "Biomedical_Entity", "mmcui": "C3274161", "rxcui": 1297244, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.44.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.49-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.49", "sentence": "Acebutolol is excreted through the GI tract, but the active metabolite, diacetolol, is eliminated predominantly by the kidney. ", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0000946", "rxcui": 142130, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.49.e.1"}, "arg2": {"span": [[72, 82]], "type": "Biomedical_Entity", "mmcui": "C0057670", "rxcui": "NA", "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.49.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.60-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.60", "sentence": "Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with -blocking agents. ", "arg1": {"span": [[0, 29]], "type": "Drug_Class", "mmcui": "C0007412", "rxcui": 990350, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.60.e.1"}, "arg2": {"span": [[94, 110]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 1023276, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.60.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.62-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.62", "sentence": "Exaggerated hypertensive responses have been reported from the combined use of -adrenergic antagonists and -adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops. ", "arg1": {"span": [[79, 102]], "type": "Drug_Class", "mmcui": "C0242889", "rxcui": 1430615, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.62.e.7"}, "arg2": {"span": [[107, 129]], "type": "Drug_Class", "mmcui": "C0304402", "rxcui": 1430615, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.62.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.64-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.64", "sentence": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.", "arg1": {"span": [[43, 76]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 370, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.64.e.2"}, "arg2": {"span": [[80, 116]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 402125, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.64.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.66-0", "sentence_id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.66", "sentence": "Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. ", "arg1": {"span": [[5, 25]], "type": "Biomedical_Entity", "mmcui": "C0012253", "rxcui": 91235, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.66.e.0"}, "arg2": {"span": [[30, 43]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.7eee95bf-0452-4d6e-9712-33403768695a.s.66.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1", "sentence": "Drug Label for drug brand Revatio, containing sildenafil citrate.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.1"}, "arg2": {"span": [[46, 64]], "type": "Biomedical_Entity", "mmcui": "C0724693", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1", "sentence": "Drug Label for drug brand Revatio, containing sildenafil citrate.", "arg1": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.2"}, "arg2": {"span": [[46, 64]], "type": "Biomedical_Entity", "mmcui": "C0724693", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1-2", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1", "sentence": "Drug Label for drug brand Revatio, containing sildenafil citrate.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.1"}, "arg2": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27", "sentence": "Before prescribing REVATIO, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension BP less than 90/50, fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). ", "arg1": {"span": [[19, 26]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.1"}, "arg2": {"span": [[175, 191]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.27.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28", "sentence": "Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO.", "arg1": {"span": [[45, 74]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 1629, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.0"}, "arg2": {"span": [[80, 87]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.28.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31", "sentence": "Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.2"}, "arg2": {"span": [[121, 128]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31", "sentence": "Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.2"}, "arg2": {"span": [[54, 61]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.31.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36", "sentence": "The incidence of epistaxis was also higher in REVATIO-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).", "arg1": {"span": [[46, 53]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.0"}, "arg2": {"span": [[78, 115]], "type": "Drug_Class", "mmcui": "C2267235", "rxcui": 984607, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.36.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39", "sentence": "When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil. ", "arg1": {"span": [[235, 278]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 8228, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.0"}, "arg2": {"span": [[290, 300]], "type": "Biomedical_Entity", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.39.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42", "sentence": "Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking PDE-5 inhibitors, including REVATIO. ", "arg1": {"span": [[125, 141]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.1"}, "arg2": {"span": [[153, 160]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.42.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43", "sentence": "Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors.", "arg1": {"span": [[193, 205]], "type": "Biomedical_Entity", "mmcui": "C0042402", "rxcui": 11146, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.1"}, "arg2": {"span": [[215, 231]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.43.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44", "sentence": "There are no controlled clinical data on the safety or efficacy of REVATIO in patients with retinitis pigmentosa, a minority whom have genetic disorders of retinal phosphodiesterases. ", "arg1": {"span": [[10, 37]], "type": "Biomedical_Entity", "mmcui": "C1572381", "rxcui": 53704, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.1"}, "arg2": {"span": [[67, 74]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.44.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47", "sentence": "Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including REVATIO. ", "arg1": {"span": [[156, 172]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.1"}, "arg2": {"span": [[184, 191]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.47.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51", "sentence": "Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including REVATIO.", "arg1": {"span": [[113, 129]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.1"}, "arg2": {"span": [[141, 148]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.51.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53", "sentence": "Sildenafil is also marketed as VIAGRA. ", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.1"}, "arg2": {"span": [[31, 37]], "type": "Biomedical_Entity", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.53.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54", "sentence": "The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. ", "arg1": {"span": [[56, 62]], "type": "Biomedical_Entity", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.0"}, "arg2": {"span": [[72, 88]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54", "sentence": "The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. ", "arg1": {"span": [[43, 50]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.2"}, "arg2": {"span": [[56, 62]], "type": "Biomedical_Entity", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54-2", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54", "sentence": "The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. ", "arg1": {"span": [[43, 50]], "type": "Biomedical_Entity", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.2"}, "arg2": {"span": [[72, 88]], "type": "Biomedical_Entity", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.54.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55", "sentence": "Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors.", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2"}, "arg2": {"span": [[59, 75]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55", "sentence": "Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors.", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.2"}, "arg2": {"span": [[43, 49]], "type": "Drug", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55-2", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55", "sentence": "Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors.", "arg1": {"span": [[43, 49]], "type": "Drug", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.3"}, "arg2": {"span": [[59, 75]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.55.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64", "sentence": "<item>Concomitant alpha-blockers or amlodipine: Note additive blood pressure lowering effects. ", "arg1": {"span": [[18, 32]], "type": "Drug_Class", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.2"}, "arg2": {"span": [[36, 46]], "type": "Drug", "mmcui": "C0051696", "rxcui": 104416, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.64.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66", "sentence": "<item>Use with ritonavir and other potent CYP3A inhibitors: Not recommended. ", "arg1": {"span": [[15, 24]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.2"}, "arg2": {"span": [[35, 58]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.66.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68", "sentence": "<item>Concomitant PDE-5 inhibitors: Avoid use with Viagra or other PDE-5 inhibitors. ", "arg1": {"span": [[51, 57]], "type": "Drug", "mmcui": "C0663448", "rxcui": 190465, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.2"}, "arg2": {"span": [[67, 83]], "type": "Drug_Class", "mmcui": "C1318700", "rxcui": 1022271, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.68.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71", "sentence": "Concomitant use of REVATIO with nitrates in any form is contraindicated see Contraindications (4).", "arg1": {"span": [[19, 26]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.0"}, "arg2": {"span": [[32, 40]], "type": "Drug_Class", "rxcui": 202927, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.71.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73", "sentence": "Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended see Clinical Pharmacology (12.3).", "arg1": {"span": [[19, 26]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2"}, "arg2": {"span": [[52, 75]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73", "sentence": "Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended see Clinical Pharmacology (12.3).", "arg1": {"span": [[19, 26]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.2"}, "arg2": {"span": [[32, 41]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73-2", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73", "sentence": "Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended see Clinical Pharmacology (12.3).", "arg1": {"span": [[32, 41]], "type": "Drug", "mmcui": "C0292818", "rxcui": 85762, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.3"}, "arg2": {"span": [[52, 75]], "type": "Drug_Class", "rxcui": 402226, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.73.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76", "sentence": "In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. ", "arg1": {"span": [[79, 92]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1"}, "arg2": {"span": [[93, 102]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76-1", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76", "sentence": "In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. ", "arg1": {"span": [[34, 44]], "type": "Biomedical_Entity", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3"}, "arg2": {"span": [[93, 102]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76-2", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76", "sentence": "In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. ", "arg1": {"span": [[79, 92]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1"}, "arg2": {"span": [[217, 226]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76-3", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76", "sentence": "In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. ", "arg1": {"span": [[34, 44]], "type": "Biomedical_Entity", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3"}, "arg2": {"span": [[79, 92]], "type": "Biomedical_Entity", "mmcui": "C0001641", "rxcui": 1023426, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76-4", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76", "sentence": "In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. ", "arg1": {"span": [[34, 44]], "type": "Biomedical_Entity", "mmcui": "C0529793", "rxcui": 136411, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.3"}, "arg2": {"span": [[217, 226]], "type": "Biomedical_Entity", "mmcui": "C0114873", "rxcui": 39173, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.76.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83-0", "sentence_id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83", "sentence": "Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO see Warnings and Precautions (5.2).", "arg1": {"span": [[45, 74]], "type": "Drug_Class", "mmcui": "C0003364", "rxcui": 1629, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.0"}, "arg2": {"span": [[80, 87]], "type": "Drug", "mmcui": "C1614029", "rxcui": 581642, "id": "Dailymed.f158fe10-d5dc-4432-b2c9-fc665401291b.s.83.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2", "sentence": "Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.0"}, "arg2": {"span": [[144, 152]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2", "sentence": "Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.0"}, "arg2": {"span": [[33, 41]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2", "sentence": "Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.0"}, "arg2": {"span": [[72, 81]], "type": "Biomedical_Entity", "mmcui": "C0120446", "rxcui": 50676, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2-3", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2", "sentence": "Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents.", "arg1": {"span": [[72, 81]], "type": "Biomedical_Entity", "mmcui": "C0120446", "rxcui": 50676, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.3"}, "arg2": {"span": [[144, 152]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2-4", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2", "sentence": "Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents.", "arg1": {"span": [[33, 41]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.2"}, "arg2": {"span": [[72, 81]], "type": "Biomedical_Entity", "mmcui": "C0120446", "rxcui": 50676, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.2.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.5-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.5", "sentence": "Amiloride HCl should not be used in the presence of elevated serum potassium levels (greater than 5.5 mEq per liter).", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.5.e.1"}, "arg2": {"span": [[67, 76]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.5.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.7-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.7", "sentence": "Amiloride HCl should not be given to patients receiving other potassium-conserving agents, such as spironolactone or triamterene. ", "arg1": {"span": [[0, 13]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.7.e.1"}, "arg2": {"span": [[62, 89]], "type": "Drug_Class", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.7.e.0"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[0, 25]], "type": "Drug_Class", "mmcui": "C0561938", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.0"}, "arg2": {"span": [[140, 153]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[96, 115]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.2"}, "arg2": {"span": [[140, 153]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[53, 90]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.1"}, "arg2": {"span": [[140, 153]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-3", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[0, 25]], "type": "Drug_Class", "mmcui": "C0561938", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.0"}, "arg2": {"span": [[96, 115]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-4", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[0, 25]], "type": "Drug_Class", "mmcui": "C0561938", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.0"}, "arg2": {"span": [[53, 90]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8-5", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8", "sentence": "Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. ", "arg1": {"span": [[53, 90]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.1"}, "arg2": {"span": [[96, 115]], "type": "Substance", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.10-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.10", "sentence": "If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.", "arg1": {"span": [[3, 28]], "type": "Biomedical_Entity", "mmcui": "C0561938", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.10.e.1"}, "arg2": {"span": [[70, 79]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.10.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13", "sentence": "Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. ", "arg1": {"span": [[61, 65]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 11002, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.1"}, "arg2": {"span": [[271, 283]], "type": "Biomedical_Entity", "mmcui": "C3536863", "rxcui": 3793, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13", "sentence": "Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. ", "arg1": {"span": [[271, 283]], "type": "Biomedical_Entity", "mmcui": "C3536863", "rxcui": 3793, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.0"}, "arg2": {"span": [[301, 304]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 221770, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13", "sentence": "Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. ", "arg1": {"span": [[66, 95]], "type": "Biomedical_Entity", "mmcui": "C3662986", "rxcui": 7456, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.3"}, "arg2": {"span": [[271, 283]], "type": "Biomedical_Entity", "mmcui": "C3536863", "rxcui": 3793, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13-3", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13", "sentence": "Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. ", "arg1": {"span": [[61, 65]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 11002, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.1"}, "arg2": {"span": [[66, 95]], "type": "Biomedical_Entity", "mmcui": "C3662986", "rxcui": 7456, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13-4", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13", "sentence": "Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. ", "arg1": {"span": [[66, 95]], "type": "Biomedical_Entity", "mmcui": "C3662986", "rxcui": 7456, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.3"}, "arg2": {"span": [[301, 304]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 221770, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.13.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19", "sentence": "Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. ", "arg1": {"span": [[40, 49]], "type": "Biomedical_Entity", "mmcui": "C0002502", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19.e.0"}, "arg2": {"span": [[80, 89]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19", "sentence": "Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. ", "arg1": {"span": [[11, 20]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19.e.2"}, "arg2": {"span": [[40, 49]], "type": "Biomedical_Entity", "mmcui": "C0002502", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.19.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.20-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.20", "sentence": "Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. ", "arg1": {"span": [[46, 55]], "type": "Biomedical_Entity", "mmcui": "C0002502", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.20.e.0"}, "arg2": {"span": [[85, 93]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.20.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.22-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.22", "sentence": "When amiloride HCl is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1-2 percent. ", "arg1": {"span": [[5, 18]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.22.e.0"}, "arg2": {"span": [[48, 65]], "type": "Drug_Class", "mmcui": "C0012802", "rxcui": 141801, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.22.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.23-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.23", "sentence": "It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.", "arg1": {"span": [[90, 99]], "type": "Drug", "mmcui": "C0002502", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.23.e.2"}, "arg2": {"span": [[158, 166]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.23.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.32-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.32", "sentence": "If the serum potassium level exceeds 6.5 mEq per liter, active measures should be taken to reduce it. ", "arg1": {"span": [[13, 22]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.32.e.1"}, "arg2": {"span": [[37, 44]], "type": "Biomedical_Entity", "mmcui": "C0378958", "rxcui": "NA", "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.32.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33", "sentence": "Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. ", "arg1": {"span": [[56, 83]], "type": "Biomedical_Entity", "mmcui": "C2987686", "rxcui": 9853, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.1"}, "arg2": {"span": [[106, 153]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33", "sentence": "Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. ", "arg1": {"span": [[106, 153]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.0"}, "arg2": {"span": [[121, 141]], "type": "Biomedical_Entity", "mmcui": "C0356365", "rxcui": 105361, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33", "sentence": "Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. ", "arg1": {"span": [[56, 83]], "type": "Biomedical_Entity", "mmcui": "C2987686", "rxcui": 9853, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.1"}, "arg2": {"span": [[121, 141]], "type": "Biomedical_Entity", "mmcui": "C0356365", "rxcui": 105361, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.33.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37", "sentence": "In diabetic patients, hyperkalemia has been reported with the use of all potassium-conserving diuretics, including amiloride HCl, even in patients without evidence of diabetic nephropathy. ", "arg1": {"span": [[73, 82]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.0"}, "arg2": {"span": [[115, 128]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37", "sentence": "In diabetic patients, hyperkalemia has been reported with the use of all potassium-conserving diuretics, including amiloride HCl, even in patients without evidence of diabetic nephropathy. ", "arg1": {"span": [[73, 82]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.0"}, "arg2": {"span": [[94, 103]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37", "sentence": "In diabetic patients, hyperkalemia has been reported with the use of all potassium-conserving diuretics, including amiloride HCl, even in patients without evidence of diabetic nephropathy. ", "arg1": {"span": [[94, 103]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.2"}, "arg2": {"span": [[115, 128]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.37.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.38-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.38", "sentence": "Therefore, amiloride HCl should be avoided, if possible, in diabetic patients and, if it is used, serum electrolytes and renal function must be monitored frequently.", "arg1": {"span": [[11, 24]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.38.e.0"}, "arg2": {"span": [[104, 116]], "type": "Biomedical_Entity", "mmcui": "C0013832", "rxcui": 3793, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.38.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.39-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.39", "sentence": "Amiloride HCl should be discontinued at least three days before glucose tolerance testing.", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.39.e.0"}, "arg2": {"span": [[64, 71]], "type": "Biomedical_Entity", "mmcui": "C0017725", "rxcui": 4850, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.39.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.47-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.47", "sentence": "Hyponatremia and hypochloremia may occur when amiloride HCl is used with other diuretics and increases in BUN levels have been reported. ", "arg1": {"span": [[46, 59]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.47.e.4"}, "arg2": {"span": [[79, 88]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.47.e.5"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.49-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.49", "sentence": "Therefore, when amiloride HCl is given with other diuretics to such patients, careful monitoring of serum electrolytes and BUN levels is important. ", "arg1": {"span": [[16, 29]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.49.e.0"}, "arg2": {"span": [[50, 59]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.49.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.50-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.50", "sentence": "In patients with pre-existing severe liver disease, hepatic encephalopathy, manifested by tremors, confusion, and coma, and increased jaundice, have been reported in association with diuretics, including amiloride HCl.", "arg1": {"span": [[183, 192]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.50.e.1"}, "arg2": {"span": [[204, 217]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.50.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.58-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.58", "sentence": "Therefore, when amiloride HCl and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. ", "arg1": {"span": [[16, 29]], "type": "Drug", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.58.e.0"}, "arg2": {"span": [[34, 72]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 1005832, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.58.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.59-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.59", "sentence": "Since indomethacin and potassium-sparing diuretics, including amiloride HCl, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "arg1": {"span": [[6, 18]], "type": "Drug", "mmcui": "C0021246", "rxcui": 5781, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.59.e.0"}, "arg2": {"span": [[23, 50]], "type": "Drug_Class", "mmcui": "C0304490", "rxcui": 1437061, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.59.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62", "sentence": "Amiloride HCl, one 5 mg tablet daily, should be added to the usual antihypertensive or diuretic dosage of a kaliuretic diuretic. ", "arg1": {"span": [[67, 83]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.0"}, "arg2": {"span": [[87, 95]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62-1", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62", "sentence": "Amiloride HCl, one 5 mg tablet daily, should be added to the usual antihypertensive or diuretic dosage of a kaliuretic diuretic. ", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.2"}, "arg2": {"span": [[67, 83]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62-2", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62", "sentence": "Amiloride HCl, one 5 mg tablet daily, should be added to the usual antihypertensive or diuretic dosage of a kaliuretic diuretic. ", "arg1": {"span": [[0, 13]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.2"}, "arg2": {"span": [[87, 95]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.62.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.66-0", "sentence_id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.66", "sentence": "In treating patients with congestive heart failure after an initial diuresis has been achieved, potassium loss may also decrease and the need for amiloride HCl should be re-evaluated. ", "arg1": {"span": [[96, 105]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.66.e.1"}, "arg2": {"span": [[146, 159]], "type": "Biomedical_Entity", "mmcui": "C0546849", "rxcui": 142424, "id": "Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.66.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1", "sentence": "Drug Label for drug brand Trental, containing pentoxifylline.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.1"}, "arg2": {"span": [[46, 60]], "type": "Biomedical_Entity", "mmcui": "C0030899", "rxcui": 8013, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1-1", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1", "sentence": "Drug Label for drug brand Trental, containing pentoxifylline.", "arg1": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.2"}, "arg2": {"span": [[46, 60]], "type": "Biomedical_Entity", "mmcui": "C0030899", "rxcui": 8013, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1-2", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1", "sentence": "Drug Label for drug brand Trental, containing pentoxifylline.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.1"}, "arg2": {"span": [[26, 33]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.0"}, "arg2": {"span": [[162, 177]], "type": "Biomedical_Entity", "mmcui": "C0066447", "rxcui": 29933, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-1", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.0"}, "arg2": {"span": [[196, 208]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-2", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.0"}, "arg2": {"span": [[214, 225]], "type": "Biomedical_Entity", "mmcui": "C0039763", "rxcui": 10437, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-3", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.0"}, "arg2": {"span": [[186, 194]], "type": "Biomedical_Entity", "mmcui": "C0006644", "rxcui": 236112, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-4", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[162, 177]], "type": "Biomedical_Entity", "mmcui": "C0066447", "rxcui": 29933, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.1"}, "arg2": {"span": [[196, 208]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-5", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[162, 177]], "type": "Biomedical_Entity", "mmcui": "C0066447", "rxcui": 29933, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.1"}, "arg2": {"span": [[214, 225]], "type": "Biomedical_Entity", "mmcui": "C0039763", "rxcui": 10437, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-6", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[162, 177]], "type": "Biomedical_Entity", "mmcui": "C0066447", "rxcui": 29933, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.1"}, "arg2": {"span": [[186, 194]], "type": "Biomedical_Entity", "mmcui": "C0006644", "rxcui": 236112, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-7", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[196, 208]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.2"}, "arg2": {"span": [[214, 225]], "type": "Biomedical_Entity", "mmcui": "C0039763", "rxcui": 10437, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-8", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[186, 194]], "type": "Biomedical_Entity", "mmcui": "C0006644", "rxcui": 236112, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.4"}, "arg2": {"span": [[196, 208]], "type": "Biomedical_Entity", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3-9", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3", "sentence": "TRENTAL should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.", "arg1": {"span": [[186, 194]], "type": "Biomedical_Entity", "mmcui": "C0006644", "rxcui": 236112, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.4"}, "arg2": {"span": [[214, 225]], "type": "Biomedical_Entity", "mmcui": "C0039763", "rxcui": 10437, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.9-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.9", "sentence": "Controlled trials do not show that TRENTAL causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses. ", "arg1": {"span": [[35, 42]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.9.e.1"}, "arg2": {"span": [[112, 126]], "type": "Biomedical_Entity", "mmcui": "C3536939", "rxcui": 29933, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.9.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[177, 191]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.1"}, "arg2": {"span": [[195, 226]], "type": "Biomedical_Entity", "mmcui": "C0032177", "rxcui": 42402, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-1", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[110, 121]], "type": "Biomedical_Entity", "mmcui": "C2828369", "rxcui": 1441688, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.2"}, "arg2": {"span": [[195, 226]], "type": "Biomedical_Entity", "mmcui": "C0032177", "rxcui": 42402, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-2", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[152, 159]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.3"}, "arg2": {"span": [[195, 226]], "type": "Biomedical_Entity", "mmcui": "C0032177", "rxcui": 42402, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-3", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[110, 121]], "type": "Biomedical_Entity", "mmcui": "C2828369", "rxcui": 1441688, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.2"}, "arg2": {"span": [[177, 191]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-4", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[152, 159]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.3"}, "arg2": {"span": [[177, 191]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12-5", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12", "sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "arg1": {"span": [[110, 121]], "type": "Biomedical_Entity", "mmcui": "C2828369", "rxcui": 1441688, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.2"}, "arg2": {"span": [[152, 159]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.12.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.19-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.19", "sentence": "Postmarketing cases of increased anticoagulant activity have been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. ", "arg1": {"span": [[114, 128]], "type": "Drug", "mmcui": "C0030899", "rxcui": 8013, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.19.e.3"}, "arg2": {"span": [[133, 154]], "type": "Drug_Class", "mmcui": "C3653316", "rxcui": 604318, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.19.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.35-0", "sentence_id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.35", "sentence": "TRENTAL (pentoxifylline) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C0699487", "rxcui": 202727, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.35.e.1"}, "arg2": {"span": [[9, 23]], "type": "Biomedical_Entity", "mmcui": "C0030899", "rxcui": 8013, "id": "Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.35.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1", "sentence": "Drug Label for drug brand Microzide, containing Hydrochlorothiazide.", "arg1": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.1"}, "arg2": {"span": [[48, 67]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1", "sentence": "Drug Label for drug brand Microzide, containing Hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.2"}, "arg2": {"span": [[48, 67]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1-2", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1", "sentence": "Drug Label for drug brand Microzide, containing Hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.2"}, "arg2": {"span": [[26, 35]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3", "sentence": "<main>MICROZIDE (hydrochlorothiazide, USP) Capsules 12.5 mg is the 3,4-dihydro derivative of chlorothiazide. ", "arg1": {"span": [[6, 15]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.0"}, "arg2": {"span": [[17, 36]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3", "sentence": "<main>MICROZIDE (hydrochlorothiazide, USP) Capsules 12.5 mg is the 3,4-dihydro derivative of chlorothiazide. ", "arg1": {"span": [[6, 15]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.0"}, "arg2": {"span": [[93, 107]], "type": "Biomedical_Entity", "mmcui": "C0008273", "rxcui": 2396, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3-2", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3", "sentence": "<main>MICROZIDE (hydrochlorothiazide, USP) Capsules 12.5 mg is the 3,4-dihydro derivative of chlorothiazide. ", "arg1": {"span": [[17, 36]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.1"}, "arg2": {"span": [[93, 107]], "type": "Biomedical_Entity", "mmcui": "C0008273", "rxcui": 2396, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4", "sentence": "Its chemical name is 6-chloro-3,4-dihydro-2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. ", "arg1": {"span": [[52, 68]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 1414, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.0"}, "arg2": {"span": [[71, 82]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4", "sentence": "Its chemical name is 6-chloro-3,4-dihydro-2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. ", "arg1": {"span": [[52, 68]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 1414, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.0"}, "arg2": {"span": [[87, 94]], "type": "Biomedical_Entity", "mmcui": "C0678717", "rxcui": 29263, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4-2", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4", "sentence": "Its chemical name is 6-chloro-3,4-dihydro-2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. ", "arg1": {"span": [[71, 82]], "type": "Biomedical_Entity", "mmcui": "C0599503", "rxcui": 1427600, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.1"}, "arg2": {"span": [[87, 94]], "type": "Biomedical_Entity", "mmcui": "C0678717", "rxcui": 29263, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.4.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[68, 87]], "type": "Biomedical_Entity", "mmcui": "C1658042", "rxcui": 6211, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.1"}, "arg2": {"span": [[89, 107]], "type": "Biomedical_Entity", "mmcui": "C0126791", "rxcui": 6574, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[55, 66]], "type": "Biomedical_Entity", "mmcui": "C1384515", "rxcui": 892547, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.2"}, "arg2": {"span": [[89, 107]], "type": "Biomedical_Entity", "mmcui": "C0126791", "rxcui": 6574, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-2", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[28, 53]], "type": "Biomedical_Entity", "mmcui": "C0982384", "rxcui": 221082, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.3"}, "arg2": {"span": [[89, 107]], "type": "Biomedical_Entity", "mmcui": "C0126791", "rxcui": 6574, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-3", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[55, 66]], "type": "Biomedical_Entity", "mmcui": "C1384515", "rxcui": 892547, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.2"}, "arg2": {"span": [[68, 87]], "type": "Biomedical_Entity", "mmcui": "C1658042", "rxcui": 6211, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-4", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[28, 53]], "type": "Biomedical_Entity", "mmcui": "C0982384", "rxcui": 221082, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.3"}, "arg2": {"span": [[68, 87]], "type": "Biomedical_Entity", "mmcui": "C1658042", "rxcui": 6211, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8-5", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8", "sentence": "<item>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. ", "arg1": {"span": [[28, 53]], "type": "Biomedical_Entity", "mmcui": "C0982384", "rxcui": 221082, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.3"}, "arg2": {"span": [[55, 66]], "type": "Biomedical_Entity", "mmcui": "C1384515", "rxcui": 892547, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.12-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.12", "sentence": "1, gelatin, titanium dioxide. ", "arg1": {"span": [[3, 10]], "type": "Biomedical_Entity", "mmcui": "C0017237", "rxcui": 4716, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.12.e.0"}, "arg2": {"span": [[12, 28]], "type": "Biomedical_Entity", "mmcui": "C0076733", "rxcui": 1305547, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.12.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.23-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.23", "sentence": "Acute Myopia and Secondary Angle-Closure Glaucoma: Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. ", "arg1": {"span": [[51, 70]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.23.e.1"}, "arg2": {"span": [[74, 85]], "type": "Biomedical_Entity", "mmcui": "C3536763", "rxcui": 1427600, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.23.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.29-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.29", "sentence": "Diabetes and Hypoglycemia: Latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose.", "arg1": {"span": [[100, 109]], "type": "Drug_Class", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.29.e.0"}, "arg2": {"span": [[142, 149]], "type": "Drug", "mmcui": "C0021641", "rxcui": 5856, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.29.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.33-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.33", "sentence": "Electrolyte and Fluid Balance Status: In published studies, clinically significant hypokalemia has been consistently less common in patients who received 12.5 mg of hydrochlorothiazide than in patients who received higher doses. ", "arg1": {"span": [[0, 11]], "type": "Biomedical_Entity", "mmcui": "C3536863", "rxcui": 3793, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.33.e.1"}, "arg2": {"span": [[154, 184]], "type": "Biomedical_Entity", "mmcui": "C0986524", "rxcui": "NA", "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.33.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.37-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.37", "sentence": "Hypokalemia may develop, especially with brisk diuresis when severe cirrhosis is present, during concomitant use of corticosteroid or adrenocorticotropic hormone (ACTH) or after prolonged therapy. ", "arg1": {"span": [[116, 130]], "type": "Drug_Class", "mmcui": "C0001617", "rxcui": 1427675, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.37.e.2"}, "arg2": {"span": [[134, 168]], "type": "Drug", "mmcui": "C0001655", "rxcui": 376, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.37.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.40-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.40", "sentence": "Hypokalemia may be avoided or treated by potassium supplementation or increased intake of potassium rich foods.", "arg1": {"span": [[41, 66]], "type": "Biomedical_Entity", "mmcui": "C0561938", "rxcui": 8588, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.40.e.1"}, "arg2": {"span": [[90, 99]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.40.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46", "sentence": "Parathyroid Disease: Calcium excretion is decreased by thiazides, and pathologic changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have been observed in a few patients on prolonged thiazide therapy.", "arg1": {"span": [[21, 28]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46.e.1"}, "arg2": {"span": [[207, 215]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46", "sentence": "Parathyroid Disease: Calcium excretion is decreased by thiazides, and pathologic changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have been observed in a few patients on prolonged thiazide therapy.", "arg1": {"span": [[21, 28]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46.e.1"}, "arg2": {"span": [[55, 64]], "type": "Biomedical_Entity", "mmcui": "C0541746", "rxcui": 141801, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.46.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48", "sentence": "Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur.", "arg1": {"span": [[0, 7]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.0"}, "arg2": {"span": [[26, 35]], "type": "Drug_Class", "mmcui": "C0027415", "rxcui": 992359, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48", "sentence": "Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur.", "arg1": {"span": [[9, 21]], "type": "Drug_Class", "mmcui": "C0004745", "rxcui": 1437144, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.1"}, "arg2": {"span": [[26, 35]], "type": "Drug_Class", "mmcui": "C0027415", "rxcui": 992359, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48-2", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48", "sentence": "Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur.", "arg1": {"span": [[0, 7]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.0"}, "arg2": {"span": [[9, 21]], "type": "Drug_Class", "mmcui": "C0004745", "rxcui": 1437144, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.48.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51", "sentence": "Cholestyramine and colestipol resins - Cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "arg1": {"span": [[39, 53]], "type": "Drug", "mmcui": "C0008402", "rxcui": 2447, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51.e.0"}, "arg2": {"span": [[58, 75]], "type": "Drug_Class", "mmcui": "C0009279", "rxcui": 104485, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.52-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.52", "sentence": "Corticosteroid, ACTH intensified electrolyte depletion, particularly hypokalemia.", "arg1": {"span": [[0, 14]], "type": "Drug_Class", "mmcui": "C0001617", "rxcui": 1427675, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.52.e.0"}, "arg2": {"span": [[16, 20]], "type": "Drug", "rxcui": 376, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.52.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.55-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.55", "sentence": "Lithium - generally should not be given with diuretics. ", "arg1": {"span": [[0, 7]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.55.e.2"}, "arg2": {"span": [[45, 54]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.55.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56", "sentence": "Diuretic agents reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity. ", "arg1": {"span": [[0, 15]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.0"}, "arg2": {"span": [[46, 53]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.5"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56-1", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56", "sentence": "Diuretic agents reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity. ", "arg1": {"span": [[0, 15]], "type": "Drug_Class", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.0"}, "arg2": {"span": [[87, 94]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.6"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.57-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.57", "sentence": "Refer to the package insert for lithium preparations before use of such preparations with MICROZIDE.", "arg1": {"span": [[32, 39]], "type": "Biomedical_Entity", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.57.e.0"}, "arg2": {"span": [[90, 99]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.57.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.59-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.59", "sentence": "When MICROZIDE and non-steroidal anti-inflammatory agents are used concomitantly, the patients should be observed closely to determine if the desired effect of the diuretic is obtained.", "arg1": {"span": [[5, 14]], "type": "Drug", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.59.e.0"}, "arg2": {"span": [[19, 57]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 1005832, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.59.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.74-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.74", "sentence": "A greater blood pressure reduction and an increase in side effects may be observed in the elderly (i.e., 65 years) with hydrochlorothiazide. ", "arg1": {"span": [[99, 107]], "type": "Biomedical_Entity", "mmcui": "C0063251", "rxcui": "NA", "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.74.e.0"}, "arg2": {"span": [[120, 139]], "type": "Biomedical_Entity", "mmcui": "C0020261", "rxcui": 5487, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.74.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.78-0", "sentence_id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.78", "sentence": "For Control of Hypertension: The adult initial dose of MICROZIDE is one capsule given once daily whether given alone or in combination with other antihypertensives. ", "arg1": {"span": [[55, 64]], "type": "Biomedical_Entity", "mmcui": "C0721720", "rxcui": 218369, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.78.e.0"}, "arg2": {"span": [[146, 163]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.78.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1", "sentence": "PRADAXA (dabigatran etexilate mesylate) capsule", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.1"}, "arg2": {"span": [[9, 38]], "type": "Biomedical_Entity", "mmcui": "C2343849", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2", "sentence": "The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is  -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate.", "arg1": {"span": [[22, 51]], "type": "Biomedical_Entity", "mmcui": "C2343849", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.0"}, "arg2": {"span": [[55, 80]], "type": "Biomedical_Entity", "mmcui": "C0003440", "rxcui": 3525, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11", "sentence": "If PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant [see Dosage and Administration (2.6)].", "arg1": {"span": [[3, 10]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.0"}, "arg2": {"span": [[110, 123]], "type": "Biomedical_Entity", "mmcui": "C3536711", "rxcui": 923, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17", "sentence": "PRADAXA s anticoagulant activity and half-life are increased in patients with renal impairment [see Clinical Pharmacology (12.2)].", "arg1": {"span": [[0, 7]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.1"}, "arg2": {"span": [[10, 23]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[57, 62]], "type": "Biomedical_Entity", "mmcui": "C0082559", "rxcui": 968897, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0"}, "arg2": {"span": [[136, 138]], "type": "Biomedical_Entity", "mmcui": "C0015491", "rxcui": 4249, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[57, 62]], "type": "Biomedical_Entity", "mmcui": "C0082559", "rxcui": 968897, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0"}, "arg2": {"span": [[68, 91]], "type": "Biomedical_Entity", "mmcui": "C0534191", "rxcui": 8410, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[0, 42]], "type": "Biomedical_Entity", "mmcui": "C0358606", "rxcui": 751543, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3"}, "arg2": {"span": [[57, 62]], "type": "Biomedical_Entity", "mmcui": "C0082559", "rxcui": 968897, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[57, 62]], "type": "Biomedical_Entity", "mmcui": "C0082559", "rxcui": 968897, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0"}, "arg2": {"span": [[112, 134]], "type": "Biomedical_Entity", "mmcui": "C0033706", "rxcui": 1637, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[68, 91]], "type": "Biomedical_Entity", "mmcui": "C0534191", "rxcui": 8410, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"}, "arg2": {"span": [[136, 138]], "type": "Biomedical_Entity", "mmcui": "C0015491", "rxcui": 4249, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[0, 42]], "type": "Biomedical_Entity", "mmcui": "C0358606", "rxcui": 751543, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3"}, "arg2": {"span": [[136, 138]], "type": "Biomedical_Entity", "mmcui": "C0015491", "rxcui": 4249, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-6", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[112, 134]], "type": "Biomedical_Entity", "mmcui": "C0033706", "rxcui": 1637, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"}, "arg2": {"span": [[136, 138]], "type": "Biomedical_Entity", "mmcui": "C0015491", "rxcui": 4249, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-7", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[0, 42]], "type": "Biomedical_Entity", "mmcui": "C0358606", "rxcui": 751543, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3"}, "arg2": {"span": [[68, 91]], "type": "Biomedical_Entity", "mmcui": "C0534191", "rxcui": 8410, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-8", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[68, 91]], "type": "Biomedical_Entity", "mmcui": "C0534191", "rxcui": 8410, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"}, "arg2": {"span": [[112, 134]], "type": "Biomedical_Entity", "mmcui": "C0033706", "rxcui": 1637, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21-9", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21", "sentence": "Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. ", "arg1": {"span": [[0, 42]], "type": "Biomedical_Entity", "mmcui": "C0358606", "rxcui": 751543, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3"}, "arg2": {"span": [[112, 134]], "type": "Biomedical_Entity", "mmcui": "C0033706", "rxcui": 1637, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0042878", "rxcui": 604318, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1"}, "arg2": {"span": [[89, 99]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[63, 76]], "type": "Biomedical_Entity", "mmcui": "C3536711", "rxcui": 923, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2"}, "arg2": {"span": [[89, 99]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[0, 17]], "type": "Biomedical_Entity", "mmcui": "C0033602", "rxcui": 236471, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3"}, "arg2": {"span": [[89, 99]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0042878", "rxcui": 604318, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1"}, "arg2": {"span": [[63, 76]], "type": "Biomedical_Entity", "mmcui": "C3536711", "rxcui": 923, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[0, 17]], "type": "Biomedical_Entity", "mmcui": "C0033602", "rxcui": 236471, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3"}, "arg2": {"span": [[22, 31]], "type": "Biomedical_Entity", "mmcui": "C0042878", "rxcui": 604318, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22", "sentence": "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. ", "arg1": {"span": [[0, 17]], "type": "Biomedical_Entity", "mmcui": "C0033602", "rxcui": 236471, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3"}, "arg2": {"span": [[63, 76]], "type": "Biomedical_Entity", "mmcui": "C3536711", "rxcui": 923, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23", "sentence": "Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs have been used.", "arg1": {"span": [[27, 48]], "type": "Biomedical_Entity", "mmcui": "C2362067", "rxcui": 42402, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.1"}, "arg2": {"span": [[107, 125]], "type": "Biomedical_Entity", "mmcui": "C0085826", "rxcui": 42539, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25", "sentence": "The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. ", "arg1": {"span": [[121, 126]], "type": "Biomedical_Entity", "mmcui": "C2369992", "rxcui": 827148, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0"}, "arg2": {"span": [[347, 354]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25", "sentence": "The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. ", "arg1": {"span": [[121, 126]], "type": "Biomedical_Entity", "mmcui": "C2369992", "rxcui": 827148, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0"}, "arg2": {"span": [[312, 320]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25", "sentence": "The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.3"}, "arg2": {"span": [[121, 126]], "type": "Biomedical_Entity", "mmcui": "C2369992", "rxcui": 827148, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25", "sentence": "The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. ", "arg1": {"span": [[312, 320]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2"}, "arg2": {"span": [[347, 354]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25", "sentence": "The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. ", "arg1": {"span": [[27, 34]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.3"}, "arg2": {"span": [[312, 320]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26", "sentence": "RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm. ", "arg1": {"span": [[319, 326]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.1"}, "arg2": {"span": [[360, 368]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26", "sentence": "RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm. ", "arg1": {"span": [[3, 8]], "type": "Biomedical_Entity", "mmcui": "C2369992", "rxcui": 827148, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.2"}, "arg2": {"span": [[360, 368]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26", "sentence": "RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm. ", "arg1": {"span": [[3, 8]], "type": "Biomedical_Entity", "mmcui": "C2369992", "rxcui": 827148, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.2"}, "arg2": {"span": [[319, 326]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30", "sentence": "5.4 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure", "arg1": {"span": [[2, 18]], "type": "Biomedical_Entity", "mmcui": "C0061833", "rxcui": "NA", "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.1"}, "arg2": {"span": [[46, 56]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31", "sentence": "The concomitant use of PRADAXA with P-gp inducers (e.g. rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)].", "arg1": {"span": [[36, 49]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1"}, "arg2": {"span": [[86, 96]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.6"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33", "sentence": "Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.", "arg1": {"span": [[19, 34]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.0"}, "arg2": {"span": [[114, 124]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34", "sentence": "Consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA in patients with moderate renal impairment (CrCl 30-50 mL/min). ", "arg1": {"span": [[79, 100]], "type": "Drug", "mmcui": "C0022625", "rxcui": 691707, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4"}, "arg2": {"span": [[124, 131]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34", "sentence": "Consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA in patients with moderate renal impairment (CrCl 30-50 mL/min). ", "arg1": {"span": [[64, 75]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3"}, "arg2": {"span": [[124, 131]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34", "sentence": "Consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA in patients with moderate renal impairment (CrCl 30-50 mL/min). ", "arg1": {"span": [[64, 75]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3"}, "arg2": {"span": [[79, 100]], "type": "Drug", "mmcui": "C0022625", "rxcui": 691707, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35", "sentence": "Avoid use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7) and Use in Specific Populations (8.6)].", "arg1": {"span": [[13, 20]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.3"}, "arg2": {"span": [[25, 40]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37", "sentence": "The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)].", "arg1": {"span": [[36, 49]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1"}, "arg2": {"span": [[87, 97]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.6"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39", "sentence": "Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.", "arg1": {"span": [[19, 34]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.0"}, "arg2": {"span": [[114, 124]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40", "sentence": "In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitor dronedarone or systemic ketoconazole. ", "arg1": {"span": [[94, 101]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3"}, "arg2": {"span": [[194, 215]], "type": "Drug", "mmcui": "C0022625", "rxcui": 691707, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40", "sentence": "In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitor dronedarone or systemic ketoconazole. ", "arg1": {"span": [[94, 101]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3"}, "arg2": {"span": [[179, 190]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40", "sentence": "In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitor dronedarone or systemic ketoconazole. ", "arg1": {"span": [[179, 190]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5"}, "arg2": {"span": [[194, 215]], "type": "Drug", "mmcui": "C0022625", "rxcui": 691707, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[39, 49]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1"}, "arg2": {"span": [[66, 80]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[28, 37]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2"}, "arg2": {"span": [[66, 80]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[66, 80]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"}, "arg2": {"span": [[120, 127]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[51, 60]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"}, "arg2": {"span": [[66, 80]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[28, 37]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2"}, "arg2": {"span": [[39, 49]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[39, 49]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1"}, "arg2": {"span": [[120, 127]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-6", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[39, 49]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1"}, "arg2": {"span": [[51, 60]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-7", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[28, 37]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2"}, "arg2": {"span": [[120, 127]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-8", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[28, 37]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2"}, "arg2": {"span": [[51, 60]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41-9", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41", "sentence": "The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. ", "arg1": {"span": [[51, 60]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"}, "arg2": {"span": [[120, 127]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43", "sentence": "The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided [see Warnings and Precautions (5.4), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].", "arg1": {"span": [[23, 30]], "type": "Drug", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.0"}, "arg2": {"span": [[35, 50]], "type": "Drug_Class", "rxcui": 71576, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46", "sentence": "Rifampin: Rifampin 600 mg once daily for 7 days followed by a single dose of dabigatran decreased its AUC and Cmax by 66% and 67%, respectively. ", "arg1": {"span": [[10, 18]], "type": "Drug", "mmcui": "C1104996", "rxcui": 9384, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.0"}, "arg2": {"span": [[77, 87]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.1"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47", "sentence": "By Day 7 after cessation of rifampin treatment, dabigatran exposure was close to normal [see Warnings and Precautions (5.4) and Drug Interactions (7)].", "arg1": {"span": [[28, 36]], "type": "Biomedical_Entity", "mmcui": "C0035608", "rxcui": 9384, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.0"}, "arg2": {"span": [[48, 58]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[36, 48]], "type": "Biomedical_Entity", "mmcui": "C0022625", "rxcui": 6135, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0"}, "arg2": {"span": [[50, 60]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[36, 48]], "type": "Biomedical_Entity", "mmcui": "C0022625", "rxcui": 6135, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0"}, "arg2": {"span": [[77, 86]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[36, 48]], "type": "Biomedical_Entity", "mmcui": "C0022625", "rxcui": 6135, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0"}, "arg2": {"span": [[62, 71]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[36, 48]], "type": "Biomedical_Entity", "mmcui": "C0022625", "rxcui": 6135, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0"}, "arg2": {"span": [[153, 163]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[50, 60]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1"}, "arg2": {"span": [[77, 86]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[50, 60]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1"}, "arg2": {"span": [[62, 71]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-6", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[50, 60]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1"}, "arg2": {"span": [[153, 163]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-7", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[62, 71]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"}, "arg2": {"span": [[77, 86]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-8", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[77, 86]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"}, "arg2": {"span": [[153, 163]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49-9", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49", "sentence": "In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. ", "arg1": {"span": [[62, 71]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"}, "arg2": {"span": [[153, 163]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51", "sentence": "Dronedarone: Simultaneous administration of dabigatran etexilate and dronedarone (administered once or twice daily) increases exposure to dabigatran by 70 to 140% compared to dabigatran alone. ", "arg1": {"span": [[69, 80]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.1"}, "arg2": {"span": [[138, 148]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52", "sentence": "The increase in exposure is only 30 to 60% higher compared to dabigatran alone when dronedarone is administered 2 hours after dabigatran etexilate.", "arg1": {"span": [[84, 95]], "type": "Drug", "mmcui": "C0766326", "rxcui": 233698, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.2"}, "arg2": {"span": [[126, 146]], "type": "Drug", "mmcui": "C1571583", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53", "sentence": "Ketoconazole: Systemic ketoconazole increased dabigatran AUC and Cmax values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg.", "arg1": {"span": [[14, 35]], "type": "Drug", "mmcui": "C0022625", "rxcui": 691707, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.3"}, "arg2": {"span": [[46, 56]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54", "sentence": "Verapamil: When dabigatran etexilate was coadministered with oral verapamil, the Cmax and AUC of dabigatran were increased. ", "arg1": {"span": [[61, 75]], "type": "Drug", "mmcui": "C0042523", "rxcui": "NA", "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.4"}, "arg2": {"span": [[97, 107]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57", "sentence": "If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible. ", "arg1": {"span": [[3, 12]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.1"}, "arg2": {"span": [[36, 46]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58", "sentence": "In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received verapamil.", "arg1": {"span": [[77, 87]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.1"}, "arg2": {"span": [[141, 150]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60", "sentence": "The increase in exposure was mitigated by a 65% increase in the renal clearance of dabigatran in the presence of amiodarone. ", "arg1": {"span": [[83, 93]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.2"}, "arg2": {"span": [[113, 123]], "type": "Drug", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.3"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62", "sentence": "In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone.", "arg1": {"span": [[77, 87]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.0"}, "arg2": {"span": [[141, 151]], "type": "Biomedical_Entity", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64", "sentence": "Dabigatran etexilate was given over 3 consecutive days, the last evening dose on Day 3 with or without quinidine pre-dosing. ", "arg1": {"span": [[0, 20]], "type": "Biomedical_Entity", "mmcui": "C1571583", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.0"}, "arg2": {"span": [[103, 112]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65", "sentence": "Concomitant quinidine administration increased dabigatran s AUC and Cmax by 53% and 56%, respectively.", "arg1": {"span": [[12, 21]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.0"}, "arg2": {"span": [[47, 57]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66", "sentence": "Clarithromycin: Coadministered clarithromycin had no impact on the exposure to dabigatran.", "arg1": {"span": [[0, 14]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.0"}, "arg2": {"span": [[79, 89]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66", "sentence": "Clarithromycin: Coadministered clarithromycin had no impact on the exposure to dabigatran.", "arg1": {"span": [[31, 45]], "type": "Biomedical_Entity", "mmcui": "C0055856", "rxcui": 21212, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.1"}, "arg2": {"span": [[79, 89]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68", "sentence": "Clopidogrel: When dabigatran etexilate was given concomitantly with a loading dose of 300 mg or 600 mg clopidogrel, the dabigatran AUC and Cmax increased by approximately 30% and 40%, respectively. ", "arg1": {"span": [[103, 114]], "type": "Drug", "mmcui": "C0070166", "rxcui": 236991, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.4"}, "arg2": {"span": [[120, 130]], "type": "Drug", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69", "sentence": "The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. ", "arg1": {"span": [[34, 54]], "type": "Biomedical_Entity", "mmcui": "C1571583", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.2"}, "arg2": {"span": [[147, 158]], "type": "Biomedical_Entity", "mmcui": "C0070166", "rxcui": 236991, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69", "sentence": "The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. ", "arg1": {"span": [[34, 54]], "type": "Biomedical_Entity", "mmcui": "C1571583", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.2"}, "arg2": {"span": [[59, 70]], "type": "Biomedical_Entity", "mmcui": "C0070166", "rxcui": 236991, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70", "sentence": "When comparing combined treatment and the respective mono-treatments, the coagulation measures for dabigatran s effect (aPTT, ECT, and TT) remained unchanged, and inhibition of platelet aggregation (IPA), a measurement of clopidogrel s effect, remained unchanged.", "arg1": {"span": [[99, 109]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.1"}, "arg2": {"span": [[222, 233]], "type": "Biomedical_Entity", "mmcui": "C0070166", "rxcui": 236991, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71", "sentence": "Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.", "arg1": {"span": [[12, 22]], "type": "Biomedical_Entity", "mmcui": "C0206460", "rxcui": 67108, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.0"}, "arg2": {"span": [[160, 170]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71", "sentence": "Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.", "arg1": {"span": [[12, 22]], "type": "Biomedical_Entity", "mmcui": "C0206460", "rxcui": 67108, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.0"}, "arg2": {"span": [[119, 126]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71", "sentence": "Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0206460", "rxcui": 67108, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.2"}, "arg2": {"span": [[160, 170]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71", "sentence": "Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.", "arg1": {"span": [[119, 126]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3"}, "arg2": {"span": [[160, 170]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71", "sentence": "Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0206460", "rxcui": 67108, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.2"}, "arg2": {"span": [[119, 126]], "type": "Biomedical_Entity", "mmcui": "C2940579", "rxcui": 1037046, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0012091", "rxcui": 3355, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1"}, "arg2": {"span": [[12, 22]], "type": "Biomedical_Entity", "mmcui": "C0034665", "rxcui": 203136, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[12, 22]], "type": "Biomedical_Entity", "mmcui": "C0034665", "rxcui": 203136, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0"}, "arg2": {"span": [[76, 86]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[12, 22]], "type": "Biomedical_Entity", "mmcui": "C0034665", "rxcui": 203136, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0"}, "arg2": {"span": [[28, 35]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0012091", "rxcui": 3355, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1"}, "arg2": {"span": [[76, 86]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0012091", "rxcui": 3355, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1"}, "arg2": {"span": [[28, 35]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72", "sentence": "Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.", "arg1": {"span": [[28, 35]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3"}, "arg2": {"span": [[76, 86]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-0", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[23, 45]], "type": "Biomedical_Entity", "mmcui": "C0358591", "rxcui": 8879, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1"}, "arg2": {"span": [[67, 74]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-1", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[47, 61]], "type": "Biomedical_Entity", "mmcui": "C0019593", "rxcui": 34748, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2"}, "arg2": {"span": [[67, 74]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-2", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[67, 74]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0"}, "arg2": {"span": [[130, 140]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-3", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[23, 45]], "type": "Biomedical_Entity", "mmcui": "C0358591", "rxcui": 8879, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1"}, "arg2": {"span": [[47, 61]], "type": "Biomedical_Entity", "mmcui": "C0019593", "rxcui": 34748, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-4", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[23, 45]], "type": "Biomedical_Entity", "mmcui": "C0358591", "rxcui": 8879, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1"}, "arg2": {"span": [[130, 140]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74-5", "sentence_id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74", "sentence": "The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.", "arg1": {"span": [[47, 61]], "type": "Biomedical_Entity", "mmcui": "C0019593", "rxcui": 34748, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2"}, "arg2": {"span": [[130, 140]], "type": "Biomedical_Entity", "mmcui": "C2348066", "rxcui": 814696, "id": "Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1-0", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1", "sentence": "Drug Label for drug brand Thiola, containing tiopronin.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.1"}, "arg2": {"span": [[26, 32]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1-1", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1", "sentence": "Drug Label for drug brand Thiola, containing tiopronin.", "arg1": {"span": [[26, 32]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.0"}, "arg2": {"span": [[45, 54]], "type": "Biomedical_Entity", "mmcui": "C0025405", "rxcui": 6765, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1-2", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1", "sentence": "Drug Label for drug brand Thiola, containing tiopronin.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.1"}, "arg2": {"span": [[45, 54]], "type": "Biomedical_Entity", "mmcui": "C0025405", "rxcui": 6765, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7-0", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7", "sentence": "Despite apparent lower toxicity of THIOLA, THIOLA may potentially cause all the serious adverse reactions reported for d-penicillamine. ", "arg1": {"span": [[43, 49]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7.e.0"}, "arg2": {"span": [[121, 134]], "type": "Biomedical_Entity", "mmcui": "C0030817", "rxcui": 7975, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7-1", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7", "sentence": "Despite apparent lower toxicity of THIOLA, THIOLA may potentially cause all the serious adverse reactions reported for d-penicillamine. ", "arg1": {"span": [[35, 41]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7.e.2"}, "arg2": {"span": [[121, 134]], "type": "Biomedical_Entity", "mmcui": "C0030817", "rxcui": 7975, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.7.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8-0", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8", "sentence": "Thus, although no death has been reported to result directly from THIOLA treatment, a fatal outcome from THIOLA is possible, as has been reported with d-penicillamine therapy from such complications as aplastic anemia, agranulocytosis, thrombocytopenia, Goodpasture s syndrome or myasthenia gravis.", "arg1": {"span": [[105, 111]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8.e.0"}, "arg2": {"span": [[153, 166]], "type": "Biomedical_Entity", "mmcui": "C0030817", "rxcui": 7975, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8-1", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8", "sentence": "Thus, although no death has been reported to result directly from THIOLA treatment, a fatal outcome from THIOLA is possible, as has been reported with d-penicillamine therapy from such complications as aplastic anemia, agranulocytosis, thrombocytopenia, Goodpasture s syndrome or myasthenia gravis.", "arg1": {"span": [[66, 72]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8.e.1"}, "arg2": {"span": [[153, 166]], "type": "Biomedical_Entity", "mmcui": "C0030817", "rxcui": 7975, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.15-0", "sentence_id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.15", "sentence": "The following complications, though rare, have been reported during d-penicillamine therapy and could occur during THIOLA treatment. ", "arg1": {"span": [[70, 83]], "type": "Biomedical_Entity", "mmcui": "C0030817", "rxcui": 7975, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.15.e.0"}, "arg2": {"span": [[115, 121]], "type": "Biomedical_Entity", "mmcui": "C0733414", "rxcui": 227253, "id": "Dailymed.494a714e-923c-cd57-df6c-12886afb265a.s.15.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.1-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.1", "sentence": "DIOVAN (valsartan) tablet", "arg1": {"span": [[0, 6]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.1.e.0"}, "arg2": {"span": [[8, 17]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.4-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.4", "sentence": "Do not coadminister aliskiren with Diovan in patients with diabetes [See Drug Interactions (7)].", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.4.e.2"}, "arg2": {"span": [[35, 41]], "type": "Drug", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.4.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.15-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.15", "sentence": "In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. ", "arg1": {"span": [[36, 47]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.15.e.1"}, "arg2": {"span": [[126, 135]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.15.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20", "sentence": "In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), hypotension in post-myocardial infarction patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients.", "arg1": {"span": [[171, 180]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20.e.0"}, "arg2": {"span": [[210, 219]], "type": "Biomedical_Entity", "mmcui": "C0006938", "rxcui": 1998, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20-1", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20", "sentence": "In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), hypotension in post-myocardial infarction patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients.", "arg1": {"span": [[7, 16]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20.e.1"}, "arg2": {"span": [[210, 219]], "type": "Biomedical_Entity", "mmcui": "C0006938", "rxcui": 1998, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.20.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.24-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.24", "sentence": "Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. ", "arg1": {"span": [[102, 113]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.24.e.1"}, "arg2": {"span": [[128, 137]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.24.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.25-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.25", "sentence": "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g. patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on Diovan. ", "arg1": {"span": [[78, 89]], "type": "Biomedical_Entity", "mmcui": "C0003018", "rxcui": 839, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.25.e.0"}, "arg2": {"span": [[281, 287]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.25.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.35-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.35", "sentence": "The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.", "arg1": {"span": [[4, 13]], "type": "Drug", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.35.e.0"}, "arg2": {"span": [[14, 22]], "type": "Drug", "mmcui": "C0004147", "rxcui": 1202, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.35.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[118, 131]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.1"}, "arg2": {"span": [[146, 154]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-1", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.3"}, "arg2": {"span": [[146, 154]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-2", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[82, 91]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.4"}, "arg2": {"span": [[146, 154]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-3", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[34, 42]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.2"}, "arg2": {"span": [[118, 131]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-4", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.3"}, "arg2": {"span": [[118, 131]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-5", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[82, 91]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.4"}, "arg2": {"span": [[118, 131]], "type": "Biomedical_Entity", "mmcui": "C0003280", "rxcui": 923, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-6", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[20, 29]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.3"}, "arg2": {"span": [[34, 42]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36-7", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36", "sentence": "Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.", "arg1": {"span": [[34, 42]], "type": "Biomedical_Entity", "mmcui": "C0043031", "rxcui": 11289, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.2"}, "arg2": {"span": [[82, 91]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.36.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.37-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.37", "sentence": "CYP 450 Interactions: In vitro  metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and coadministered drugs are unlikely because of the low extent of metabolism [see Clinical Pharmacology (12.3)].", "arg1": {"span": [[73, 81]], "type": "Biomedical_Entity", "mmcui": "C0127400", "rxcui": 985488, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.37.e.0"}, "arg2": {"span": [[108, 117]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.37.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.44-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.44", "sentence": "Monitor renal function periodically in patients receiving valsartan and NSAID therapy.", "arg1": {"span": [[58, 67]], "type": "Drug", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.44.e.2"}, "arg2": {"span": [[72, 77]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.44.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.45-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.45", "sentence": "The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.", "arg1": {"span": [[31, 66]], "type": "Drug_Class", "mmcui": "C0521942", "rxcui": 839, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.45.e.0"}, "arg2": {"span": [[109, 115]], "type": "Drug_Class", "mmcui": "C0003211", "rxcui": 889, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.45.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.47-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.47", "sentence": "Closely monitor blood pressure, renal function and electrolytes in patients on Diovan and other agents that affect the RAS.", "arg1": {"span": [[79, 85]], "type": "Drug", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.47.e.2"}, "arg2": {"span": [[96, 122]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 126263, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.47.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.48-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.48", "sentence": "Do not coadminister aliskiren with Diovan in patients with diabetes. ", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.48.e.2"}, "arg2": {"span": [[35, 41]], "type": "Drug", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.48.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.49-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.49", "sentence": "Avoid use of aliskiren with Diovan in patients with renal impairment (GFR <60 mL/min).", "arg1": {"span": [[13, 22]], "type": "Drug", "mmcui": "C1120110", "rxcui": 325646, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.49.e.2"}, "arg2": {"span": [[28, 34]], "type": "Drug", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.49.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.54-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.54", "sentence": "In post-myocardial infarction patients, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients and 3.4% of captopril-treated patients.", "arg1": {"span": [[93, 102]], "type": "Biomedical_Entity", "mmcui": "C0216784", "rxcui": 69749, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.54.e.1"}, "arg2": {"span": [[132, 141]], "type": "Biomedical_Entity", "mmcui": "C0006938", "rxcui": 1998, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.54.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60", "sentence": "Serum Potassium: In hypertensive patients, greater than 20% increases in serum potassium were observed in 4.4% of Diovan-treated patients compared to 2.9% of placebo-treated patients. ", "arg1": {"span": [[6, 15]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60.e.0"}, "arg2": {"span": [[114, 120]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60-1", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60", "sentence": "Serum Potassium: In hypertensive patients, greater than 20% increases in serum potassium were observed in 4.4% of Diovan-treated patients compared to 2.9% of placebo-treated patients. ", "arg1": {"span": [[79, 88]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60.e.2"}, "arg2": {"span": [[114, 120]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.60.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.61-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.61", "sentence": "In heart failure patients, greater than 20% increases in serum potassium were observed in 10.0% of Diovan-treated patients compared to 5.1% of placebo-treated patients.", "arg1": {"span": [[63, 72]], "type": "Biomedical_Entity", "mmcui": "C0597277", "rxcui": 8588, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.61.e.1"}, "arg2": {"span": [[99, 105]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.61.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62-0", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62", "sentence": "Blood Urea Nitrogen (BUN): In heart failure trials, greater than 50% increases in BUN were observed in 16.6% of Diovan-treated patients compared to 6.3% of placebo-treated patients.", "arg1": {"span": [[82, 85]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 221770, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62.e.0"}, "arg2": {"span": [[112, 118]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62-1", "sentence_id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62", "sentence": "Blood Urea Nitrogen (BUN): In heart failure trials, greater than 50% increases in BUN were observed in 16.6% of Diovan-treated patients compared to 6.3% of placebo-treated patients.", "arg1": {"span": [[6, 10]], "type": "Biomedical_Entity", "mmcui": "C0041942", "rxcui": 11002, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62.e.2"}, "arg2": {"span": [[112, 118]], "type": "Biomedical_Entity", "mmcui": "C0719949", "rxcui": 216652, "id": "Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.62.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1", "sentence": "Drug Label for drug brand Cardizem CD, containing Diltiazem Hydrochloride.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.0"}, "arg2": {"span": [[50, 73]], "type": "Biomedical_Entity", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1", "sentence": "Drug Label for drug brand Cardizem CD, containing Diltiazem Hydrochloride.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.0"}, "arg2": {"span": [[26, 37]], "type": "Biomedical_Entity", "mmcui": "C0719166", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1", "sentence": "Drug Label for drug brand Cardizem CD, containing Diltiazem Hydrochloride.", "arg1": {"span": [[26, 37]], "type": "Biomedical_Entity", "mmcui": "C0719166", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.2"}, "arg2": {"span": [[50, 73]], "type": "Biomedical_Entity", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8", "sentence": "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ", "arg1": {"span": [[19, 28]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.3"}, "arg2": {"span": [[51, 60]], "type": "Drug", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8", "sentence": "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ", "arg1": {"span": [[19, 28]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.3"}, "arg2": {"span": [[34, 47]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.4"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8", "sentence": "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. ", "arg1": {"span": [[34, 47]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.4"}, "arg2": {"span": [[51, 60]], "type": "Drug", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.8.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14", "sentence": "Experience with the use of CARDIZEM (diltiazem hydrochloride) in combination with beta-blockers in patients with impaired ventricular function is limited. ", "arg1": {"span": [[27, 35]], "type": "Biomedical_Entity", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.1"}, "arg2": {"span": [[82, 95]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14", "sentence": "Experience with the use of CARDIZEM (diltiazem hydrochloride) in combination with beta-blockers in patients with impaired ventricular function is limited. ", "arg1": {"span": [[37, 60]], "type": "Biomedical_Entity", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.2"}, "arg2": {"span": [[82, 95]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14", "sentence": "Experience with the use of CARDIZEM (diltiazem hydrochloride) in combination with beta-blockers in patients with impaired ventricular function is limited. ", "arg1": {"span": [[27, 35]], "type": "Biomedical_Entity", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.1"}, "arg2": {"span": [[37, 60]], "type": "Biomedical_Entity", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.14.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.26-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.26", "sentence": "CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.26.e.1"}, "arg2": {"span": [[10, 33]], "type": "Biomedical_Entity", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.26.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.36-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.36", "sentence": "Due to the potential for additive effects, caution and careful titration are warranted in patients receiving CARDIZEM concomitantly with other agents known to affect cardiac contractility and/or conduction (see WARNINGS ). ", "arg1": {"span": [[109, 117]], "type": "Drug", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.36.e.2"}, "arg2": {"span": [[143, 187]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 126263, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.36.e.4"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37", "sentence": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM (see WARNINGS ).", "arg1": {"span": [[105, 118]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.3"}, "arg2": {"span": [[151, 159]], "type": "Drug", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37", "sentence": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM (see WARNINGS ).", "arg1": {"span": [[122, 131]], "type": "Drug", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.4"}, "arg2": {"span": [[151, 159]], "type": "Drug", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37", "sentence": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM (see WARNINGS ).", "arg1": {"span": [[105, 118]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.3"}, "arg2": {"span": [[122, 131]], "type": "Drug", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.37.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.39-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.39", "sentence": "Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.39.e.1"}, "arg2": {"span": [[37, 81]], "type": "Biomedical_Entity", "mmcui": "C0919438", "rxcui": "NA", "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.39.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.41-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.41", "sentence": "Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.", "arg1": {"span": [[37, 61]], "type": "Drug_Class", "rxcui": 838, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.41.e.4"}, "arg2": {"span": [[204, 213]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.41.e.5"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.44-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.44", "sentence": "When used concomitantly, anesthetics and calcium blockers should be titrated carefully.", "arg1": {"span": [[25, 36]], "type": "Drug_Class", "mmcui": "C0002932", "rxcui": 817, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.44.e.2"}, "arg2": {"span": [[41, 57]], "type": "Drug_Class", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.44.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46", "sentence": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. ", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.2"}, "arg2": {"span": [[51, 60]], "type": "Drug", "mmcui": "C0026056", "rxcui": 203128, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46", "sentence": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. ", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.2"}, "arg2": {"span": [[65, 74]], "type": "Drug", "mmcui": "C0040879", "rxcui": 10767, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47", "sentence": "The elimination half-life of midazolam and triazolam also increased (1.5- to 2.5-fold) during coadministration with diltiazem. ", "arg1": {"span": [[29, 38]], "type": "Drug", "mmcui": "C0026056", "rxcui": 203128, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.2"}, "arg2": {"span": [[116, 125]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47", "sentence": "The elimination half-life of midazolam and triazolam also increased (1.5- to 2.5-fold) during coadministration with diltiazem. ", "arg1": {"span": [[43, 52]], "type": "Drug", "mmcui": "C0040879", "rxcui": 10767, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.4"}, "arg2": {"span": [[116, 125]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48", "sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam.", "arg1": {"span": [[42, 51]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.3"}, "arg2": {"span": [[159, 168]], "type": "Drug", "mmcui": "C0040879", "rxcui": 10767, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48", "sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam.", "arg1": {"span": [[42, 51]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.3"}, "arg2": {"span": [[145, 154]], "type": "Drug", "mmcui": "C0026056", "rxcui": 203128, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.4"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48", "sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam.", "arg1": {"span": [[145, 154]], "type": "Drug", "mmcui": "C0026056", "rxcui": 203128, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.4"}, "arg2": {"span": [[159, 168]], "type": "Drug", "mmcui": "C0040879", "rxcui": 10767, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.48.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.50-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.50", "sentence": "Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.", "arg1": {"span": [[77, 85]], "type": "Biomedical_Entity", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.50.e.1"}, "arg2": {"span": [[90, 103]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.50.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51", "sentence": "Administration of CARDIZEM (diltiazem hydrochloride) concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%. ", "arg1": {"span": [[28, 51]], "type": "Drug", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51.e.3"}, "arg2": {"span": [[132, 143]], "type": "Drug", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51", "sentence": "Administration of CARDIZEM (diltiazem hydrochloride) concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%. ", "arg1": {"span": [[28, 51]], "type": "Drug", "mmcui": "C0700579", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51.e.3"}, "arg2": {"span": [[190, 201]], "type": "Drug", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51.e.7"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55", "sentence": "In nine healthy subjects, diltiazem significantly increased the mean buspirone AUC 5.5-fold and Cmax 4.1-fold compared to placebo. ", "arg1": {"span": [[26, 35]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55.e.3"}, "arg2": {"span": [[69, 78]], "type": "Drug", "mmcui": "C0006462", "rxcui": 1827, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.56-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.56", "sentence": "The T1/2 and Tmax of buspirone were not significantly affected by diltiazem. ", "arg1": {"span": [[21, 30]], "type": "Biomedical_Entity", "mmcui": "C0006462", "rxcui": 1827, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.56.e.0"}, "arg2": {"span": [[66, 75]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.56.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57", "sentence": "Enhanced effects and increased toxicity of buspirone may be possible during concomitant administration with diltiazem. ", "arg1": {"span": [[43, 52]], "type": "Drug", "mmcui": "C0006462", "rxcui": 1827, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57.e.3"}, "arg2": {"span": [[108, 117]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60", "sentence": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases. ", "arg1": {"span": [[30, 39]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60.e.2"}, "arg2": {"span": [[115, 128]], "type": "Drug", "mmcui": "C0006949", "rxcui": 2002, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63", "sentence": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of diltiazem 60 mg. ", "arg1": {"span": [[75, 84]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63.e.3"}, "arg2": {"span": [[161, 171]], "type": "Drug", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[30, 42]], "type": "Biomedical_Entity", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.0"}, "arg2": {"span": [[133, 137]], "type": "Biomedical_Entity", "mmcui": "C0030125", "rxcui": 7833, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[30, 42]], "type": "Biomedical_Entity", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.0"}, "arg2": {"span": [[152, 161]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[18, 26]], "type": "Biomedical_Entity", "mmcui": "C0127400", "rxcui": 985488, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.3"}, "arg2": {"span": [[30, 42]], "type": "Biomedical_Entity", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-3", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[133, 137]], "type": "Biomedical_Entity", "mmcui": "C0030125", "rxcui": 7833, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.1"}, "arg2": {"span": [[152, 161]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-4", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[18, 26]], "type": "Biomedical_Entity", "mmcui": "C0127400", "rxcui": 985488, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.3"}, "arg2": {"span": [[133, 137]], "type": "Biomedical_Entity", "mmcui": "C0030125", "rxcui": 7833, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65-5", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65", "sentence": "The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. ", "arg1": {"span": [[18, 26]], "type": "Biomedical_Entity", "mmcui": "C0127400", "rxcui": 985488, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.3"}, "arg2": {"span": [[152, 161]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.65.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.66-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.66", "sentence": "Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. ", "arg1": {"span": [[29, 38]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.66.e.2"}, "arg2": {"span": [[163, 173]], "type": "Drug", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.66.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.69-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.69", "sentence": "Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with diltiazem. ", "arg1": {"span": [[120, 129]], "type": "Drug", "mmcui": "C0009014", "rxcui": 2599, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.69.e.2"}, "arg2": {"span": [[148, 157]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.69.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.70-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.70", "sentence": "Monitor heart rate in patients receiving concomitant diltiazem and clonidine.", "arg1": {"span": [[53, 62]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.70.e.3"}, "arg2": {"span": [[67, 76]], "type": "Drug", "mmcui": "C0009014", "rxcui": 2599, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.70.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.72-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.72", "sentence": "A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. ", "arg1": {"span": [[38, 47]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.72.e.5"}, "arg2": {"span": [[52, 64]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.72.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73", "sentence": "In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem. ", "arg1": {"span": [[59, 71]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73.e.4"}, "arg2": {"span": [[209, 218]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.74-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.74", "sentence": "If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.", "arg1": {"span": [[53, 65]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.74.e.2"}, "arg2": {"span": [[118, 127]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.74.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.75-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.75", "sentence": "The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.", "arg1": {"span": [[14, 26]], "type": "Biomedical_Entity", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.75.e.1"}, "arg2": {"span": [[30, 39]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.75.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77", "sentence": "Administration of CARDIZEM with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%. ", "arg1": {"span": [[18, 26]], "type": "Drug", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77.e.4"}, "arg2": {"span": [[85, 92]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.79-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.79", "sentence": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing CARDIZEM therapy to avoid possible over- or under-digitalization (see WARNINGS ).", "arg1": {"span": [[105, 112]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.79.e.3"}, "arg2": {"span": [[179, 187]], "type": "Drug", "mmcui": "C0700940", "rxcui": 203494, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.79.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81", "sentence": "Diltiazem significantly increases the AUC(0 ) of quinidine by 51%, T1/2 by 36%, and decreases its CLoral by 33%. ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81.e.3"}, "arg2": {"span": [[49, 58]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84", "sentence": "Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels. ", "arg1": {"span": [[20, 28]], "type": "Drug", "mmcui": "C0035608", "rxcui": 9384, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84.e.3"}, "arg2": {"span": [[56, 65]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84.e.2"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85", "sentence": "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.3"}, "arg2": {"span": [[57, 71]], "type": "Drug_Class", "rxcui": 340933, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85", "sentence": "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.", "arg1": {"span": [[20, 29]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.3"}, "arg2": {"span": [[35, 43]], "type": "Drug", "mmcui": "C0035608", "rxcui": 9384, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.4"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85", "sentence": "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.", "arg1": {"span": [[35, 43]], "type": "Drug", "mmcui": "C0035608", "rxcui": 9384, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.4"}, "arg2": {"span": [[57, 71]], "type": "Drug_Class", "rxcui": 340933, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.85.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87", "sentence": "Diltiazem is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins. ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87.e.3"}, "arg2": {"span": [[97, 104]], "type": "Drug_Class", "mmcui": "C0360714", "rxcui": 108229, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.88-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.88", "sentence": "The risk of myopathy and rhabdomyolysis with statins metabolized by CYP3A4 may be increased with concomitant use of diltiazem. ", "arg1": {"span": [[45, 74]], "type": "Drug_Class", "mmcui": "C0360714", "rxcui": 108229, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.88.e.3"}, "arg2": {"span": [[116, 125]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.88.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90", "sentence": "In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of simvastatin at the end of a 14 day regimen with 120 mg BID diltiazem SR resulted in a 5-fold increase in mean simvastatin AUC versus simvastatin alone. ", "arg1": {"span": [[151, 163]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90.e.3"}, "arg2": {"span": [[202, 213]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90.e.4"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.91-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.91", "sentence": "Subjects with increased average steady-state exposures of diltiazem showed a greater fold increase in simvastatin exposure. ", "arg1": {"span": [[58, 67]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.91.e.1"}, "arg2": {"span": [[102, 113]], "type": "Biomedical_Entity", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.91.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92", "sentence": "Computer-based simulations showed that at a daily dose of 480 mg of diltiazem, an 8- to 9-fold mean increase in simvastatin AUC can be expected. ", "arg1": {"span": [[68, 77]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92.e.2"}, "arg2": {"span": [[112, 123]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.93-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.93", "sentence": "If co-administration of simvastatin with diltiazem is required, limit the daily doses of simvastatin to 10 mg and diltiazem to 240 mg.", "arg1": {"span": [[89, 100]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.93.e.2"}, "arg2": {"span": [[114, 123]], "type": "Drug", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.93.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94", "sentence": "In a ten-subject randomized, open label, 4-way cross-over study, co-administration of diltiazem (120 mg BID diltiazem SR for 2 weeks) with a single 20 mg dose of lovastatin resulted in 3- to 4-fold increase in mean lovastatin AUC and Cmax versus lovastatin alone. ", "arg1": {"span": [[108, 120]], "type": "Drug", "mmcui": "C2346927", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94.e.2"}, "arg2": {"span": [[215, 225]], "type": "Drug", "mmcui": "C0024027", "rxcui": 6472, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.95-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.95", "sentence": "In the same study, there was no significant change in 20 mg single dose pravastatin AUC and Cmax during diltiazem coadministration. ", "arg1": {"span": [[72, 83]], "type": "Biomedical_Entity", "mmcui": "C0085542", "rxcui": 42463, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.95.e.0"}, "arg2": {"span": [[104, 113]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.95.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96-0", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96", "sentence": "Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.0"}, "arg2": {"span": [[73, 84]], "type": "Biomedical_Entity", "mmcui": "C0085542", "rxcui": 42463, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96-1", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96", "sentence": "Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.0"}, "arg2": {"span": [[59, 69]], "type": "Biomedical_Entity", "mmcui": "C0024027", "rxcui": 6472, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96-2", "sentence_id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96", "sentence": "Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.", "arg1": {"span": [[59, 69]], "type": "Biomedical_Entity", "mmcui": "C0024027", "rxcui": 6472, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.2"}, "arg2": {"span": [[73, 84]], "type": "Biomedical_Entity", "mmcui": "C0085542", "rxcui": 42463, "id": "Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.96.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.1"}, "arg2": {"span": [[95, 117]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[11, 34]], "type": "Biomedical_Entity", "mmcui": "C0700468", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.2"}, "arg2": {"span": [[95, 117]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[76, 91]], "type": "Biomedical_Entity", "mmcui": "C0870261", "rxcui": 20793, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.3"}, "arg2": {"span": [[95, 117]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-3", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.4"}, "arg2": {"span": [[95, 117]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-4", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.1"}, "arg2": {"span": [[11, 34]], "type": "Biomedical_Entity", "mmcui": "C0700468", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-5", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.1"}, "arg2": {"span": [[76, 91]], "type": "Biomedical_Entity", "mmcui": "C0870261", "rxcui": 20793, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-6", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.1"}, "arg2": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-7", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[11, 34]], "type": "Biomedical_Entity", "mmcui": "C0700468", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.2"}, "arg2": {"span": [[76, 91]], "type": "Biomedical_Entity", "mmcui": "C0870261", "rxcui": 20793, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-8", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[11, 34]], "type": "Biomedical_Entity", "mmcui": "C0700468", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.2"}, "arg2": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2-9", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2", "sentence": "COVERA-HS (verapamil hydrochloride) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). ", "arg1": {"span": [[41, 52]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.4"}, "arg2": {"span": [[76, 91]], "type": "Biomedical_Entity", "mmcui": "C0870261", "rxcui": 20793, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.2.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.0"}, "arg2": {"span": [[101, 134]], "type": "Biomedical_Entity", "mmcui": "C2740045", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.0"}, "arg2": {"span": [[142, 150]], "type": "Biomedical_Entity", "mmcui": "C0939879", "rxcui": 1307767, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.0"}, "arg2": {"span": [[190, 223]], "type": "Biomedical_Entity", "mmcui": "C2740041", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-3", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[101, 134]], "type": "Biomedical_Entity", "mmcui": "C2740045", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.1"}, "arg2": {"span": [[142, 150]], "type": "Biomedical_Entity", "mmcui": "C0939879", "rxcui": 1307767, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-4", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[101, 134]], "type": "Biomedical_Entity", "mmcui": "C2740045", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.1"}, "arg2": {"span": [[190, 223]], "type": "Biomedical_Entity", "mmcui": "C2740041", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3-5", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3", "sentence": "COVERA-HS is available for oral administration as pale yellow, round, film-coated tablets containing 240 mg of verapamil hydrochloride and as lavender, round, film-coated tablets containing 180 mg of verapamil hydrochloride.", "arg1": {"span": [[142, 150]], "type": "Biomedical_Entity", "mmcui": "C0939879", "rxcui": 1307767, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.2"}, "arg2": {"span": [[190, 223]], "type": "Biomedical_Entity", "mmcui": "C2740041", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.3.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.5-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.5", "sentence": "The COVERA-HS formulation has been designed to initiate the release of verapamil 4 5 hours after ingestion. ", "arg1": {"span": [[4, 13]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.5.e.0"}, "arg2": {"span": [[71, 80]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.5.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14", "sentence": "Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.2"}, "arg2": {"span": [[52, 75]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14", "sentence": "Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). ", "arg1": {"span": [[15, 26]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.3"}, "arg2": {"span": [[52, 75]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14", "sentence": "Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.2"}, "arg2": {"span": [[79, 105]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14-3", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14", "sentence": "Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). ", "arg1": {"span": [[15, 26]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.3"}, "arg2": {"span": [[79, 105]], "type": "Biomedical_Entity", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14-4", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14", "sentence": "Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.2"}, "arg2": {"span": [[15, 26]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.14.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15", "sentence": "Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.", "arg1": {"span": [[97, 110]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 5958, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.1"}, "arg2": {"span": [[220, 227]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15", "sentence": "Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.2"}, "arg2": {"span": [[220, 227]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15", "sentence": "Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.2"}, "arg2": {"span": [[97, 110]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 5958, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.15.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.21-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.21", "sentence": "Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). ", "arg1": {"span": [[62, 78]], "type": "Biomedical_Entity", "mmcui": "C0012315", "rxcui": 3427, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.21.e.1"}, "arg2": {"span": [[144, 159]], "type": "Biomedical_Entity", "mmcui": "C0017963", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.21.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.24-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.24", "sentence": "Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.24.e.1"}, "arg2": {"span": [[23, 39]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.24.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.29-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.29", "sentence": "COVERA-HS does not alter total serum calcium levels. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.29.e.1"}, "arg2": {"span": [[37, 44]], "type": "Biomedical_Entity", "mmcui": "C0006675", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.29.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.30-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.30", "sentence": "However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.", "arg1": {"span": [[39, 46]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.30.e.0"}, "arg2": {"span": [[113, 122]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.30.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.36-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.36", "sentence": "The results of these studies demonstrate that COVERA-HS, at 180 540 mg, is a consistently and significantly more effective antihypertensive agent than placebo in reducing ambulatory blood pressures. ", "arg1": {"span": [[46, 55]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.36.e.0"}, "arg2": {"span": [[123, 145]], "type": "Biomedical_Entity", "mmcui": "C0003364", "rxcui": 968, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.36.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.41-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.41", "sentence": "Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.41.e.0"}, "arg2": {"span": [[182, 192]], "type": "Biomedical_Entity", "mmcui": "C0014704", "rxcui": 4021, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.41.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.56-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.56", "sentence": "By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.", "arg1": {"span": [[28, 35]], "type": "Biomedical_Entity", "mmcui": "C2936886", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.56.e.1"}, "arg2": {"span": [[37, 46]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.56.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.59-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.59", "sentence": "COVERA-HS does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization, and conduction in depressed atrial fibers. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0719560", "rxcui": 216270, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.59.e.0"}, "arg2": {"span": [[185, 191]], "type": "Biomedical_Entity", "mmcui": "C0225326", "rxcui": 70727, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.59.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.1"}, "arg2": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C0002934", "rxcui": 992023, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C0002934", "rxcui": 992023, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.0"}, "arg2": {"span": [[91, 96]], "type": "Biomedical_Entity", "mmcui": "C1874451", "rxcui": 1046801, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[16, 32]], "type": "Biomedical_Entity", "mmcui": "C0002934", "rxcui": 992023, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.0"}, "arg2": {"span": [[66, 74]], "type": "Biomedical_Entity", "mmcui": "C0033218", "rxcui": 8701, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-3", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.1"}, "arg2": {"span": [[91, 96]], "type": "Biomedical_Entity", "mmcui": "C1874451", "rxcui": 1046801, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-4", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[0, 9]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.1"}, "arg2": {"span": [[66, 74]], "type": "Biomedical_Entity", "mmcui": "C0033218", "rxcui": 8701, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62-5", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62", "sentence": "Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. ", "arg1": {"span": [[66, 74]], "type": "Biomedical_Entity", "mmcui": "C0033218", "rxcui": 8701, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.3"}, "arg2": {"span": [[91, 96]], "type": "Biomedical_Entity", "mmcui": "C1874451", "rxcui": 1046801, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.62.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.68-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.68", "sentence": "Verapamil should be avoided in patients with severe left ventricular dysfunction (e.g., ejection fraction less than 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see PRECAUTIONS, Drug interactions). ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.68.e.1"}, "arg2": {"span": [[254, 277]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.68.e.0"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69", "sentence": "Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment is started. ", "arg1": {"span": [[102, 111]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.0"}, "arg2": {"span": [[119, 128]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69", "sentence": "Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment is started. ", "arg1": {"span": [[102, 111]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.0"}, "arg2": {"span": [[136, 145]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69-2", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69", "sentence": "Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment is started. ", "arg1": {"span": [[119, 128]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.1"}, "arg2": {"span": [[136, 145]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.69.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.84-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.84", "sentence": "Some patients with paroxysmal and/or chronic atrial fibrillation or atrial flutter and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or ventricular fibrillation after receiving intravenous verapamil (or digitalis). ", "arg1": {"span": [[319, 328]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.84.e.0"}, "arg2": {"span": [[333, 342]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.84.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.94-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.94", "sentence": "In 120 patients with hypertrophic cardiomyopathy (most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects were seen. ", "arg1": {"span": [[91, 102]], "type": "Biomedical_Entity", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.94.e.0"}, "arg2": {"span": [[130, 139]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.94.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114", "sentence": "It has been reported that verapamil decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, prolongs recovery from the neuromuscular blocking agent vecuronium, and causes a worsening of myasthenia gravis. ", "arg1": {"span": [[26, 35]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114.e.1"}, "arg2": {"span": [[177, 187]], "type": "Drug", "mmcui": "C0242531", "rxcui": 71535, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114.e.0"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.131-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.131", "sentence": "The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.", "arg1": {"span": [[11, 66]], "type": "Drug_Class", "mmcui": "C0360714", "rxcui": 27274, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.131.e.0"}, "arg2": {"span": [[87, 96]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.131.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132", "sentence": "Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. ", "arg1": {"span": [[48, 57]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132.e.0"}, "arg2": {"span": [[105, 116]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.133-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.133", "sentence": "Limit the dose of simvastatin in patients on verapamil to 10 mg daily. ", "arg1": {"span": [[18, 29]], "type": "Drug", "mmcui": "C0074554", "rxcui": 36567, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.133.e.0"}, "arg2": {"span": [[45, 54]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.133.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137", "sentence": "Verapamil may increase blood alcohol concentrations and prolong its effects.", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137.e.0"}, "arg2": {"span": [[29, 36]], "type": "Substance", "mmcui": "C0001975", "rxcui": 448, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.139-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.139", "sentence": "In a few reported cases, co-administration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.", "arg1": {"span": [[46, 55]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.139.e.0"}, "arg2": {"span": [[61, 68]], "type": "Drug", "mmcui": "C0004057", "rxcui": 1191, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.139.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141", "sentence": "Grapefruit juice may significantly increase concentrations of verapamil. ", "arg1": {"span": [[0, 16]], "type": "Substance", "mmcui": "C0440280", "rxcui": 124323, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141.e.1"}, "arg2": {"span": [[62, 71]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141.e.0"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142", "sentence": "Grapefruit juice given to nine healthy volunteers increased S- and R- verapamil AUC0 12 by 36% and 28%, respectively. ", "arg1": {"span": [[0, 16]], "type": "Substance", "mmcui": "C0440280", "rxcui": 124323, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142.e.0"}, "arg2": {"span": [[70, 79]], "type": "Drug", "mmcui": "C0280858", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143", "sentence": "Steady state Cmax and Cmin of S-verapamil increased by 57% and 16.7%, respectively, with grapefruit juice compared to control. ", "arg1": {"span": [[32, 41]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143.e.1"}, "arg2": {"span": [[89, 105]], "type": "Substance", "mmcui": "C0440280", "rxcui": 124323, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143.e.0"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.145-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.145", "sentence": "Grapefruit juice did not affect half-life, nor was there a significant change in AUC0 12 ratio R/S compared to control. ", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0440280", "rxcui": 124323, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.145.e.0"}, "arg2": {"span": [[57, 88]], "type": "Biomedical_Entity", "mmcui": "C0620347", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.145.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.146-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.146", "sentence": "Grapefruit juice did not cause a significant difference in the PK of norverapamil. ", "arg1": {"span": [[0, 10]], "type": "Biomedical_Entity", "mmcui": "C0440280", "rxcui": 124323, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.146.e.0"}, "arg2": {"span": [[69, 81]], "type": "Biomedical_Entity", "mmcui": "C0069036", "rxcui": 32033, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.146.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.149-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.149", "sentence": "Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility. ", "arg1": {"span": [[25, 49]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.149.e.0"}, "arg2": {"span": [[54, 63]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.149.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.150-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.150", "sentence": "The combination of sustained-release verapamil and beta-adrenergic blocking agents has not been studied. ", "arg1": {"span": [[37, 46]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.150.e.0"}, "arg2": {"span": [[51, 82]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.150.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155", "sentence": "A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. ", "arg1": {"span": [[14, 24]], "type": "Drug", "mmcui": "C0025859", "rxcui": 6918, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.1"}, "arg2": {"span": [[121, 130]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.0"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155", "sentence": "A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. ", "arg1": {"span": [[29, 40]], "type": "Drug", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.2"}, "arg2": {"span": [[121, 130]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.0"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.156-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.156", "sentence": "A variable effect has been seen when verapamil and atenolol were given together.", "arg1": {"span": [[37, 46]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.156.e.1"}, "arg2": {"span": [[51, 59]], "type": "Biomedical_Entity", "mmcui": "C0004147", "rxcui": 1202, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.156.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.158-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.158", "sentence": "Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. ", "arg1": {"span": [[16, 25]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.158.e.0"}, "arg2": {"span": [[100, 107]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.158.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159", "sentence": "However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. ", "arg1": {"span": [[17, 26]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.0"}, "arg2": {"span": [[56, 63]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159-1", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159", "sentence": "However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. ", "arg1": {"span": [[17, 26]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.0"}, "arg2": {"span": [[142, 151]], "type": "Drug", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.6"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.160-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.160", "sentence": "In patients with hepatic cirrhosis, the influence of verapamil on digoxin kinetics is magnified. ", "arg1": {"span": [[53, 62]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.160.e.1"}, "arg2": {"span": [[66, 73]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.160.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161", "sentence": "Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161.e.0"}, "arg2": {"span": [[70, 79]], "type": "Drug", "mmcui": "C0012258", "rxcui": 3403, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161.e.5"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.169-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.169", "sentence": "Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. ", "arg1": {"span": [[19, 66]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 126263, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.169.e.0"}, "arg2": {"span": [[72, 81]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.169.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.170-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.170", "sentence": "Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.", "arg1": {"span": [[85, 94]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.170.e.3"}, "arg2": {"span": [[99, 107]], "type": "Drug", "mmcui": "C0032912", "rxcui": 8629, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.170.e.0"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.173-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.173", "sentence": "Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "arg1": {"span": [[85, 97]], "type": "Drug", "mmcui": "C0012702", "rxcui": 3541, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.173.e.0"}, "arg2": {"span": [[166, 175]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.173.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.175-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.175", "sentence": "A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. ", "arg1": {"span": [[76, 86]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.175.e.0"}, "arg2": {"span": [[91, 100]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.175.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.176-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.176", "sentence": "Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.", "arg1": {"span": [[25, 35]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.176.e.0"}, "arg2": {"span": [[40, 49]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.176.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.178-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.178", "sentence": "In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. ", "arg1": {"span": [[90, 99]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.178.e.1"}, "arg2": {"span": [[104, 113]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.178.e.2"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.179-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.179", "sentence": "Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.", "arg1": {"span": [[53, 62]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.179.e.0"}, "arg2": {"span": [[67, 76]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.179.e.1"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.180-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.180", "sentence": "The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. ", "arg1": {"span": [[34, 43]], "type": "Biomedical_Entity", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.180.e.1"}, "arg2": {"span": [[48, 57]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.180.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.181-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.181", "sentence": "Verapamil significantly counteracted the effects of quinidine on AV conduction. ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.181.e.0"}, "arg2": {"span": [[52, 61]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.181.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182", "sentence": "There has been a report of increased quinidine levels during verapamil therapy.", "arg1": {"span": [[37, 46]], "type": "Drug", "mmcui": "C0034414", "rxcui": 9068, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182.e.0"}, "arg2": {"span": [[61, 70]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.188-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.188", "sentence": "The interaction between cimetidine and chronically administered verapamil has not been studied. ", "arg1": {"span": [[24, 34]], "type": "Biomedical_Entity", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.188.e.0"}, "arg2": {"span": [[64, 73]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.188.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.192-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.192", "sentence": "Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy; ", "arg1": {"span": [[40, 47]], "type": "Drug", "mmcui": "C0023870", "rxcui": 1428998, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.192.e.0"}, "arg2": {"span": [[101, 110]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.192.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196", "sentence": "Verapamil therapy may increase carbamazepine concentrations during combined therapy. ", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196.e.0"}, "arg2": {"span": [[31, 44]], "type": "Drug", "mmcui": "C0006949", "rxcui": 2002, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199", "sentence": "Therapy with rifampin may markedly reduce oral verapamil bioavailability.", "arg1": {"span": [[13, 21]], "type": "Drug", "mmcui": "C0035608", "rxcui": 9384, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199.e.0"}, "arg2": {"span": [[42, 56]], "type": "Drug", "mmcui": "C0042523", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199.e.3"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201", "sentence": "Phenobarbital therapy may increase verapamil clearance.", "arg1": {"span": [[0, 13]], "type": "Drug", "mmcui": "C0031412", "rxcui": 8134, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201.e.0"}, "arg2": {"span": [[35, 44]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201.e.1"}, "ddi_label": 1, "ddi_type": "Decrease_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203", "sentence": "Verapamil therapy may increase serum levels of cyclosporine.", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203.e.0"}, "arg2": {"span": [[47, 59]], "type": "Drug", "mmcui": "C0010592", "rxcui": 3008, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205", "sentence": "Verapamil may inhibit the clearance and increase the plasma levels of theophylline.", "arg1": {"span": [[0, 9]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205.e.0"}, "arg2": {"span": [[70, 82]], "type": "Drug", "mmcui": "C0039771", "rxcui": 10438, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205.e.1"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.207-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.207", "sentence": "Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. ", "arg1": {"span": [[35, 57]], "type": "Biomedical_Entity", "mmcui": "C0242903", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.207.e.1"}, "arg2": {"span": [[127, 139]], "type": "Biomedical_Entity", "mmcui": "C0596235", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.207.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.208-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.208", "sentence": "When used concomitantly, inhalation anesthetics and calcium channel blocking agents, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.", "arg1": {"span": [[25, 47]], "type": "Drug_Class", "mmcui": "C0242903", "rxcui": "NA", "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.208.e.0"}, "arg2": {"span": [[52, 83]], "type": "Drug_Class", "mmcui": "C0006684", "rxcui": 1895, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.208.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210", "sentence": "Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). ", "arg1": {"span": [[46, 55]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210.e.0"}, "arg2": {"span": [[87, 147]], "type": "Drug_Class", "mmcui": "C1254351", "rxcui": 1036249, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210.e.3"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.211-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.211", "sentence": "It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.", "arg1": {"span": [[44, 53]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.211.e.0"}, "arg2": {"span": [[77, 105]], "type": "Drug_Class", "mmcui": "C0027866", "rxcui": 1036249, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.211.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.215-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.215", "sentence": "Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. ", "arg1": {"span": [[120, 129]], "type": "Drug", "mmcui": "C0009014", "rxcui": 2599, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.215.e.0"}, "arg2": {"span": [[148, 157]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.215.e.1"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.216-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.216", "sentence": "Monitor heart rate in patients receiving concomitant verapamil and clonidine.", "arg1": {"span": [[53, 62]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.216.e.2"}, "arg2": {"span": [[67, 76]], "type": "Drug", "mmcui": "C0009014", "rxcui": 2599, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.216.e.3"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.233-0", "sentence_id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.233", "sentence": "Such adverse experiences have not been reported in the literature, despite a long history of use of verapamil in Europe in the treatment of cardiac side effects of beta-adrenergic agonist agents used to treat premature labor.", "arg1": {"span": [[100, 109]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.233.e.1"}, "arg2": {"span": [[164, 187]], "type": "Biomedical_Entity", "mmcui": "C0001644", "rxcui": 9162, "id": "Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.233.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1", "sentence": "Drug Label for drug brand TAMBOCOR, containing flecainide acetate.", "arg1": {"span": [[26, 34]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.0"}, "arg2": {"span": [[47, 65]], "type": "Biomedical_Entity", "mmcui": "C0086303", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1-1", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1", "sentence": "Drug Label for drug brand TAMBOCOR, containing flecainide acetate.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.2"}, "arg2": {"span": [[26, 34]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1-2", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1", "sentence": "Drug Label for drug brand TAMBOCOR, containing flecainide acetate.", "arg1": {"span": [[0, 19]], "type": "Biomedical_Entity", "mmcui": "C0013231", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.2"}, "arg2": {"span": [[47, 65]], "type": "Biomedical_Entity", "mmcui": "C0086303", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.1.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.3-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.3", "sentence": "TAMBOCOR is contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.3.e.0"}, "arg2": {"span": [[219, 226]], "type": "Biomedical_Entity", "mmcui": "C2732140", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.3.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.18-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.18", "sentence": "As with other Class I agents, patients treated with TAMBOCOR for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. ", "arg1": {"span": [[20, 28]], "type": "Biomedical_Entity", "mmcui": "C0047291", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.18.e.1"}, "arg2": {"span": [[52, 60]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.18.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.20-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.20", "sentence": "Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication.", "arg1": {"span": [[50, 57]], "type": "Biomedical_Entity", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.20.e.0"}, "arg2": {"span": [[61, 74]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 371, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.20.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23", "sentence": "TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.1"}, "arg2": {"span": [[53, 75]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23-1", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23", "sentence": "TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. ", "arg1": {"span": [[53, 75]], "type": "Biomedical_Entity", "mmcui": "C0304520", "rxcui": 91235, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.0"}, "arg2": {"span": [[79, 110]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23-2", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23", "sentence": "TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.1"}, "arg2": {"span": [[79, 110]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": 9162, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.23.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24", "sentence": "During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13% - 19% increase in plasma digoxin levels occurred at six hours postdose.", "arg1": {"span": [[34, 56]], "type": "Drug", "mmcui": "C0592158", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24.e.3"}, "arg2": {"span": [[153, 160]], "type": "Drug", "mmcui": "C0012265", "rxcui": 3407, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25", "sentence": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values. ", "arg1": {"span": [[48, 56]], "type": "Drug", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25.e.6"}, "arg2": {"span": [[141, 152]], "type": "Drug", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25.e.5"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.26-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.26", "sentence": "In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects, when the drugs were administered together, the effects were additive. ", "arg1": {"span": [[34, 42]], "type": "Drug", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.26.e.5"}, "arg2": {"span": [[47, 58]], "type": "Drug", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.26.e.6"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.27-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.27", "sentence": "The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive. ", "arg1": {"span": [[45, 53]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.27.e.1"}, "arg2": {"span": [[58, 69]], "type": "Biomedical_Entity", "mmcui": "C0033497", "rxcui": 82084, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.27.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.28-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.28", "sentence": "In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects. ", "arg1": {"span": [[3, 11]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.28.e.0"}, "arg2": {"span": [[57, 70]], "type": "Biomedical_Entity", "mmcui": "C0001645", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.28.e.1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.29-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.29", "sentence": "Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.", "arg1": {"span": [[72, 85]], "type": "Drug_Class", "mmcui": "C0001645", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.29.e.2"}, "arg2": {"span": [[90, 100]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.29.e.3"}, "ddi_label": 1, "ddi_type": "Specific_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.31-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.31", "sentence": "In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less. ", "arg1": {"span": [[102, 112]], "type": "Biomedical_Entity", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.31.e.1"}, "arg2": {"span": [[124, 136]], "type": "Biomedical_Entity", "mmcui": "C0544357", "rxcui": 831503, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.31.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.33-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.33", "sentence": "TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction. ", "arg1": {"span": [[0, 8]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.33.e.1"}, "arg2": {"span": [[63, 72]], "type": "Biomedical_Entity", "mmcui": "C0012798", "rxcui": 3567, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.33.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35", "sentence": "In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.", "arg1": {"span": [[30, 40]], "type": "Drug", "mmcui": "C0008783", "rxcui": 2541, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35.e.5"}, "arg2": {"span": [[75, 85]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36", "sentence": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced. ", "arg1": {"span": [[5, 15]], "type": "Drug", "mmcui": "C0002598", "rxcui": 203114, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36.e.3"}, "arg2": {"span": [[55, 65]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36.e.2"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38", "sentence": "Drugs that inhibit cytochrome P450IID6, such as quinidine, might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy, especially if these patients are extensive metabolizers.", "arg1": {"span": [[0, 38]], "type": "Drug_Class", "mmcui": "C0013227", "rxcui": "NA", "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38.e.2"}, "arg2": {"span": [[103, 113]], "type": "Drug", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38.e.5"}, "ddi_label": 1, "ddi_type": "Increase_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39", "sentence": "There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil. ", "arg1": {"span": [[62, 70]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.1"}, "arg2": {"span": [[82, 94]], "type": "Biomedical_Entity", "mmcui": "C0012702", "rxcui": 3541, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39-1", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39", "sentence": "There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil. ", "arg1": {"span": [[82, 94]], "type": "Biomedical_Entity", "mmcui": "C0012702", "rxcui": 3541, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.0"}, "arg2": {"span": [[98, 107]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39-2", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39", "sentence": "There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil. ", "arg1": {"span": [[62, 70]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.1"}, "arg2": {"span": [[98, 107]], "type": "Biomedical_Entity", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.39.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40", "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks. ", "arg1": {"span": [[151, 160]], "type": "Drug", "mmcui": "C0042523", "rxcui": 11170, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40.e.4"}, "arg2": {"span": [[202, 210]], "type": "Drug", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40-1", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40", "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks. ", "arg1": {"span": [[134, 146]], "type": "Drug", "mmcui": "C0012702", "rxcui": 3541, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40.e.3"}, "arg2": {"span": [[202, 210]], "type": "Drug", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.40.e.2"}, "ddi_label": 1, "ddi_type": "Caution_Interaction"}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41", "sentence": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "arg1": {"span": [[66, 74]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.1"}, "arg2": {"span": [[94, 103]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41-1", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41", "sentence": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "arg1": {"span": [[80, 90]], "type": "Biomedical_Entity", "mmcui": "C0028066", "rxcui": 7417, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.2"}, "arg2": {"span": [[94, 103]], "type": "Biomedical_Entity", "mmcui": "C0012373", "rxcui": 203211, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41-2", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41", "sentence": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "arg1": {"span": [[66, 74]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.1"}, "arg2": {"span": [[80, 90]], "type": "Biomedical_Entity", "mmcui": "C0028066", "rxcui": 7417, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.41.e.2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.54-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.54", "sentence": "Results from a multiple dose study conducted in mothers soon after delivery indicates that flecainide is excreted in human breast milk in concentrations as high as 4 times (with average levels about 2.5 times) corresponding plasma levels, assuming a maternal plasma level at the top of the therapeutic range (1 g/mL), the calculated daily dose to a nursing infant (assuming about 700 mL breast milk over 24 hours) would be less than 3 mg.", "arg1": {"span": [[91, 101]], "type": "Biomedical_Entity", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.54.e.1"}, "arg2": {"span": [[117, 134]], "type": "Biomedical_Entity", "mmcui": "C0885503", "rxcui": 831503, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.54.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.58-0", "sentence_id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.58", "sentence": "Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, TAMBOCOR should not be used in such patients unless the potential benefits clearly outweigh the risks. ", "arg1": {"span": [[6, 16]], "type": "Biomedical_Entity", "mmcui": "C0016229", "rxcui": 4441, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.58.e.1"}, "arg2": {"span": [[113, 121]], "type": "Biomedical_Entity", "mmcui": "C0592158", "rxcui": 152403, "id": "Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.58.e.0"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d570.s0-0", "sentence_id": "DDI-DrugBank.d570.s0", "sentence": "Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.", "arg1": {"span": [[97, 105]], "type": "group", "id": "DDI-DrugBank.d570.s0.e0"}, "arg2": {"span": [[122, 136]], "type": "group", "id": "DDI-DrugBank.d570.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s2-0", "sentence_id": "DDI-DrugBank.d485.s2", "sentence": "Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s2.e0"}, "arg2": {"span": [[52, 71]], "type": "group", "id": "DDI-DrugBank.d485.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s3-0", "sentence_id": "DDI-DrugBank.d485.s3", "sentence": "Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.", "arg1": {"span": [[12, 35]], "type": "group", "id": "DDI-DrugBank.d485.s3.e0"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d485.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s4-0", "sentence_id": "DDI-DrugBank.d485.s4", "sentence": "Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d485.s4.e0"}, "arg2": {"span": [[66, 75]], "type": "group", "id": "DDI-DrugBank.d485.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s6-0", "sentence_id": "DDI-DrugBank.d485.s6", "sentence": "Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.", "arg1": {"span": [[0, 17]], "type": "drug", "id": "DDI-DrugBank.d485.s6.e0"}, "arg2": {"span": [[50, 60]], "type": "group", "id": "DDI-DrugBank.d485.s6.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s8-0", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-1", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-2", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-3", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[0, 11]], "type": "group", "id": "DDI-DrugBank.d485.s8.e0"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-4", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-5", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-6", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e1"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-7", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "arg2": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-8", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[25, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s8.e2"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s8-9", "sentence_id": "DDI-DrugBank.d485.s8", "sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "arg1": {"span": [[173, 184]], "type": "group", "id": "DDI-DrugBank.d485.s8.e3"}, "arg2": {"span": [[213, 231]], "type": "group", "id": "DDI-DrugBank.d485.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-0", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d485.s10.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-1", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d485.s10.e0"}, "arg2": {"span": [[92, 112]], "type": "group", "id": "DDI-DrugBank.d485.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s10-2", "sentence_id": "DDI-DrugBank.d485.s10", "sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s10.e1"}, "arg2": {"span": [[92, 112]], "type": "group", "id": "DDI-DrugBank.d485.s10.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s14-0", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-1", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-2", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e0"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-3", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "arg2": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s14-4", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e1"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s14-5", "sentence_id": "DDI-DrugBank.d485.s14", "sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "arg1": {"span": [[39, 48]], "type": "drug", "id": "DDI-DrugBank.d485.s14.e2"}, "arg2": {"span": [[113, 132]], "type": "group", "id": "DDI-DrugBank.d485.s14.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-0", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-1", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-2", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e0"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s16-3", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "arg2": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-4", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e1"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s16-5", "sentence_id": "DDI-DrugBank.d485.s16", "sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "arg1": {"span": [[49, 62]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e2"}, "arg2": {"span": [[67, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s16.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-0", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[0, 14]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-1", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[0, 14]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e0"}, "arg2": {"span": [[82, 96]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s18-2", "sentence_id": "DDI-DrugBank.d485.s18", "sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s18.e1"}, "arg2": {"span": [[82, 96]], "type": "drug_n", "id": "DDI-DrugBank.d485.s18.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s19-0", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e0"}, "arg2": {"span": [[26, 49]], "type": "group", "id": "DDI-DrugBank.d485.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s19-1", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e0"}, "arg2": {"span": [[80, 92]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s19-2", "sentence_id": "DDI-DrugBank.d485.s19", "sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "arg1": {"span": [[26, 49]], "type": "group", "id": "DDI-DrugBank.d485.s19.e1"}, "arg2": {"span": [[80, 92]], "type": "drug", "id": "DDI-DrugBank.d485.s19.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s23-0", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s23-1", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e0"}, "arg2": {"span": [[56, 91]], "type": "group", "id": "DDI-DrugBank.d485.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s23-2", "sentence_id": "DDI-DrugBank.d485.s23", "sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d485.s23.e1"}, "arg2": {"span": [[56, 91]], "type": "group", "id": "DDI-DrugBank.d485.s23.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s26-0", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e0"}, "arg2": {"span": [[22, 45]], "type": "group", "id": "DDI-DrugBank.d485.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s26-1", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e0"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s26-2", "sentence_id": "DDI-DrugBank.d485.s26", "sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "arg1": {"span": [[22, 45]], "type": "group", "id": "DDI-DrugBank.d485.s26.e1"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d485.s26.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s27-0", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-1", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-2", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[0, 47]], "type": "group", "id": "DDI-DrugBank.d485.s27.e0"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-3", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-4", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[49, 55]], "type": "group", "id": "DDI-DrugBank.d485.s27.e1"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s27-5", "sentence_id": "DDI-DrugBank.d485.s27", "sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "arg1": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d485.s27.e2"}, "arg2": {"span": [[99, 134]], "type": "group", "id": "DDI-DrugBank.d485.s27.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s31-0", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e0"}, "arg2": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s31-1", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e0"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s31-2", "sentence_id": "DDI-DrugBank.d485.s31", "sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "arg1": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e1"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s31.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s34-0", "sentence_id": "DDI-DrugBank.d485.s34", "sentence": "Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d485.s34.e0"}, "arg2": {"span": [[54, 89]], "type": "group", "id": "DDI-DrugBank.d485.s34.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-0", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-1", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-2", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-3", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e0"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-4", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-5", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-6", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e1"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s36-7", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "arg2": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-8", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[47, 64]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e2"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s36-9", "sentence_id": "DDI-DrugBank.d485.s36", "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "arg1": {"span": [[74, 84]], "type": "group", "id": "DDI-DrugBank.d485.s36.e3"}, "arg2": {"span": [[86, 99]], "type": "drug", "id": "DDI-DrugBank.d485.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-0", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e0"}, "arg2": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s38.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-1", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e0"}, "arg2": {"span": [[82, 96]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s38-2", "sentence_id": "DDI-DrugBank.d485.s38", "sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "arg1": {"span": [[28, 51]], "type": "group", "id": "DDI-DrugBank.d485.s38.e1"}, "arg2": {"span": [[82, 96]], "type": "drug", "id": "DDI-DrugBank.d485.s38.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s39-0", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e0"}, "arg2": {"span": [[12, 47]], "type": "group", "id": "DDI-DrugBank.d485.s39.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s39-1", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e0"}, "arg2": {"span": [[88, 98]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s39-2", "sentence_id": "DDI-DrugBank.d485.s39", "sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "arg1": {"span": [[12, 47]], "type": "group", "id": "DDI-DrugBank.d485.s39.e1"}, "arg2": {"span": [[88, 98]], "type": "drug", "id": "DDI-DrugBank.d485.s39.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s40-0", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e0"}, "arg2": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s40-1", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e0"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s40-2", "sentence_id": "DDI-DrugBank.d485.s40", "sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "arg1": {"span": [[14, 31]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e1"}, "arg2": {"span": [[62, 74]], "type": "drug", "id": "DDI-DrugBank.d485.s40.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d485.s43-0", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-1", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-2", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e0"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-3", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "arg2": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-4", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[62, 70]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e1"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d485.s43-5", "sentence_id": "DDI-DrugBank.d485.s43", "sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "arg1": {"span": [[90, 125]], "type": "group", "id": "DDI-DrugBank.d485.s43.e2"}, "arg2": {"span": [[153, 161]], "type": "drug", "id": "DDI-DrugBank.d485.s43.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d485.s44-0", "sentence_id": "DDI-DrugBank.d485.s44", "sentence": "Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;", "arg1": {"span": [[27, 44]], "type": "drug", "id": "DDI-DrugBank.d485.s44.e0"}, "arg2": {"span": [[94, 106]], "type": "drug", "id": "DDI-DrugBank.d485.s44.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d227.s0-0", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d227.s0.e0"}, "arg2": {"span": [[57, 73]], "type": "group", "id": "DDI-DrugBank.d227.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d227.s0-1", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d227.s0.e0"}, "arg2": {"span": [[88, 120]], "type": "group", "id": "DDI-DrugBank.d227.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d227.s0-2", "sentence_id": "DDI-DrugBank.d227.s0", "sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "arg1": {"span": [[57, 73]], "type": "group", "id": "DDI-DrugBank.d227.s0.e1"}, "arg2": {"span": [[88, 120]], "type": "group", "id": "DDI-DrugBank.d227.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-0", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-1", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-2", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-3", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d564.s0.e0"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-4", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s0-5", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-6", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e1"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-7", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-8", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s0.e2"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s0-9", "sentence_id": "DDI-DrugBank.d564.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d564.s0.e3"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d564.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s1-0", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d564.s1.e0"}, "arg2": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d564.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d564.s1-1", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d564.s1.e0"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s1-2", "sentence_id": "DDI-DrugBank.d564.s1", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d564.s1.e1"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d564.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d564.s4-0", "sentence_id": "DDI-DrugBank.d564.s4", "sentence": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "arg1": {"span": [[29, 46]], "type": "group", "id": "DDI-DrugBank.d564.s4.e0"}, "arg2": {"span": [[114, 139]], "type": "group", "id": "DDI-DrugBank.d564.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-0", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[0, 5]], "type": "brand", "id": "DDI-DrugBank.d497.s0.e0"}, "arg2": {"span": [[7, 19]], "type": "drug", "id": "DDI-DrugBank.d497.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-1", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[0, 5]], "type": "brand", "id": "DDI-DrugBank.d497.s0.e0"}, "arg2": {"span": [[57, 85]], "type": "group", "id": "DDI-DrugBank.d497.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s0-2", "sentence_id": "DDI-DrugBank.d497.s0", "sentence": "AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.", "arg1": {"span": [[7, 19]], "type": "drug", "id": "DDI-DrugBank.d497.s0.e1"}, "arg2": {"span": [[57, 85]], "type": "group", "id": "DDI-DrugBank.d497.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d497.s2-0", "sentence_id": "DDI-DrugBank.d497.s2", "sentence": "However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.", "arg1": {"span": [[39, 68]], "type": "group", "id": "DDI-DrugBank.d497.s2.e0"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d497.s2.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d497.s3-0", "sentence_id": "DDI-DrugBank.d497.s3", "sentence": "Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.", "arg1": {"span": [[94, 99]], "type": "brand", "id": "DDI-DrugBank.d497.s3.e0"}, "arg2": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d497.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-0", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-1", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-2", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e0"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-3", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "arg2": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-4", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[13, 25]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e1"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d109.s0-5", "sentence_id": "DDI-DrugBank.d109.s0", "sentence": "Ketoconazole/Itraconazole, Macrolides, Including Erythromycin", "arg1": {"span": [[27, 37]], "type": "group", "id": "DDI-DrugBank.d109.s0.e2"}, "arg2": {"span": [[49, 61]], "type": "drug", "id": "DDI-DrugBank.d109.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s3-0", "sentence_id": "DDI-DrugBank.d98.s3", "sentence": "Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d98.s3.e0"}, "arg2": {"span": [[80, 89]], "type": "brand", "id": "DDI-DrugBank.d98.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s4-0", "sentence_id": "DDI-DrugBank.d98.s4", "sentence": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s4.e0"}, "arg2": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s5-0", "sentence_id": "DDI-DrugBank.d98.s5", "sentence": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "arg1": {"span": [[63, 72]], "type": "group", "id": "DDI-DrugBank.d98.s5.e0"}, "arg2": {"span": [[78, 87]], "type": "group", "id": "DDI-DrugBank.d98.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d98.s7-0", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s7.e0"}, "arg2": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s7-1", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s7.e0"}, "arg2": {"span": [[95, 104]], "type": "group", "id": "DDI-DrugBank.d98.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s7-2", "sentence_id": "DDI-DrugBank.d98.s7", "sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "arg1": {"span": [[11, 20]], "type": "group", "id": "DDI-DrugBank.d98.s7.e1"}, "arg2": {"span": [[95, 104]], "type": "group", "id": "DDI-DrugBank.d98.s7.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d98.s8-0", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e0"}, "arg2": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s8-1", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e0"}, "arg2": {"span": [[79, 88]], "type": "group", "id": "DDI-DrugBank.d98.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s8-2", "sentence_id": "DDI-DrugBank.d98.s8", "sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "arg1": {"span": [[14, 26]], "type": "drug", "id": "DDI-DrugBank.d98.s8.e1"}, "arg2": {"span": [[79, 88]], "type": "group", "id": "DDI-DrugBank.d98.s8.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d98.s10-0", "sentence_id": "DDI-DrugBank.d98.s10", "sentence": "However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.", "arg1": {"span": [[45, 57]], "type": "drug", "id": "DDI-DrugBank.d98.s10.e0"}, "arg2": {"span": [[63, 72]], "type": "group", "id": "DDI-DrugBank.d98.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-0", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d98.s11.e0"}, "arg2": {"span": [[72, 91]], "type": "group", "id": "DDI-DrugBank.d98.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-1", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d98.s11.e0"}, "arg2": {"span": [[131, 146]], "type": "group", "id": "DDI-DrugBank.d98.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s11-2", "sentence_id": "DDI-DrugBank.d98.s11", "sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "arg1": {"span": [[72, 91]], "type": "group", "id": "DDI-DrugBank.d98.s11.e1"}, "arg2": {"span": [[131, 146]], "type": "group", "id": "DDI-DrugBank.d98.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d98.s13-0", "sentence_id": "DDI-DrugBank.d98.s13", "sentence": "Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.", "arg1": {"span": [[0, 9]], "type": "group", "id": "DDI-DrugBank.d98.s13.e0"}, "arg2": {"span": [[46, 65]], "type": "group", "id": "DDI-DrugBank.d98.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s14-0", "sentence_id": "DDI-DrugBank.d98.s14", "sentence": "Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d98.s14.e0"}, "arg2": {"span": [[55, 62]], "type": "drug", "id": "DDI-DrugBank.d98.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-0", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-1", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-2", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e0"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-3", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "arg2": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d98.s15-4", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d98.s15.e1"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d98.s15-5", "sentence_id": "DDI-DrugBank.d98.s15", "sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "arg1": {"span": [[50, 58]], "type": "group", "id": "DDI-DrugBank.d98.s15.e2"}, "arg2": {"span": [[140, 149]], "type": "group", "id": "DDI-DrugBank.d98.s15.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d281.s0-0", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d281.s0.e0"}, "arg2": {"span": [[51, 65]], "type": "group", "id": "DDI-DrugBank.d281.s0.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d281.s0-1", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d281.s0.e0"}, "arg2": {"span": [[132, 145]], "type": "group", "id": "DDI-DrugBank.d281.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d281.s0-2", "sentence_id": "DDI-DrugBank.d281.s0", "sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "arg1": {"span": [[51, 65]], "type": "group", "id": "DDI-DrugBank.d281.s0.e1"}, "arg2": {"span": [[132, 145]], "type": "group", "id": "DDI-DrugBank.d281.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-0", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s1.e0"}, "arg2": {"span": [[11, 23]], "type": "group", "id": "DDI-DrugBank.d46.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-1", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s1.e0"}, "arg2": {"span": [[28, 37]], "type": "group", "id": "DDI-DrugBank.d46.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s1-2", "sentence_id": "DDI-DrugBank.d46.s1", "sentence": "- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur", "arg1": {"span": [[11, 23]], "type": "group", "id": "DDI-DrugBank.d46.s1.e1"}, "arg2": {"span": [[28, 37]], "type": "group", "id": "DDI-DrugBank.d46.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-0", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[2, 20]], "type": "group", "id": "DDI-DrugBank.d46.s3.e0"}, "arg2": {"span": [[39, 46]], "type": "drug", "id": "DDI-DrugBank.d46.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-1", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[2, 20]], "type": "group", "id": "DDI-DrugBank.d46.s3.e0"}, "arg2": {"span": [[73, 90]], "type": "group", "id": "DDI-DrugBank.d46.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s3-2", "sentence_id": "DDI-DrugBank.d46.s3", "sentence": "- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required", "arg1": {"span": [[39, 46]], "type": "drug", "id": "DDI-DrugBank.d46.s3.e1"}, "arg2": {"span": [[73, 90]], "type": "group", "id": "DDI-DrugBank.d46.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s9-0", "sentence_id": "DDI-DrugBank.d46.s9", "sentence": "- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia", "arg1": {"span": [[2, 17]], "type": "group", "id": "DDI-DrugBank.d46.s9.e0"}, "arg2": {"span": [[19, 23]], "type": "drug", "id": "DDI-DrugBank.d46.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-0", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[2, 27]], "type": "group", "id": "DDI-DrugBank.d46.s13.e0"}, "arg2": {"span": [[52, 64]], "type": "drug", "id": "DDI-DrugBank.d46.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-1", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[2, 27]], "type": "group", "id": "DDI-DrugBank.d46.s13.e0"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d46.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s13-2", "sentence_id": "DDI-DrugBank.d46.s13", "sentence": "- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant", "arg1": {"span": [[52, 64]], "type": "drug", "id": "DDI-DrugBank.d46.s13.e1"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d46.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s15-0", "sentence_id": "DDI-DrugBank.d46.s15", "sentence": "- Lithium: Generally should not be given with diuretics.", "arg1": {"span": [[2, 9]], "type": "drug", "id": "DDI-DrugBank.d46.s15.e0"}, "arg2": {"span": [[46, 55]], "type": "group", "id": "DDI-DrugBank.d46.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s16-0", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d46.s16.e0"}, "arg2": {"span": [[46, 53]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d46.s16-1", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d46.s16.e0"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d46.s16-2", "sentence_id": "DDI-DrugBank.d46.s16", "sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "arg1": {"span": [[46, 53]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e1"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d46.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s17-0", "sentence_id": "DDI-DrugBank.d46.s17", "sentence": "Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide", "arg1": {"span": [[32, 39]], "type": "drug", "id": "DDI-DrugBank.d46.s17.e0"}, "arg2": {"span": [[90, 104]], "type": "drug", "id": "DDI-DrugBank.d46.s17.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s19-0", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[2, 39]], "type": "group", "id": "DDI-DrugBank.d46.s19.e0"}, "arg2": {"span": [[83, 120]], "type": "group", "id": "DDI-DrugBank.d46.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s19-1", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[2, 39]], "type": "group", "id": "DDI-DrugBank.d46.s19.e0"}, "arg2": {"span": [[219, 237]], "type": "drug", "id": "DDI-DrugBank.d46.s19.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s19-2", "sentence_id": "DDI-DrugBank.d46.s19", "sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "arg1": {"span": [[83, 120]], "type": "group", "id": "DDI-DrugBank.d46.s19.e1"}, "arg2": {"span": [[219, 237]], "type": "drug", "id": "DDI-DrugBank.d46.s19.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d46.s20-0", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[16, 30]], "type": "drug", "id": "DDI-DrugBank.d46.s20.e0"}, "arg2": {"span": [[35, 73]], "type": "group", "id": "DDI-DrugBank.d46.s20.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d46.s20-1", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[16, 30]], "type": "drug", "id": "DDI-DrugBank.d46.s20.e0"}, "arg2": {"span": [[179, 187]], "type": "group", "id": "DDI-DrugBank.d46.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d46.s20-2", "sentence_id": "DDI-DrugBank.d46.s20", "sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "arg1": {"span": [[35, 73]], "type": "group", "id": "DDI-DrugBank.d46.s20.e1"}, "arg2": {"span": [[179, 187]], "type": "group", "id": "DDI-DrugBank.d46.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-0", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-1", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-2", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d343.s0.e0"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-3", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "arg2": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-4", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e1"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d343.s0-5", "sentence_id": "DDI-DrugBank.d343.s0", "sentence": "Aspirin, warfarin, heparin, NSAIDs", "arg1": {"span": [[19, 26]], "type": "drug", "id": "DDI-DrugBank.d343.s0.e2"}, "arg2": {"span": [[28, 34]], "type": "group", "id": "DDI-DrugBank.d343.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d439.s0-0", "sentence_id": "DDI-DrugBank.d439.s0", "sentence": "Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d439.s0.e0"}, "arg2": {"span": [[66, 74]], "type": "group", "id": "DDI-DrugBank.d439.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d386.s3-0", "sentence_id": "DDI-DrugBank.d386.s3", "sentence": "Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.", "arg1": {"span": [[69, 94]], "type": "group", "id": "DDI-DrugBank.d386.s3.e0"}, "arg2": {"span": [[96, 100]], "type": "group", "id": "DDI-DrugBank.d386.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-0", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-1", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-2", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e0"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-3", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "arg2": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-4", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d386.s9.e1"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s9-5", "sentence_id": "DDI-DrugBank.d386.s9", "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).", "arg1": {"span": [[83, 97]], "type": "group", "id": "DDI-DrugBank.d386.s9.e2"}, "arg2": {"span": [[148, 158]], "type": "drug", "id": "DDI-DrugBank.d386.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-0", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-1", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-2", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[14, 53]], "type": "group", "id": "DDI-DrugBank.d386.s10.e0"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-3", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-4", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[55, 60]], "type": "group", "id": "DDI-DrugBank.d386.s10.e1"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s10-5", "sentence_id": "DDI-DrugBank.d386.s10", "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "arg1": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e2"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d386.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s11-0", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[20, 24]], "type": "group", "id": "DDI-DrugBank.d386.s11.e0"}, "arg2": {"span": [[25, 28]], "type": "group", "id": "DDI-DrugBank.d386.s11.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d386.s11-1", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[20, 24]], "type": "group", "id": "DDI-DrugBank.d386.s11.e0"}, "arg2": {"span": [[141, 145]], "type": "group", "id": "DDI-DrugBank.d386.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s11-2", "sentence_id": "DDI-DrugBank.d386.s11", "sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "arg1": {"span": [[25, 28]], "type": "group", "id": "DDI-DrugBank.d386.s11.e1"}, "arg2": {"span": [[141, 145]], "type": "group", "id": "DDI-DrugBank.d386.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s12-0", "sentence_id": "DDI-DrugBank.d386.s12", "sentence": "Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.", "arg1": {"span": [[63, 67]], "type": "group", "id": "DDI-DrugBank.d386.s12.e0"}, "arg2": {"span": [[84, 89]], "type": "group", "id": "DDI-DrugBank.d386.s12.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d386.s14-0", "sentence_id": "DDI-DrugBank.d386.s14", "sentence": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "arg1": {"span": [[19, 44]], "type": "group", "id": "DDI-DrugBank.d386.s14.e0"}, "arg2": {"span": [[156, 180]], "type": "group", "id": "DDI-DrugBank.d386.s14.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s16-0", "sentence_id": "DDI-DrugBank.d386.s16", "sentence": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "arg1": {"span": [[27, 30]], "type": "group", "id": "DDI-DrugBank.d386.s16.e0"}, "arg2": {"span": [[56, 59]], "type": "group", "id": "DDI-DrugBank.d386.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s18-0", "sentence_id": "DDI-DrugBank.d386.s18", "sentence": "Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.", "arg1": {"span": [[107, 122]], "type": "group", "id": "DDI-DrugBank.d386.s18.e0"}, "arg2": {"span": [[126, 147]], "type": "group", "id": "DDI-DrugBank.d386.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s24-0", "sentence_id": "DDI-DrugBank.d386.s24", "sentence": "Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.", "arg1": {"span": [[53, 72]], "type": "group", "id": "DDI-DrugBank.d386.s24.e0"}, "arg2": {"span": [[103, 114]], "type": "drug", "id": "DDI-DrugBank.d386.s24.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d386.s26-0", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[29, 39]], "type": "drug", "id": "DDI-DrugBank.d386.s26.e0"}, "arg2": {"span": [[44, 69]], "type": "group", "id": "DDI-DrugBank.d386.s26.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d386.s26-1", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[29, 39]], "type": "drug", "id": "DDI-DrugBank.d386.s26.e0"}, "arg2": {"span": [[143, 168]], "type": "group", "id": "DDI-DrugBank.d386.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s26-2", "sentence_id": "DDI-DrugBank.d386.s26", "sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "arg1": {"span": [[44, 69]], "type": "group", "id": "DDI-DrugBank.d386.s26.e1"}, "arg2": {"span": [[143, 168]], "type": "group", "id": "DDI-DrugBank.d386.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s27-0", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[46, 71]], "type": "group", "id": "DDI-DrugBank.d386.s27.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d386.s27.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d386.s27-1", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[46, 71]], "type": "group", "id": "DDI-DrugBank.d386.s27.e0"}, "arg2": {"span": [[190, 214]], "type": "group", "id": "DDI-DrugBank.d386.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s27-2", "sentence_id": "DDI-DrugBank.d386.s27", "sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d386.s27.e1"}, "arg2": {"span": [[190, 214]], "type": "group", "id": "DDI-DrugBank.d386.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d386.s28-0", "sentence_id": "DDI-DrugBank.d386.s28", "sentence": "There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.", "arg1": {"span": [[86, 111]], "type": "group", "id": "DDI-DrugBank.d386.s28.e0"}, "arg2": {"span": [[117, 127]], "type": "drug", "id": "DDI-DrugBank.d386.s28.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d166.s0-0", "sentence_id": "DDI-DrugBank.d166.s0", "sentence": "Trecator has been found to temporarily raise serum concentrations of isoniazid.", "arg1": {"span": [[0, 8]], "type": "brand", "id": "DDI-DrugBank.d166.s0.e0"}, "arg2": {"span": [[69, 78]], "type": "drug", "id": "DDI-DrugBank.d166.s0.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d166.s1-0", "sentence_id": "DDI-DrugBank.d166.s1", "sentence": "Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.", "arg1": {"span": [[0, 8]], "type": "brand", "id": "DDI-DrugBank.d166.s1.e0"}, "arg2": {"span": [[53, 74]], "type": "group", "id": "DDI-DrugBank.d166.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d166.s2-0", "sentence_id": "DDI-DrugBank.d166.s2", "sentence": "In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d166.s2.e0"}, "arg2": {"span": [[84, 95]], "type": "drug", "id": "DDI-DrugBank.d166.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d199.s0-0", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-1", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-2", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[0, 14]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e0"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-3", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "arg2": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d199.s0-4", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d199.s0.e1"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s0-5", "sentence_id": "DDI-DrugBank.d199.s0", "sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "arg1": {"span": [[50, 64]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e2"}, "arg2": {"span": [[172, 182]], "type": "drug", "id": "DDI-DrugBank.d199.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-0", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-1", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-2", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e0"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-3", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-4", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e1"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d199.s2-5", "sentence_id": "DDI-DrugBank.d199.s2", "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "arg1": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d199.s2.e2"}, "arg2": {"span": [[99, 106]], "type": "brand", "id": "DDI-DrugBank.d199.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-0", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d178.s7-1", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-2", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[31, 40]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e0"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-3", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "arg2": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-4", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e1"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s7-5", "sentence_id": "DDI-DrugBank.d178.s7", "sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "arg1": {"span": [[62, 88]], "type": "group", "id": "DDI-DrugBank.d178.s7.e2"}, "arg2": {"span": [[167, 176]], "type": "drug", "id": "DDI-DrugBank.d178.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s9-0", "sentence_id": "DDI-DrugBank.d178.s9", "sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d178.s9.e0"}, "arg2": {"span": [[57, 76]], "type": "group", "id": "DDI-DrugBank.d178.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d178.s11-0", "sentence_id": "DDI-DrugBank.d178.s11", "sentence": "Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d178.s11.e0"}, "arg2": {"span": [[78, 87]], "type": "drug", "id": "DDI-DrugBank.d178.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d178.s13-0", "sentence_id": "DDI-DrugBank.d178.s13", "sentence": "Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.", "arg1": {"span": [[35, 44]], "type": "drug", "id": "DDI-DrugBank.d178.s13.e0"}, "arg2": {"span": [[85, 94]], "type": "drug", "id": "DDI-DrugBank.d178.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s0-0", "sentence_id": "DDI-DrugBank.d135.s0", "sentence": "Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.", "arg1": {"span": [[11, 20]], "type": "drug", "id": "DDI-DrugBank.d135.s0.e0"}, "arg2": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s5-0", "sentence_id": "DDI-DrugBank.d135.s5", "sentence": "Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.", "arg1": {"span": [[57, 66]], "type": "drug", "id": "DDI-DrugBank.d135.s5.e0"}, "arg2": {"span": [[189, 198]], "type": "drug", "id": "DDI-DrugBank.d135.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-0", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e0"}, "arg2": {"span": [[44, 56]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-1", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e0"}, "arg2": {"span": [[139, 148]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s7-2", "sentence_id": "DDI-DrugBank.d135.s7", "sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "arg1": {"span": [[44, 56]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e1"}, "arg2": {"span": [[139, 148]], "type": "drug", "id": "DDI-DrugBank.d135.s7.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d135.s8-0", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e0"}, "arg2": {"span": [[65, 78]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s8-1", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e0"}, "arg2": {"span": [[176, 185]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s8-2", "sentence_id": "DDI-DrugBank.d135.s8", "sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "arg1": {"span": [[65, 78]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e1"}, "arg2": {"span": [[176, 185]], "type": "drug", "id": "DDI-DrugBank.d135.s8.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d135.s10-0", "sentence_id": "DDI-DrugBank.d135.s10", "sentence": "If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.", "arg1": {"span": [[3, 9]], "type": "brand", "id": "DDI-DrugBank.d135.s10.e0"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d135.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-0", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e0"}, "arg2": {"span": [[92, 104]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-1", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[77, 86]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e0"}, "arg2": {"span": [[192, 204]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d135.s11-2", "sentence_id": "DDI-DrugBank.d135.s11", "sentence": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "arg1": {"span": [[92, 104]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e1"}, "arg2": {"span": [[192, 204]], "type": "drug", "id": "DDI-DrugBank.d135.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d261.s0-0", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e0"}, "arg2": {"span": [[16, 41]], "type": "group", "id": "DDI-DrugBank.d261.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d261.s0-1", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e0"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d261.s0-2", "sentence_id": "DDI-DrugBank.d261.s0", "sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "arg1": {"span": [[16, 41]], "type": "group", "id": "DDI-DrugBank.d261.s0.e1"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-DrugBank.d261.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-0", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-1", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-2", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e0"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-3", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "arg2": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-4", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e1"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s4-5", "sentence_id": "DDI-DrugBank.d198.s4", "sentence": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "arg1": {"span": [[113, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e2"}, "arg2": {"span": [[156, 166]], "type": "drug", "id": "DDI-DrugBank.d198.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s5-0", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e0"}, "arg2": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s5-1", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e0"}, "arg2": {"span": [[129, 139]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s5-2", "sentence_id": "DDI-DrugBank.d198.s5", "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "arg1": {"span": [[58, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e1"}, "arg2": {"span": [[129, 139]], "type": "drug", "id": "DDI-DrugBank.d198.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s6-0", "sentence_id": "DDI-DrugBank.d198.s6", "sentence": "It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.", "arg1": {"span": [[54, 64]], "type": "drug", "id": "DDI-DrugBank.d198.s6.e0"}, "arg2": {"span": [[115, 127]], "type": "drug", "id": "DDI-DrugBank.d198.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s7-0", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e0"}, "arg2": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s7-1", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e0"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s7-2", "sentence_id": "DDI-DrugBank.d198.s7", "sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e1"}, "arg2": {"span": [[135, 145]], "type": "drug", "id": "DDI-DrugBank.d198.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s8-0", "sentence_id": "DDI-DrugBank.d198.s8", "sentence": "A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.", "arg1": {"span": [[7, 17]], "type": "drug", "id": "DDI-DrugBank.d198.s8.e0"}, "arg2": {"span": [[94, 106]], "type": "drug", "id": "DDI-DrugBank.d198.s8.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s9-0", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e0"}, "arg2": {"span": [[122, 132]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s9-1", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e0"}, "arg2": {"span": [[206, 218]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s9-2", "sentence_id": "DDI-DrugBank.d198.s9", "sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "arg1": {"span": [[122, 132]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e1"}, "arg2": {"span": [[206, 218]], "type": "drug", "id": "DDI-DrugBank.d198.s9.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s11-0", "sentence_id": "DDI-DrugBank.d198.s11", "sentence": "It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s11.e0"}, "arg2": {"span": [[114, 123]], "type": "drug", "id": "DDI-DrugBank.d198.s11.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s12-0", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s12-1", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-2", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e0"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-3", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "arg2": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-4", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e1"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s12-5", "sentence_id": "DDI-DrugBank.d198.s12", "sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "arg1": {"span": [[97, 107]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e2"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d198.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s13-0", "sentence_id": "DDI-DrugBank.d198.s13", "sentence": "The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d198.s13.e0"}, "arg2": {"span": [[81, 90]], "type": "drug", "id": "DDI-DrugBank.d198.s13.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s14-0", "sentence_id": "DDI-DrugBank.d198.s14", "sentence": "Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s14.e0"}, "arg2": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d198.s14.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s15-0", "sentence_id": "DDI-DrugBank.d198.s15", "sentence": "Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.", "arg1": {"span": [[62, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s15.e0"}, "arg2": {"span": [[128, 137]], "type": "drug", "id": "DDI-DrugBank.d198.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s17-0", "sentence_id": "DDI-DrugBank.d198.s17", "sentence": "In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.", "arg1": {"span": [[7, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s17.e0"}, "arg2": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d198.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-0", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-1", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-2", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[17, 25]], "type": "group", "id": "DDI-DrugBank.d198.s22.e0"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-3", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "arg2": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s22-4", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[77, 85]], "type": "group", "id": "DDI-DrugBank.d198.s22.e1"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s22-5", "sentence_id": "DDI-DrugBank.d198.s22", "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "arg1": {"span": [[121, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e2"}, "arg2": {"span": [[227, 237]], "type": "drug", "id": "DDI-DrugBank.d198.s22.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s23-0", "sentence_id": "DDI-DrugBank.d198.s23", "sentence": "These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d198.s23.e0"}, "arg2": {"span": [[84, 87]], "type": "drug", "id": "DDI-DrugBank.d198.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-0", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[43, 51]], "type": "group", "id": "DDI-DrugBank.d198.s24.e0"}, "arg2": {"span": [[140, 150]], "type": "drug", "id": "DDI-DrugBank.d198.s24.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-1", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[43, 51]], "type": "group", "id": "DDI-DrugBank.d198.s24.e0"}, "arg2": {"span": [[155, 163]], "type": "group", "id": "DDI-DrugBank.d198.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s24-2", "sentence_id": "DDI-DrugBank.d198.s24", "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "arg1": {"span": [[140, 150]], "type": "drug", "id": "DDI-DrugBank.d198.s24.e1"}, "arg2": {"span": [[155, 163]], "type": "group", "id": "DDI-DrugBank.d198.s24.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s25-0", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-1", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-2", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e0"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-3", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-4", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[12, 22]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e1"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s25-5", "sentence_id": "DDI-DrugBank.d198.s25", "sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "arg1": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e2"}, "arg2": {"span": [[192, 202]], "type": "drug", "id": "DDI-DrugBank.d198.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s26-0", "sentence_id": "DDI-DrugBank.d198.s26", "sentence": "Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s26.e0"}, "arg2": {"span": [[46, 56]], "type": "drug", "id": "DDI-DrugBank.d198.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s27-0", "sentence_id": "DDI-DrugBank.d198.s27", "sentence": "In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-DrugBank.d198.s27.e0"}, "arg2": {"span": [[69, 79]], "type": "drug", "id": "DDI-DrugBank.d198.s27.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s28-0", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d198.s28.e0"}, "arg2": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s28-1", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d198.s28.e0"}, "arg2": {"span": [[131, 140]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s28-2", "sentence_id": "DDI-DrugBank.d198.s28", "sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e1"}, "arg2": {"span": [[131, 140]], "type": "drug", "id": "DDI-DrugBank.d198.s28.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s29-0", "sentence_id": "DDI-DrugBank.d198.s29", "sentence": "With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "arg1": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d198.s29.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s29.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s30-0", "sentence_id": "DDI-DrugBank.d198.s30", "sentence": "With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "arg1": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d198.s30.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d198.s30.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s31-0", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[5, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e0"}, "arg2": {"span": [[42, 51]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s31-1", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[5, 15]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e0"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s31-2", "sentence_id": "DDI-DrugBank.d198.s31", "sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e1"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d198.s31.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-0", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[24, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e0"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-1", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[24, 34]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e0"}, "arg2": {"span": [[107, 117]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s32-2", "sentence_id": "DDI-DrugBank.d198.s32", "sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e1"}, "arg2": {"span": [[107, 117]], "type": "drug", "id": "DDI-DrugBank.d198.s32.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s33-0", "sentence_id": "DDI-DrugBank.d198.s33", "sentence": "Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d198.s33.e0"}, "arg2": {"span": [[66, 76]], "type": "drug", "id": "DDI-DrugBank.d198.s33.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d198.s34-0", "sentence_id": "DDI-DrugBank.d198.s34", "sentence": "The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d198.s34.e0"}, "arg2": {"span": [[53, 67]], "type": "group", "id": "DDI-DrugBank.d198.s34.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s35-0", "sentence_id": "DDI-DrugBank.d198.s35", "sentence": "Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.", "arg1": {"span": [[21, 31]], "type": "drug", "id": "DDI-DrugBank.d198.s35.e0"}, "arg2": {"span": [[66, 79]], "type": "group", "id": "DDI-DrugBank.d198.s35.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d198.s36-0", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-1", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-2", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-3", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e0"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-4", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-5", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-6", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e1"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-7", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s36-8", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e2"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s36-9", "sentence_id": "DDI-DrugBank.d198.s36", "sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "arg1": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e3"}, "arg2": {"span": [[126, 135]], "type": "drug", "id": "DDI-DrugBank.d198.s36.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s37-0", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[32, 42]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e0"}, "arg2": {"span": [[59, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d198.s37-1", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[32, 42]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e0"}, "arg2": {"span": [[90, 99]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s37-2", "sentence_id": "DDI-DrugBank.d198.s37", "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "arg1": {"span": [[59, 68]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e1"}, "arg2": {"span": [[90, 99]], "type": "drug", "id": "DDI-DrugBank.d198.s37.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-0", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e0"}, "arg2": {"span": [[9, 16]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-1", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e0"}, "arg2": {"span": [[103, 113]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s38-2", "sentence_id": "DDI-DrugBank.d198.s38", "sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "arg1": {"span": [[9, 16]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e1"}, "arg2": {"span": [[103, 113]], "type": "drug", "id": "DDI-DrugBank.d198.s38.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-0", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-1", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e0"}, "arg2": {"span": [[155, 162]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s39-2", "sentence_id": "DDI-DrugBank.d198.s39", "sentence": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e1"}, "arg2": {"span": [[155, 162]], "type": "drug", "id": "DDI-DrugBank.d198.s39.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-0", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e0"}, "arg2": {"span": [[9, 19]], "type": "drug", "id": "DDI-DrugBank.d198.s40.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-1", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e0"}, "arg2": {"span": [[97, 104]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s40-2", "sentence_id": "DDI-DrugBank.d198.s40", "sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "arg1": {"span": [[9, 19]], "type": "drug", "id": "DDI-DrugBank.d198.s40.e1"}, "arg2": {"span": [[97, 104]], "type": "brand", "id": "DDI-DrugBank.d198.s40.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-0", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e0"}, "arg2": {"span": [[72, 81]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-1", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e0"}, "arg2": {"span": [[123, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d198.s41-2", "sentence_id": "DDI-DrugBank.d198.s41", "sentence": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "arg1": {"span": [[72, 81]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e1"}, "arg2": {"span": [[123, 131]], "type": "drug", "id": "DDI-DrugBank.d198.s41.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-0", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[54, 62]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e0"}, "arg2": {"span": [[83, 96]], "type": "group", "id": "DDI-DrugBank.d536.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-1", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[54, 62]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e0"}, "arg2": {"span": [[100, 107]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s3-2", "sentence_id": "DDI-DrugBank.d536.s3", "sentence": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "arg1": {"span": [[83, 96]], "type": "group", "id": "DDI-DrugBank.d536.s3.e1"}, "arg2": {"span": [[100, 107]], "type": "drug", "id": "DDI-DrugBank.d536.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s5-0", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e0"}, "arg2": {"span": [[54, 61]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s5-1", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e0"}, "arg2": {"span": [[111, 118]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s5-2", "sentence_id": "DDI-DrugBank.d536.s5", "sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "arg1": {"span": [[54, 61]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e1"}, "arg2": {"span": [[111, 118]], "type": "drug", "id": "DDI-DrugBank.d536.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-0", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-1", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-2", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-3", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e0"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-4", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-5", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-6", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[123, 130]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e1"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-7", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "arg2": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-8", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[132, 142]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e2"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s6-9", "sentence_id": "DDI-DrugBank.d536.s6", "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.", "arg1": {"span": [[144, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e3"}, "arg2": {"span": [[160, 170]], "type": "drug", "id": "DDI-DrugBank.d536.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-0", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e0"}, "arg2": {"span": [[69, 81]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-1", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e0"}, "arg2": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s7-2", "sentence_id": "DDI-DrugBank.d536.s7", "sentence": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "arg1": {"span": [[69, 81]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e1"}, "arg2": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d536.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-0", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-1", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-2", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-3", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e0"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-4", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-5", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-6", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[20, 27]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e1"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-7", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "arg2": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-8", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[79, 86]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e2"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s8-9", "sentence_id": "DDI-DrugBank.d536.s8", "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "arg1": {"span": [[148, 155]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e3"}, "arg2": {"span": [[240, 247]], "type": "drug", "id": "DDI-DrugBank.d536.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s9-0", "sentence_id": "DDI-DrugBank.d536.s9", "sentence": "The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.", "arg1": {"span": [[14, 23]], "type": "drug", "id": "DDI-DrugBank.d536.s9.e0"}, "arg2": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d536.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s10-0", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[34, 43]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e0"}, "arg2": {"span": [[89, 97]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s10-1", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[34, 43]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e0"}, "arg2": {"span": [[141, 150]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d536.s10-2", "sentence_id": "DDI-DrugBank.d536.s10", "sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "arg1": {"span": [[89, 97]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e1"}, "arg2": {"span": [[141, 150]], "type": "drug", "id": "DDI-DrugBank.d536.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d536.s11-0", "sentence_id": "DDI-DrugBank.d536.s11", "sentence": "There is little if any clinically significant interaction between Acarbose and metformin.", "arg1": {"span": [[66, 74]], "type": "drug", "id": "DDI-DrugBank.d536.s11.e0"}, "arg2": {"span": [[79, 88]], "type": "drug", "id": "DDI-DrugBank.d536.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-0", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-1", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-2", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-3", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[51, 62]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e0"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-4", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-5", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-6", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[64, 74]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e1"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-7", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "arg2": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-8", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[76, 84]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e2"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s2-9", "sentence_id": "DDI-DrugBank.d197.s2", "sentence": "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e3"}, "arg2": {"span": [[102, 111]], "type": "drug", "id": "DDI-DrugBank.d197.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-0", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-1", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-2", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-3", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e0"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-4", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-5", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-6", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e1"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-7", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-8", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[72, 80]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e2"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s3-9", "sentence_id": "DDI-DrugBank.d197.s3", "sentence": "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e3"}, "arg2": {"span": [[98, 107]], "type": "drug", "id": "DDI-DrugBank.d197.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-0", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[0, 22]], "type": "group", "id": "DDI-DrugBank.d197.s5.e0"}, "arg2": {"span": [[81, 89]], "type": "brand", "id": "DDI-DrugBank.d197.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-1", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[0, 22]], "type": "group", "id": "DDI-DrugBank.d197.s5.e0"}, "arg2": {"span": [[254, 264]], "type": "drug", "id": "DDI-DrugBank.d197.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d197.s5-2", "sentence_id": "DDI-DrugBank.d197.s5", "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.", "arg1": {"span": [[81, 89]], "type": "brand", "id": "DDI-DrugBank.d197.s5.e1"}, "arg2": {"span": [[254, 264]], "type": "drug", "id": "DDI-DrugBank.d197.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-0", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-1", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-2", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-3", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[28, 48]], "type": "group", "id": "DDI-DrugBank.d153.s0.e0"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-4", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s0-5", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-6", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[60, 71]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e1"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-7", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "arg2": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-8", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[75, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s0.e2"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s0-9", "sentence_id": "DDI-DrugBank.d153.s0", "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "arg1": {"span": [[112, 140]], "type": "group", "id": "DDI-DrugBank.d153.s0.e3"}, "arg2": {"span": [[144, 169]], "type": "group", "id": "DDI-DrugBank.d153.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s3-0", "sentence_id": "DDI-DrugBank.d153.s3", "sentence": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "arg1": {"span": [[29, 46]], "type": "group", "id": "DDI-DrugBank.d153.s3.e0"}, "arg2": {"span": [[54, 79]], "type": "group", "id": "DDI-DrugBank.d153.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s4-0", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d153.s4.e0"}, "arg2": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d153.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d153.s4-1", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d153.s4.e0"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d153.s4-2", "sentence_id": "DDI-DrugBank.d153.s4", "sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "arg1": {"span": [[19, 33]], "type": "group", "id": "DDI-DrugBank.d153.s4.e1"}, "arg2": {"span": [[78, 89]], "type": "drug", "id": "DDI-DrugBank.d153.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s0-0", "sentence_id": "DDI-DrugBank.d325.s0", "sentence": "Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.", "arg1": {"span": [[8, 16]], "type": "drug", "id": "DDI-DrugBank.d325.s0.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d325.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s1-0", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[36, 50]], "type": "group", "id": "DDI-DrugBank.d325.s1.e0"}, "arg2": {"span": [[108, 120]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s1-1", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[36, 50]], "type": "group", "id": "DDI-DrugBank.d325.s1.e0"}, "arg2": {"span": [[153, 165]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s1-2", "sentence_id": "DDI-DrugBank.d325.s1", "sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "arg1": {"span": [[108, 120]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e1"}, "arg2": {"span": [[153, 165]], "type": "drug", "id": "DDI-DrugBank.d325.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s2-0", "sentence_id": "DDI-DrugBank.d325.s2", "sentence": "Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.", "arg1": {"span": [[38, 50]], "type": "drug", "id": "DDI-DrugBank.d325.s2.e0"}, "arg2": {"span": [[55, 70]], "type": "group", "id": "DDI-DrugBank.d325.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-0", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-1", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-2", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[19, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e0"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s4-3", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "arg2": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s4-4", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[47, 78]], "type": "group", "id": "DDI-DrugBank.d325.s4.e1"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s4-5", "sentence_id": "DDI-DrugBank.d325.s4", "sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "arg1": {"span": [[88, 99]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e2"}, "arg2": {"span": [[104, 114]], "type": "drug", "id": "DDI-DrugBank.d325.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s5-0", "sentence_id": "DDI-DrugBank.d325.s5", "sentence": "The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.", "arg1": {"span": [[56, 68]], "type": "drug", "id": "DDI-DrugBank.d325.s5.e0"}, "arg2": {"span": [[87, 119]], "type": "group", "id": "DDI-DrugBank.d325.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s6-0", "sentence_id": "DDI-DrugBank.d325.s6", "sentence": "Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d325.s6.e0"}, "arg2": {"span": [[90, 121]], "type": "drug", "id": "DDI-DrugBank.d325.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-0", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-1", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-2", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d325.s7.e0"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s7-3", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "arg2": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s7-4", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[24, 35]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e1"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s7-5", "sentence_id": "DDI-DrugBank.d325.s7", "sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "arg1": {"span": [[41, 55]], "type": "group", "id": "DDI-DrugBank.d325.s7.e2"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d325.s7.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-0", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s8-1", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-2", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e0"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-3", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "arg2": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-4", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[16, 51]], "type": "group", "id": "DDI-DrugBank.d325.s8.e1"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s8-5", "sentence_id": "DDI-DrugBank.d325.s8", "sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "arg1": {"span": [[177, 191]], "type": "group", "id": "DDI-DrugBank.d325.s8.e2"}, "arg2": {"span": [[201, 209]], "type": "drug", "id": "DDI-DrugBank.d325.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s10-0", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[66, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e0"}, "arg2": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s10-1", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[66, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e0"}, "arg2": {"span": [[117, 152]], "type": "group", "id": "DDI-DrugBank.d325.s10.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s10-2", "sentence_id": "DDI-DrugBank.d325.s10", "sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "arg1": {"span": [[101, 113]], "type": "drug", "id": "DDI-DrugBank.d325.s10.e1"}, "arg2": {"span": [[117, 152]], "type": "group", "id": "DDI-DrugBank.d325.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s11-0", "sentence_id": "DDI-DrugBank.d325.s11", "sentence": "It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d325.s11.e0"}, "arg2": {"span": [[148, 159]], "type": "drug", "id": "DDI-DrugBank.d325.s11.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s12-0", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[23, 34]], "type": "group", "id": "DDI-DrugBank.d325.s12.e0"}, "arg2": {"span": [[70, 80]], "type": "drug", "id": "DDI-DrugBank.d325.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s12-1", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[23, 34]], "type": "group", "id": "DDI-DrugBank.d325.s12.e0"}, "arg2": {"span": [[91, 105]], "type": "group", "id": "DDI-DrugBank.d325.s12.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s12-2", "sentence_id": "DDI-DrugBank.d325.s12", "sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "arg1": {"span": [[70, 80]], "type": "drug", "id": "DDI-DrugBank.d325.s12.e1"}, "arg2": {"span": [[91, 105]], "type": "group", "id": "DDI-DrugBank.d325.s12.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s13-0", "sentence_id": "DDI-DrugBank.d325.s13", "sentence": "Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.", "arg1": {"span": [[18, 27]], "type": "drug", "id": "DDI-DrugBank.d325.s13.e0"}, "arg2": {"span": [[50, 62]], "type": "drug", "id": "DDI-DrugBank.d325.s13.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d325.s14-0", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e0"}, "arg2": {"span": [[73, 82]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d325.s14-1", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e0"}, "arg2": {"span": [[101, 115]], "type": "group", "id": "DDI-DrugBank.d325.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d325.s14-2", "sentence_id": "DDI-DrugBank.d325.s14", "sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "arg1": {"span": [[73, 82]], "type": "drug", "id": "DDI-DrugBank.d325.s14.e1"}, "arg2": {"span": [[101, 115]], "type": "group", "id": "DDI-DrugBank.d325.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-0", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-1", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-2", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-3", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[41, 48]], "type": "brand", "id": "DDI-DrugBank.d375.s0.e0"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-4", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-5", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-6", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e1"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-7", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-8", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[97, 106]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e2"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d375.s0-9", "sentence_id": "DDI-DrugBank.d375.s0", "sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "arg1": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e3"}, "arg2": {"span": [[125, 154]], "type": "drug", "id": "DDI-DrugBank.d375.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-0", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-1", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-2", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d535.s1.e0"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-3", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "arg2": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-4", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[55, 81]], "type": "group", "id": "DDI-DrugBank.d535.s1.e1"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d535.s1-5", "sentence_id": "DDI-DrugBank.d535.s1", "sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "arg1": {"span": [[147, 158]], "type": "drug", "id": "DDI-DrugBank.d535.s1.e2"}, "arg2": {"span": [[189, 214]], "type": "group", "id": "DDI-DrugBank.d535.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-0", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s0-1", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-2", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e0"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-3", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "arg2": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-4", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[61, 73]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e1"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s0-5", "sentence_id": "DDI-DrugBank.d397.s0", "sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "arg1": {"span": [[118, 130]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e2"}, "arg2": {"span": [[152, 164]], "type": "drug", "id": "DDI-DrugBank.d397.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-0", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-1", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-2", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e0"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-3", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "arg2": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-4", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[55, 67]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e1"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s1-5", "sentence_id": "DDI-DrugBank.d397.s1", "sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "arg1": {"span": [[88, 100]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e2"}, "arg2": {"span": [[162, 174]], "type": "drug", "id": "DDI-DrugBank.d397.s1.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d397.s2-0", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[30, 42]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e0"}, "arg2": {"span": [[47, 54]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s2-1", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[30, 42]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e0"}, "arg2": {"span": [[95, 102]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s2-2", "sentence_id": "DDI-DrugBank.d397.s2", "sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "arg1": {"span": [[47, 54]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e1"}, "arg2": {"span": [[95, 102]], "type": "drug", "id": "DDI-DrugBank.d397.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s3-0", "sentence_id": "DDI-DrugBank.d397.s3", "sentence": "There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s3.e0"}, "arg2": {"span": [[86, 100]], "type": "group", "id": "DDI-DrugBank.d397.s3.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-0", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[18, 30]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e0"}, "arg2": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-1", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[18, 30]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e0"}, "arg2": {"span": [[49, 66]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s5-2", "sentence_id": "DDI-DrugBank.d397.s5", "sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e1"}, "arg2": {"span": [[49, 66]], "type": "drug", "id": "DDI-DrugBank.d397.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-0", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s6-1", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s6-2", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e0"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s6-3", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-4", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[60, 69]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e1"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s6-5", "sentence_id": "DDI-DrugBank.d397.s6", "sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "arg1": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d397.s6.e2"}, "arg2": {"span": [[140, 155]], "type": "group", "id": "DDI-DrugBank.d397.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-0", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-1", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s10-2", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s10-3", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "arg2": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-4", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[84, 98]], "type": "group", "id": "DDI-DrugBank.d397.s10.e1"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s10-5", "sentence_id": "DDI-DrugBank.d397.s10", "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "arg1": {"span": [[99, 110]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e2"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d397.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s12-0", "sentence_id": "DDI-DrugBank.d397.s12", "sentence": "In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.", "arg1": {"span": [[81, 92]], "type": "drug", "id": "DDI-DrugBank.d397.s12.e0"}, "arg2": {"span": [[97, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s12.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s13-0", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d397.s13-1", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-2", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[64, 76]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e0"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-3", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "arg2": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-4", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[100, 109]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e1"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d397.s13-5", "sentence_id": "DDI-DrugBank.d397.s13", "sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "arg1": {"span": [[289, 298]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e2"}, "arg2": {"span": [[302, 314]], "type": "drug", "id": "DDI-DrugBank.d397.s13.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d397.s15-0", "sentence_id": "DDI-DrugBank.d397.s15", "sentence": "Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;", "arg1": {"span": [[31, 41]], "type": "drug", "id": "DDI-DrugBank.d397.s15.e0"}, "arg2": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d397.s15.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d369.s1-0", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-1", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-2", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[60, 69]], "type": "group", "id": "DDI-DrugBank.d369.s1.e0"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-3", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "arg2": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-4", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[71, 80]], "type": "group", "id": "DDI-DrugBank.d369.s1.e1"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s1-5", "sentence_id": "DDI-DrugBank.d369.s1", "sentence": "These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.", "arg1": {"span": [[82, 92]], "type": "group", "id": "DDI-DrugBank.d369.s1.e2"}, "arg2": {"span": [[97, 112]], "type": "group", "id": "DDI-DrugBank.d369.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-0", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-1", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-2", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[55, 69]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e0"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-3", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "arg2": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-4", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e1"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s2-5", "sentence_id": "DDI-DrugBank.d369.s2", "sentence": "The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.", "arg1": {"span": [[126, 140]], "type": "group", "id": "DDI-DrugBank.d369.s2.e2"}, "arg2": {"span": [[145, 152]], "type": "drug", "id": "DDI-DrugBank.d369.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d369.s3-0", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[16, 23]], "type": "brand", "id": "DDI-DrugBank.d369.s3.e0"}, "arg2": {"span": [[42, 56]], "type": "group", "id": "DDI-DrugBank.d369.s3.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d369.s3-1", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[16, 23]], "type": "brand", "id": "DDI-DrugBank.d369.s3.e0"}, "arg2": {"span": [[61, 81]], "type": "group", "id": "DDI-DrugBank.d369.s3.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d369.s3-2", "sentence_id": "DDI-DrugBank.d369.s3", "sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "arg1": {"span": [[42, 56]], "type": "group", "id": "DDI-DrugBank.d369.s3.e1"}, "arg2": {"span": [[61, 81]], "type": "group", "id": "DDI-DrugBank.d369.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s0-0", "sentence_id": "DDI-DrugBank.d320.s0", "sentence": "Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.", "arg1": {"span": [[0, 10]], "type": "brand", "id": "DDI-DrugBank.d320.s0.e0"}, "arg2": {"span": [[75, 86]], "type": "group", "id": "DDI-DrugBank.d320.s0.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d320.s1-0", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s1.e0"}, "arg2": {"span": [[105, 129]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s1-1", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s1.e0"}, "arg2": {"span": [[134, 159]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s1-2", "sentence_id": "DDI-DrugBank.d320.s1", "sentence": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.", "arg1": {"span": [[105, 129]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e1"}, "arg2": {"span": [[134, 159]], "type": "drug_n", "id": "DDI-DrugBank.d320.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s2-0", "sentence_id": "DDI-DrugBank.d320.s2", "sentence": "Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.", "arg1": {"span": [[57, 67]], "type": "brand", "id": "DDI-DrugBank.d320.s2.e0"}, "arg2": {"span": [[144, 154]], "type": "brand", "id": "DDI-DrugBank.d320.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-0", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-1", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-2", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-3", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[86, 101]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e0"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d320.s3-4", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-5", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-6", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e1"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-7", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "arg2": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-8", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[167, 180]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e2"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s3-9", "sentence_id": "DDI-DrugBank.d320.s3", "sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "arg1": {"span": [[182, 190]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e3"}, "arg2": {"span": [[237, 249]], "type": "drug", "id": "DDI-DrugBank.d320.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s5-0", "sentence_id": "DDI-DrugBank.d320.s5", "sentence": "macrolide antibiotics e.g., erythromycin;", "arg1": {"span": [[0, 21]], "type": "group", "id": "DDI-DrugBank.d320.s5.e0"}, "arg2": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d320.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-0", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-1", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-2", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-3", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[4, 31]], "type": "group", "id": "DDI-DrugBank.d320.s6.e0"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-4", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-5", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-6", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[38, 47]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e1"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-7", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "arg2": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-8", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e2"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s6-9", "sentence_id": "DDI-DrugBank.d320.s6", "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).", "arg1": {"span": [[102, 113]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e3"}, "arg2": {"span": [[118, 132]], "type": "drug", "id": "DDI-DrugBank.d320.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d320.s7-0", "sentence_id": "DDI-DrugBank.d320.s7", "sentence": "Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.", "arg1": {"span": [[40, 55]], "type": "drug", "id": "DDI-DrugBank.d320.s7.e0"}, "arg2": {"span": [[142, 157]], "type": "drug", "id": "DDI-DrugBank.d320.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-0", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d330.s1.e0"}, "arg2": {"span": [[86, 96]], "type": "group", "id": "DDI-DrugBank.d330.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-1", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[66, 81]], "type": "group", "id": "DDI-DrugBank.d330.s1.e0"}, "arg2": {"span": [[182, 198]], "type": "drug", "id": "DDI-DrugBank.d330.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s1-2", "sentence_id": "DDI-DrugBank.d330.s1", "sentence": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "arg1": {"span": [[86, 96]], "type": "group", "id": "DDI-DrugBank.d330.s1.e1"}, "arg2": {"span": [[182, 198]], "type": "drug", "id": "DDI-DrugBank.d330.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-0", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-1", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-2", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-3", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[5, 13]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e0"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d330.s2-4", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-5", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-6", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[58, 70]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e1"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-7", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "arg2": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-8", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[77, 89]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e2"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s2-9", "sentence_id": "DDI-DrugBank.d330.s2", "sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "arg1": {"span": [[91, 103]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e3"}, "arg2": {"span": [[108, 122]], "type": "drug", "id": "DDI-DrugBank.d330.s2.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d330.s5-0", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[5, 21]], "type": "drug", "id": "DDI-DrugBank.d330.s5.e0"}, "arg2": {"span": [[48, 56]], "type": "group", "id": "DDI-DrugBank.d330.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d330.s5-1", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[5, 21]], "type": "drug", "id": "DDI-DrugBank.d330.s5.e0"}, "arg2": {"span": [[60, 74]], "type": "group", "id": "DDI-DrugBank.d330.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d330.s5-2", "sentence_id": "DDI-DrugBank.d330.s5", "sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "arg1": {"span": [[48, 56]], "type": "group", "id": "DDI-DrugBank.d330.s5.e1"}, "arg2": {"span": [[60, 74]], "type": "group", "id": "DDI-DrugBank.d330.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d14.s0-0", "sentence_id": "DDI-DrugBank.d14.s0", "sentence": "The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.", "arg1": {"span": [[28, 41]], "type": "drug", "id": "DDI-DrugBank.d14.s0.e0"}, "arg2": {"span": [[78, 90]], "type": "group", "id": "DDI-DrugBank.d14.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d14.s2-0", "sentence_id": "DDI-DrugBank.d14.s2", "sentence": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "arg1": {"span": [[66, 90]], "type": "group", "id": "DDI-DrugBank.d14.s2.e0"}, "arg2": {"span": [[103, 111]], "type": "group", "id": "DDI-DrugBank.d14.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d336.s0-0", "sentence_id": "DDI-DrugBank.d336.s0", "sentence": "Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.", "arg1": {"span": [[208, 222]], "type": "group", "id": "DDI-DrugBank.d336.s0.e0"}, "arg2": {"span": [[227, 243]], "type": "drug", "id": "DDI-DrugBank.d336.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d336.s1-0", "sentence_id": "DDI-DrugBank.d336.s1", "sentence": "The concomitant use of alcohol or other central nervous system depressants may have an additive effect.", "arg1": {"span": [[23, 30]], "type": "drug", "id": "DDI-DrugBank.d336.s1.e0"}, "arg2": {"span": [[40, 74]], "type": "group", "id": "DDI-DrugBank.d336.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s0-0", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[62, 77]], "type": "group", "id": "DDI-DrugBank.d378.s0.e0"}, "arg2": {"span": [[106, 114]], "type": "brand", "id": "DDI-DrugBank.d378.s0.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d378.s0-1", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[62, 77]], "type": "group", "id": "DDI-DrugBank.d378.s0.e0"}, "arg2": {"span": [[187, 213]], "type": "group", "id": "DDI-DrugBank.d378.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s0-2", "sentence_id": "DDI-DrugBank.d378.s0", "sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "arg1": {"span": [[106, 114]], "type": "brand", "id": "DDI-DrugBank.d378.s0.e1"}, "arg2": {"span": [[187, 213]], "type": "group", "id": "DDI-DrugBank.d378.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d378.s1-0", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[79, 93]], "type": "group", "id": "DDI-DrugBank.d378.s1.e0"}, "arg2": {"span": [[106, 115]], "type": "group", "id": "DDI-DrugBank.d378.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d378.s1-1", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[79, 93]], "type": "group", "id": "DDI-DrugBank.d378.s1.e0"}, "arg2": {"span": [[124, 134]], "type": "drug", "id": "DDI-DrugBank.d378.s1.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d378.s1-2", "sentence_id": "DDI-DrugBank.d378.s1", "sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "arg1": {"span": [[106, 115]], "type": "group", "id": "DDI-DrugBank.d378.s1.e1"}, "arg2": {"span": [[124, 134]], "type": "drug", "id": "DDI-DrugBank.d378.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s1-0", "sentence_id": "DDI-DrugBank.d19.s1", "sentence": "DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d19.s1.e0"}, "arg2": {"span": [[67, 76]], "type": "drug", "id": "DDI-DrugBank.d19.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s2-0", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-1", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-2", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[68, 77]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e0"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-3", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "arg2": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d19.s2-4", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[115, 125]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e1"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s2-5", "sentence_id": "DDI-DrugBank.d19.s2", "sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "arg1": {"span": [[142, 151]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e2"}, "arg2": {"span": [[172, 181]], "type": "drug", "id": "DDI-DrugBank.d19.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s6-0", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[49, 63]], "type": "group", "id": "DDI-DrugBank.d19.s6.e0"}, "arg2": {"span": [[91, 101]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s6-1", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[49, 63]], "type": "group", "id": "DDI-DrugBank.d19.s6.e0"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s6-2", "sentence_id": "DDI-DrugBank.d19.s6", "sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "arg1": {"span": [[91, 101]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e1"}, "arg2": {"span": [[109, 119]], "type": "drug", "id": "DDI-DrugBank.d19.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s7-0", "sentence_id": "DDI-DrugBank.d19.s7", "sentence": "Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;", "arg1": {"span": [[16, 25]], "type": "drug", "id": "DDI-DrugBank.d19.s7.e0"}, "arg2": {"span": [[31, 41]], "type": "drug", "id": "DDI-DrugBank.d19.s7.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d19.s9-0", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d19.s9-1", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-2", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e0"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-3", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "arg2": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-4", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[50, 57]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e1"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d19.s9-5", "sentence_id": "DDI-DrugBank.d19.s9", "sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "arg1": {"span": [[149, 159]], "type": "drug", "id": "DDI-DrugBank.d19.s9.e2"}, "arg2": {"span": [[175, 183]], "type": "group", "id": "DDI-DrugBank.d19.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d71.s3-0", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e0"}, "arg2": {"span": [[95, 98]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s3-1", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e0"}, "arg2": {"span": [[99, 102]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s3-2", "sentence_id": "DDI-DrugBank.d71.s3", "sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "arg1": {"span": [[95, 98]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e1"}, "arg2": {"span": [[99, 102]], "type": "drug", "id": "DDI-DrugBank.d71.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d71.s5-0", "sentence_id": "DDI-DrugBank.d71.s5", "sentence": "Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d71.s5.e0"}, "arg2": {"span": [[15, 26]], "type": "drug", "id": "DDI-DrugBank.d71.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d71.s6-0", "sentence_id": "DDI-DrugBank.d71.s6", "sentence": "Therefore, use of lamivudine in combination with zalcitabine is not recommended", "arg1": {"span": [[18, 28]], "type": "drug", "id": "DDI-DrugBank.d71.s6.e0"}, "arg2": {"span": [[49, 60]], "type": "drug", "id": "DDI-DrugBank.d71.s6.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d475.s3-0", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[47, 54]], "type": "brand", "id": "DDI-DrugBank.d475.s3.e0"}, "arg2": {"span": [[81, 91]], "type": "group", "id": "DDI-DrugBank.d475.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d475.s3-1", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[47, 54]], "type": "brand", "id": "DDI-DrugBank.d475.s3.e0"}, "arg2": {"span": [[114, 124]], "type": "drug", "id": "DDI-DrugBank.d475.s3.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d475.s3-2", "sentence_id": "DDI-DrugBank.d475.s3", "sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "arg1": {"span": [[81, 91]], "type": "group", "id": "DDI-DrugBank.d475.s3.e1"}, "arg2": {"span": [[114, 124]], "type": "drug", "id": "DDI-DrugBank.d475.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-0", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-1", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-2", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-3", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-4", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s0-5", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-6", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[9, 30]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-7", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "arg2": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-8", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[57, 65]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e2"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s0-9", "sentence_id": "DDI-DrugBank.d395.s0", "sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "arg1": {"span": [[90, 98]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e3"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d395.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s1-0", "sentence_id": "DDI-DrugBank.d395.s1", "sentence": "Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d395.s1.e0"}, "arg2": {"span": [[49, 70]], "type": "drug", "id": "DDI-DrugBank.d395.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d395.s2-0", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s2-1", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e0"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d395.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s2-2", "sentence_id": "DDI-DrugBank.d395.s2", "sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d395.s2.e1"}, "arg2": {"span": [[108, 123]], "type": "group", "id": "DDI-DrugBank.d395.s2.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s3-0", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s3-1", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-2", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[26, 34]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e0"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-3", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "arg2": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-4", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[103, 111]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e1"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s3-5", "sentence_id": "DDI-DrugBank.d395.s3", "sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "arg1": {"span": [[149, 157]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e2"}, "arg2": {"span": [[239, 247]], "type": "drug", "id": "DDI-DrugBank.d395.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-0", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e0"}, "arg2": {"span": [[56, 64]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-1", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e0"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s4-2", "sentence_id": "DDI-DrugBank.d395.s4", "sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "arg1": {"span": [[56, 64]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e1"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s4.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s5-0", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e0"}, "arg2": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s5-1", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e0"}, "arg2": {"span": [[100, 108]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s5-2", "sentence_id": "DDI-DrugBank.d395.s5", "sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "arg1": {"span": [[69, 77]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e1"}, "arg2": {"span": [[100, 108]], "type": "drug", "id": "DDI-DrugBank.d395.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s6-0", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-1", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-2", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e0"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-3", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "arg2": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-4", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[39, 51]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e1"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s6-5", "sentence_id": "DDI-DrugBank.d395.s6", "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "arg1": {"span": [[95, 107]], "type": "drug", "id": "DDI-DrugBank.d395.s6.e2"}, "arg2": {"span": [[134, 149]], "type": "group", "id": "DDI-DrugBank.d395.s6.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s7-0", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e0"}, "arg2": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s7-1", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[0, 7]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e0"}, "arg2": {"span": [[34, 41]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s7-2", "sentence_id": "DDI-DrugBank.d395.s7", "sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "arg1": {"span": [[9, 17]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e1"}, "arg2": {"span": [[34, 41]], "type": "drug", "id": "DDI-DrugBank.d395.s7.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s8-0", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-1", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-2", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-3", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[36, 43]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e0"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-4", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s8-5", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-6", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[64, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e1"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-7", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "arg2": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-8", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[77, 84]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e2"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s8-9", "sentence_id": "DDI-DrugBank.d395.s8", "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "arg1": {"span": [[149, 156]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e3"}, "arg2": {"span": [[175, 182]], "type": "drug", "id": "DDI-DrugBank.d395.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-0", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-1", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-2", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[0, 38]], "type": "group", "id": "DDI-DrugBank.d395.s9.e0"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-3", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "arg2": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s9-4", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[87, 95]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e1"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s9-5", "sentence_id": "DDI-DrugBank.d395.s9", "sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "arg1": {"span": [[119, 154]], "type": "group", "id": "DDI-DrugBank.d395.s9.e2"}, "arg2": {"span": [[155, 163]], "type": "drug", "id": "DDI-DrugBank.d395.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-0", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d395.s12.e0"}, "arg2": {"span": [[15, 23]], "type": "group", "id": "DDI-DrugBank.d395.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-1", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d395.s12.e0"}, "arg2": {"span": [[25, 35]], "type": "group", "id": "DDI-DrugBank.d395.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s12-2", "sentence_id": "DDI-DrugBank.d395.s12", "sentence": "Sucralfate and antacids: Quinolones form chelates with metal cations.", "arg1": {"span": [[15, 23]], "type": "group", "id": "DDI-DrugBank.d395.s12.e1"}, "arg2": {"span": [[25, 35]], "type": "group", "id": "DDI-DrugBank.d395.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-0", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-1", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-2", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-3", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[29, 39]], "type": "group", "id": "DDI-DrugBank.d395.s13.e0"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-4", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-5", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-6", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[45, 53]], "type": "group", "id": "DDI-DrugBank.d395.s13.e1"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-7", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "arg2": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-8", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[65, 72]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e2"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s13-9", "sentence_id": "DDI-DrugBank.d395.s13", "sentence": "Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;", "arg1": {"span": [[74, 83]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e3"}, "arg2": {"span": [[88, 96]], "type": "drug", "id": "DDI-DrugBank.d395.s13.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-0", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[8, 21]], "type": "group", "id": "DDI-DrugBank.d395.s16.e0"}, "arg2": {"span": [[33, 37]], "type": "drug", "id": "DDI-DrugBank.d395.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-1", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[8, 21]], "type": "group", "id": "DDI-DrugBank.d395.s16.e0"}, "arg2": {"span": [[132, 141]], "type": "group", "id": "DDI-DrugBank.d395.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s16-2", "sentence_id": "DDI-DrugBank.d395.s16", "sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "arg1": {"span": [[33, 37]], "type": "drug", "id": "DDI-DrugBank.d395.s16.e1"}, "arg2": {"span": [[132, 141]], "type": "group", "id": "DDI-DrugBank.d395.s16.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s17-0", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-1", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-2", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d395.s17.e0"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-3", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "arg2": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s17-4", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[20, 38]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e1"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s17-5", "sentence_id": "DDI-DrugBank.d395.s17", "sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "arg1": {"span": [[43, 62]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e2"}, "arg2": {"span": [[93, 101]], "type": "drug", "id": "DDI-DrugBank.d395.s17.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s18-0", "sentence_id": "DDI-DrugBank.d395.s18", "sentence": "The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.", "arg1": {"span": [[28, 36]], "type": "drug", "id": "DDI-DrugBank.d395.s18.e0"}, "arg2": {"span": [[80, 90]], "type": "drug", "id": "DDI-DrugBank.d395.s18.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s20-0", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e0"}, "arg2": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s20-1", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e0"}, "arg2": {"span": [[112, 127]], "type": "group", "id": "DDI-DrugBank.d395.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s20-2", "sentence_id": "DDI-DrugBank.d395.s20", "sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-DrugBank.d395.s20.e1"}, "arg2": {"span": [[112, 127]], "type": "group", "id": "DDI-DrugBank.d395.s20.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s21-0", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e0"}, "arg2": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s21-1", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e0"}, "arg2": {"span": [[107, 119]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s21-2", "sentence_id": "DDI-DrugBank.d395.s21", "sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "arg1": {"span": [[43, 55]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e1"}, "arg2": {"span": [[107, 119]], "type": "drug", "id": "DDI-DrugBank.d395.s21.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-0", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e0"}, "arg2": {"span": [[68, 80]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-1", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e0"}, "arg2": {"span": [[85, 93]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s22-2", "sentence_id": "DDI-DrugBank.d395.s22", "sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "arg1": {"span": [[68, 80]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e1"}, "arg2": {"span": [[85, 93]], "type": "drug", "id": "DDI-DrugBank.d395.s22.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d395.s23-0", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-1", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-2", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-3", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e0"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-4", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-5", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s23-6", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[10, 20]], "type": "group", "id": "DDI-DrugBank.d395.s23.e1"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-7", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d395.s23-8", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[32, 40]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e2"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s23-9", "sentence_id": "DDI-DrugBank.d395.s23", "sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e3"}, "arg2": {"span": [[114, 122]], "type": "drug", "id": "DDI-DrugBank.d395.s23.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-0", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e0"}, "arg2": {"span": [[120, 128]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-1", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e0"}, "arg2": {"span": [[133, 141]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s24-2", "sentence_id": "DDI-DrugBank.d395.s24", "sentence": "Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.", "arg1": {"span": [[120, 128]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e1"}, "arg2": {"span": [[133, 141]], "type": "drug", "id": "DDI-DrugBank.d395.s24.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d395.s25-0", "sentence_id": "DDI-DrugBank.d395.s25", "sentence": "Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.", "arg1": {"span": [[95, 103]], "type": "drug", "id": "DDI-DrugBank.d395.s25.e0"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d395.s25.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d16.s2-0", "sentence_id": "DDI-DrugBank.d16.s2", "sentence": "Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary", "arg1": {"span": [[6, 17]], "type": "drug", "id": "DDI-DrugBank.d16.s2.e0"}, "arg2": {"span": [[76, 97]], "type": "group", "id": "DDI-DrugBank.d16.s2.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d245.s7-0", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[48, 60]], "type": "group", "id": "DDI-DrugBank.d245.s7.e0"}, "arg2": {"span": [[94, 108]], "type": "drug", "id": "DDI-DrugBank.d245.s7.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d245.s7-1", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[48, 60]], "type": "group", "id": "DDI-DrugBank.d245.s7.e0"}, "arg2": {"span": [[110, 122]], "type": "group", "id": "DDI-DrugBank.d245.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s7-2", "sentence_id": "DDI-DrugBank.d245.s7", "sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "arg1": {"span": [[94, 108]], "type": "drug", "id": "DDI-DrugBank.d245.s7.e1"}, "arg2": {"span": [[110, 122]], "type": "group", "id": "DDI-DrugBank.d245.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s8-0", "sentence_id": "DDI-DrugBank.d245.s8", "sentence": "In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.", "arg1": {"span": [[20, 30]], "type": "drug", "id": "DDI-DrugBank.d245.s8.e0"}, "arg2": {"span": [[81, 88]], "type": "drug", "id": "DDI-DrugBank.d245.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d245.s9-0", "sentence_id": "DDI-DrugBank.d245.s9", "sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "arg1": {"span": [[37, 47]], "type": "drug", "id": "DDI-DrugBank.d245.s9.e0"}, "arg2": {"span": [[57, 76]], "type": "group", "id": "DDI-DrugBank.d245.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d120.s1-0", "sentence_id": "DDI-DrugBank.d120.s1", "sentence": "anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d120.s1.e0"}, "arg2": {"span": [[163, 173]], "type": "drug", "id": "DDI-DrugBank.d120.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-0", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-1", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-2", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e0"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-3", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "arg2": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d120.s2-4", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[33, 43]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e1"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d120.s2-5", "sentence_id": "DDI-DrugBank.d120.s2", "sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "arg1": {"span": [[61, 67]], "type": "group", "id": "DDI-DrugBank.d120.s2.e2"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d120.s2.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s0-0", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[33, 44]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e0"}, "arg2": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s0-1", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[33, 44]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e0"}, "arg2": {"span": [[175, 185]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s0-2", "sentence_id": "DDI-DrugBank.d419.s0", "sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "arg1": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e1"}, "arg2": {"span": [[175, 185]], "type": "drug", "id": "DDI-DrugBank.d419.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s1-0", "sentence_id": "DDI-DrugBank.d419.s1", "sentence": "It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d419.s1.e0"}, "arg2": {"span": [[73, 84]], "type": "drug", "id": "DDI-DrugBank.d419.s1.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s2-0", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[33, 45]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e0"}, "arg2": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d419.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s2-1", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[33, 45]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e0"}, "arg2": {"span": [[96, 108]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s2-2", "sentence_id": "DDI-DrugBank.d419.s2", "sentence": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.", "arg1": {"span": [[80, 91]], "type": "drug", "id": "DDI-DrugBank.d419.s2.e1"}, "arg2": {"span": [[96, 108]], "type": "brand", "id": "DDI-DrugBank.d419.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s4-0", "sentence_id": "DDI-DrugBank.d419.s4", "sentence": "However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.", "arg1": {"span": [[126, 138]], "type": "brand", "id": "DDI-DrugBank.d419.s4.e0"}, "arg2": {"span": [[143, 154]], "type": "drug", "id": "DDI-DrugBank.d419.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s5-0", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[21, 47]], "type": "group", "id": "DDI-DrugBank.d419.s5.e0"}, "arg2": {"span": [[49, 61]], "type": "brand", "id": "DDI-DrugBank.d419.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d419.s5-1", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[21, 47]], "type": "group", "id": "DDI-DrugBank.d419.s5.e0"}, "arg2": {"span": [[94, 108]], "type": "group", "id": "DDI-DrugBank.d419.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d419.s5-2", "sentence_id": "DDI-DrugBank.d419.s5", "sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "arg1": {"span": [[49, 61]], "type": "brand", "id": "DDI-DrugBank.d419.s5.e1"}, "arg2": {"span": [[94, 108]], "type": "group", "id": "DDI-DrugBank.d419.s5.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-0", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-1", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-2", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-3", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[5, 19]], "type": "group", "id": "DDI-DrugBank.d132.s0.e0"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-4", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-5", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-6", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[82, 92]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e1"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s0-7", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "arg2": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-8", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[97, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e2"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s0-9", "sentence_id": "DDI-DrugBank.d132.s0", "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "arg1": {"span": [[107, 120]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e3"}, "arg2": {"span": [[125, 138]], "type": "drug", "id": "DDI-DrugBank.d132.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s1-0", "sentence_id": "DDI-DrugBank.d132.s1", "sentence": "This may occur because diflunisal competitively displaces coumarins from protein binding sites.", "arg1": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d132.s1.e0"}, "arg2": {"span": [[58, 67]], "type": "group", "id": "DDI-DrugBank.d132.s1.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s2-0", "sentence_id": "DDI-DrugBank.d132.s2", "sentence": "Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.", "arg1": {"span": [[18, 28]], "type": "drug", "id": "DDI-DrugBank.d132.s2.e0"}, "arg2": {"span": [[55, 69]], "type": "group", "id": "DDI-DrugBank.d132.s2.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s4-0", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-1", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-2", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e0"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-3", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "arg2": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-4", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e1"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s4-5", "sentence_id": "DDI-DrugBank.d132.s4", "sentence": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "arg1": {"span": [[59, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e2"}, "arg2": {"span": [[108, 119]], "type": "drug", "id": "DDI-DrugBank.d132.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-0", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-1", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-2", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[0, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e0"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-3", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "arg2": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s5-4", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[73, 83]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e1"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s5-5", "sentence_id": "DDI-DrugBank.d132.s5", "sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "arg1": {"span": [[88, 107]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e2"}, "arg2": {"span": [[161, 180]], "type": "drug", "id": "DDI-DrugBank.d132.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s6-0", "sentence_id": "DDI-DrugBank.d132.s6", "sentence": "Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s6.e0"}, "arg2": {"span": [[49, 68]], "type": "drug", "id": "DDI-DrugBank.d132.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s7-0", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-1", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-2", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e0"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-3", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "arg2": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-4", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[68, 78]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e1"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s7-5", "sentence_id": "DDI-DrugBank.d132.s7", "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "arg1": {"span": [[83, 93]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e2"}, "arg2": {"span": [[136, 146]], "type": "drug", "id": "DDI-DrugBank.d132.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s8-0", "sentence_id": "DDI-DrugBank.d132.s8", "sentence": "Diflunisal decreased the hyperuricemic effect of furosemide.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d132.s8.e0"}, "arg2": {"span": [[49, 59]], "type": "drug", "id": "DDI-DrugBank.d132.s8.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s9-0", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d132.s9.e0"}, "arg2": {"span": [[40, 48]], "type": "group", "id": "DDI-DrugBank.d132.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s9-1", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d132.s9.e0"}, "arg2": {"span": [[77, 87]], "type": "drug", "id": "DDI-DrugBank.d132.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s9-2", "sentence_id": "DDI-DrugBank.d132.s9", "sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "arg1": {"span": [[40, 48]], "type": "group", "id": "DDI-DrugBank.d132.s9.e1"}, "arg2": {"span": [[77, 87]], "type": "drug", "id": "DDI-DrugBank.d132.s9.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s10-0", "sentence_id": "DDI-DrugBank.d132.s10", "sentence": "This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.", "arg1": {"span": [[46, 54]], "type": "group", "id": "DDI-DrugBank.d132.s10.e0"}, "arg2": {"span": [[95, 103]], "type": "group", "id": "DDI-DrugBank.d132.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-0", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-1", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-2", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e0"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-3", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "arg2": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s11-4", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[67, 77]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e1"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s11-5", "sentence_id": "DDI-DrugBank.d132.s11", "sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "arg1": {"span": [[82, 95]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e2"}, "arg2": {"span": [[156, 169]], "type": "drug", "id": "DDI-DrugBank.d132.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s12-0", "sentence_id": "DDI-DrugBank.d132.s12", "sentence": "Acetaminophen had no effect on plasma levels of diflunisal.", "arg1": {"span": [[0, 13]], "type": "drug", "id": "DDI-DrugBank.d132.s12.e0"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-0", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[6, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e0"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-1", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[6, 19]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e0"}, "arg2": {"span": [[120, 133]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s13-2", "sentence_id": "DDI-DrugBank.d132.s13", "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "arg1": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e1"}, "arg2": {"span": [[120, 133]], "type": "drug", "id": "DDI-DrugBank.d132.s13.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s14-0", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s14-1", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-2", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e0"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-3", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "arg2": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-4", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[45, 58]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e1"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s14-5", "sentence_id": "DDI-DrugBank.d132.s14", "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "arg1": {"span": [[188, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e2"}, "arg2": {"span": [[199, 212]], "type": "drug", "id": "DDI-DrugBank.d132.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-0", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e0"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-1", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e0"}, "arg2": {"span": [[86, 98]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s16-2", "sentence_id": "DDI-DrugBank.d132.s16", "sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "arg1": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e1"}, "arg2": {"span": [[86, 98]], "type": "drug", "id": "DDI-DrugBank.d132.s16.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s17-0", "sentence_id": "DDI-DrugBank.d132.s17", "sentence": "Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s17.e0"}, "arg2": {"span": [[93, 105]], "type": "drug", "id": "DDI-DrugBank.d132.s17.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s18-0", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-1", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-2", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e0"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-3", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "arg2": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s18-4", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[32, 67]], "type": "group", "id": "DDI-DrugBank.d132.s18.e1"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s18-5", "sentence_id": "DDI-DrugBank.d132.s18", "sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "arg1": {"span": [[87, 99]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e2"}, "arg2": {"span": [[140, 152]], "type": "drug", "id": "DDI-DrugBank.d132.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s19-0", "sentence_id": "DDI-DrugBank.d132.s19", "sentence": "NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.", "arg1": {"span": [[0, 6]], "type": "group", "id": "DDI-DrugBank.d132.s19.e0"}, "arg2": {"span": [[54, 66]], "type": "drug", "id": "DDI-DrugBank.d132.s19.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s20-0", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-1", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-2", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[0, 36]], "type": "group", "id": "DDI-DrugBank.d132.s20.e0"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-3", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "arg2": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s20-4", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[60, 70]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e1"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s20-5", "sentence_id": "DDI-DrugBank.d132.s20", "sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "arg1": {"span": [[102, 114]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e2"}, "arg2": {"span": [[194, 206]], "type": "drug", "id": "DDI-DrugBank.d132.s20.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s21-0", "sentence_id": "DDI-DrugBank.d132.s21", "sentence": "In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "arg1": {"span": [[37, 49]], "type": "drug", "id": "DDI-DrugBank.d132.s21.e0"}, "arg2": {"span": [[54, 64]], "type": "drug", "id": "DDI-DrugBank.d132.s21.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s22-0", "sentence_id": "DDI-DrugBank.d132.s22", "sentence": "Therefore, indomethacin and diflunisal should not be used concomitantly.", "arg1": {"span": [[11, 23]], "type": "drug", "id": "DDI-DrugBank.d132.s22.e0"}, "arg2": {"span": [[28, 38]], "type": "drug", "id": "DDI-DrugBank.d132.s22.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d132.s23-0", "sentence_id": "DDI-DrugBank.d132.s23", "sentence": "The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "arg1": {"span": [[23, 33]], "type": "drug", "id": "DDI-DrugBank.d132.s23.e0"}, "arg2": {"span": [[52, 58]], "type": "group", "id": "DDI-DrugBank.d132.s23.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d132.s25-0", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-1", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-2", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[0, 7]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e0"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-3", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "arg2": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-4", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[51, 61]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e1"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s25-5", "sentence_id": "DDI-DrugBank.d132.s25", "sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "arg1": {"span": [[105, 115]], "type": "drug", "id": "DDI-DrugBank.d132.s25.e2"}, "arg2": {"span": [[120, 127]], "type": "brand", "id": "DDI-DrugBank.d132.s25.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s26-0", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s26-1", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e0"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s26-2", "sentence_id": "DDI-DrugBank.d132.s26", "sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e1"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s26.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s27-0", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-1", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-2", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-3", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e0"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-4", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d132.s27-5", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-6", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[44, 54]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e1"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-7", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "arg2": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-8", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[59, 67]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e2"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s27-9", "sentence_id": "DDI-DrugBank.d132.s27", "sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "arg1": {"span": [[127, 135]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e3"}, "arg2": {"span": [[190, 198]], "type": "drug", "id": "DDI-DrugBank.d132.s27.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d132.s28-0", "sentence_id": "DDI-DrugBank.d132.s28", "sentence": "Naproxen had no effect on plasma levels of diflunisal.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d132.s28.e0"}, "arg2": {"span": [[43, 53]], "type": "drug", "id": "DDI-DrugBank.d132.s28.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-0", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-1", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-2", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-3", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[98, 117]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e0"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-4", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-5", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-6", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[119, 126]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e1"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-7", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "arg2": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-8", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[128, 136]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e2"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s0-9", "sentence_id": "DDI-DrugBank.d30.s0", "sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "arg1": {"span": [[138, 148]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e3"}, "arg2": {"span": [[153, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s1-0", "sentence_id": "DDI-DrugBank.d30.s1", "sentence": "Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-DrugBank.d30.s1.e0"}, "arg2": {"span": [[73, 81]], "type": "drug", "id": "DDI-DrugBank.d30.s1.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d30.s3-0", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-1", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-2", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e0"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-3", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "arg2": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-4", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e1"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s3-5", "sentence_id": "DDI-DrugBank.d30.s3", "sentence": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "arg1": {"span": [[116, 124]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e2"}, "arg2": {"span": [[130, 142]], "type": "drug", "id": "DDI-DrugBank.d30.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s4-0", "sentence_id": "DDI-DrugBank.d30.s4", "sentence": "Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.", "arg1": {"span": [[0, 11]], "type": "drug", "id": "DDI-DrugBank.d30.s4.e0"}, "arg2": {"span": [[95, 103]], "type": "drug", "id": "DDI-DrugBank.d30.s4.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d30.s8-0", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-1", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-2", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-3", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[81, 108]], "type": "group", "id": "DDI-DrugBank.d30.s8.e0"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-4", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-5", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-6", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[116, 130]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e1"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-7", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-8", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[132, 143]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e2"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s8-9", "sentence_id": "DDI-DrugBank.d30.s8", "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "arg1": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e3"}, "arg2": {"span": [[157, 166]], "type": "drug", "id": "DDI-DrugBank.d30.s8.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-0", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-1", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-2", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[14, 37]], "type": "group", "id": "DDI-DrugBank.d30.s9.e0"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-3", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "arg2": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d30.s9-4", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[70, 78]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e1"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d30.s9-5", "sentence_id": "DDI-DrugBank.d30.s9", "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "arg1": {"span": [[101, 137]], "type": "group", "id": "DDI-DrugBank.d30.s9.e2"}, "arg2": {"span": [[138, 150]], "type": "drug", "id": "DDI-DrugBank.d30.s9.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s2-0", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e0"}, "arg2": {"span": [[76, 86]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d393.s2-1", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[28, 40]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e0"}, "arg2": {"span": [[153, 163]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s2-2", "sentence_id": "DDI-DrugBank.d393.s2", "sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "arg1": {"span": [[76, 86]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e1"}, "arg2": {"span": [[153, 163]], "type": "drug", "id": "DDI-DrugBank.d393.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s3-0", "sentence_id": "DDI-DrugBank.d393.s3", "sentence": "The disposition of theophylline was not altered by concomitant cetirizine administration.", "arg1": {"span": [[19, 31]], "type": "drug", "id": "DDI-DrugBank.d393.s3.e0"}, "arg2": {"span": [[63, 73]], "type": "drug", "id": "DDI-DrugBank.d393.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-0", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-1", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-2", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-3", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e0"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-4", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-5", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-6", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[117, 129]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e1"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-7", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "arg2": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-8", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[131, 146]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e2"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s4-9", "sentence_id": "DDI-DrugBank.d393.s4", "sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "arg1": {"span": [[148, 160]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e3"}, "arg2": {"span": [[165, 177]], "type": "drug", "id": "DDI-DrugBank.d393.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d393.s5-0", "sentence_id": "DDI-DrugBank.d393.s5", "sentence": "There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d393.s5.e0"}, "arg2": {"span": [[85, 97]], "type": "drug", "id": "DDI-DrugBank.d393.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s0-0", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-1", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-2", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-3", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[0, 8]], "type": "group", "id": "DDI-DrugBank.d420.s0.e0"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-4", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-5", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-6", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[10, 18]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e1"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-7", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "arg2": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-8", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[23, 32]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e2"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s0-9", "sentence_id": "DDI-DrugBank.d420.s0", "sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "arg1": {"span": [[83, 91]], "type": "drug", "id": "DDI-DrugBank.d420.s0.e3"}, "arg2": {"span": [[112, 121]], "type": "brand", "id": "DDI-DrugBank.d420.s0.e4"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s2-0", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e0"}, "arg2": {"span": [[69, 76]], "type": "group", "id": "DDI-DrugBank.d420.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s2-1", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[36, 44]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s2-2", "sentence_id": "DDI-DrugBank.d420.s2", "sentence": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "arg1": {"span": [[69, 76]], "type": "group", "id": "DDI-DrugBank.d420.s2.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-DrugBank.d420.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-0", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-1", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-2", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[3, 11]], "type": "group", "id": "DDI-DrugBank.d420.s3.e0"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-3", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "arg2": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-4", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[32, 39]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e1"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s3-5", "sentence_id": "DDI-DrugBank.d420.s3", "sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "arg1": {"span": [[49, 56]], "type": "brand", "id": "DDI-DrugBank.d420.s3.e2"}, "arg2": {"span": [[110, 117]], "type": "group", "id": "DDI-DrugBank.d420.s3.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d420.s4-0", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-1", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-2", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-3", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e0"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-4", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-5", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s4-6", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[26, 46]], "type": "group", "id": "DDI-DrugBank.d420.s4.e1"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-7", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s4-8", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[48, 58]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e2"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s4-9", "sentence_id": "DDI-DrugBank.d420.s4", "sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "arg1": {"span": [[91, 99]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e3"}, "arg2": {"span": [[169, 177]], "type": "drug", "id": "DDI-DrugBank.d420.s4.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s6-0", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[3, 19]], "type": "group", "id": "DDI-DrugBank.d420.s6.e0"}, "arg2": {"span": [[40, 47]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s6-1", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[3, 19]], "type": "group", "id": "DDI-DrugBank.d420.s6.e0"}, "arg2": {"span": [[57, 64]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d420.s6-2", "sentence_id": "DDI-DrugBank.d420.s6", "sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "arg1": {"span": [[40, 47]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e1"}, "arg2": {"span": [[57, 64]], "type": "brand", "id": "DDI-DrugBank.d420.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-0", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[52, 56]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e0"}, "arg2": {"span": [[68, 72]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-1", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[52, 56]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e0"}, "arg2": {"span": [[105, 113]], "type": "drug", "id": "DDI-DrugBank.d420.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s7-2", "sentence_id": "DDI-DrugBank.d420.s7", "sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "arg1": {"span": [[68, 72]], "type": "drug_n", "id": "DDI-DrugBank.d420.s7.e1"}, "arg2": {"span": [[105, 113]], "type": "drug", "id": "DDI-DrugBank.d420.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-0", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[27, 31]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e0"}, "arg2": {"span": [[75, 79]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-1", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[27, 31]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e0"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-DrugBank.d420.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s8-2", "sentence_id": "DDI-DrugBank.d420.s8", "sentence": "Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.", "arg1": {"span": [[75, 79]], "type": "drug_n", "id": "DDI-DrugBank.d420.s8.e1"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-DrugBank.d420.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s9-0", "sentence_id": "DDI-DrugBank.d420.s9", "sentence": "Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.", "arg1": {"span": [[11, 18]], "type": "brand", "id": "DDI-DrugBank.d420.s9.e0"}, "arg2": {"span": [[64, 68]], "type": "drug_n", "id": "DDI-DrugBank.d420.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d420.s11-0", "sentence_id": "DDI-DrugBank.d420.s11", "sentence": "The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "arg1": {"span": [[77, 85]], "type": "drug", "id": "DDI-DrugBank.d420.s11.e0"}, "arg2": {"span": [[116, 120]], "type": "drug", "id": "DDI-DrugBank.d420.s11.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d420.s12-0", "sentence_id": "DDI-DrugBank.d420.s12", "sentence": "Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.", "arg1": {"span": [[112, 125]], "type": "drug", "id": "DDI-DrugBank.d420.s12.e0"}, "arg2": {"span": [[152, 169]], "type": "drug", "id": "DDI-DrugBank.d420.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s1-0", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e0"}, "arg2": {"span": [[63, 71]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d174.s1-1", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[47, 57]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e0"}, "arg2": {"span": [[117, 123]], "type": "group", "id": "DDI-DrugBank.d174.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s1-2", "sentence_id": "DDI-DrugBank.d174.s1", "sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "arg1": {"span": [[63, 71]], "type": "drug", "id": "DDI-DrugBank.d174.s1.e1"}, "arg2": {"span": [[117, 123]], "type": "group", "id": "DDI-DrugBank.d174.s1.e2"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-DrugBank.d174.s2-0", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[33, 41]], "type": "drug", "id": "DDI-DrugBank.d174.s2.e0"}, "arg2": {"span": [[53, 60]], "type": "group", "id": "DDI-DrugBank.d174.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s2-1", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[33, 41]], "type": "drug", "id": "DDI-DrugBank.d174.s2.e0"}, "arg2": {"span": [[113, 117]], "type": "drug_n", "id": "DDI-DrugBank.d174.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d174.s2-2", "sentence_id": "DDI-DrugBank.d174.s2", "sentence": "Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.", "arg1": {"span": [[53, 60]], "type": "group", "id": "DDI-DrugBank.d174.s2.e1"}, "arg2": {"span": [[113, 117]], "type": "drug_n", "id": "DDI-DrugBank.d174.s2.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s1-0", "sentence_id": "DDI-DrugBank.d237.s1", "sentence": "In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.", "arg1": {"span": [[113, 122]], "type": "drug", "id": "DDI-DrugBank.d237.s1.e0"}, "arg2": {"span": [[211, 220]], "type": "drug", "id": "DDI-DrugBank.d237.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-0", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-1", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-2", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-3", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[0, 16]], "type": "group", "id": "DDI-DrugBank.d237.s3.e0"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-4", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-5", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-6", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[55, 80]], "type": "group", "id": "DDI-DrugBank.d237.s3.e1"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s3-7", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "arg2": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s3-8", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[90, 110]], "type": "group", "id": "DDI-DrugBank.d237.s3.e2"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s3-9", "sentence_id": "DDI-DrugBank.d237.s3", "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "arg1": {"span": [[115, 126]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e3"}, "arg2": {"span": [[186, 195]], "type": "drug", "id": "DDI-DrugBank.d237.s3.e4"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s4-0", "sentence_id": "DDI-DrugBank.d237.s4", "sentence": "Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.", "arg1": {"span": [[0, 14]], "type": "group", "id": "DDI-DrugBank.d237.s4.e0"}, "arg2": {"span": [[50, 64]], "type": "group", "id": "DDI-DrugBank.d237.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s5-0", "sentence_id": "DDI-DrugBank.d237.s5", "sentence": "It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.", "arg1": {"span": [[107, 116]], "type": "drug", "id": "DDI-DrugBank.d237.s5.e0"}, "arg2": {"span": [[164, 177]], "type": "group", "id": "DDI-DrugBank.d237.s5.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s6-0", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-1", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-2", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 15]], "type": "group", "id": "DDI-DrugBank.d237.s6.e0"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-3", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "arg2": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s6-4", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[45, 55]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e1"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s6-5", "sentence_id": "DDI-DrugBank.d237.s6", "sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[83, 92]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e2"}, "arg2": {"span": [[136, 145]], "type": "drug", "id": "DDI-DrugBank.d237.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s8-0", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e0"}, "arg2": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s8-1", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[46, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s8-2", "sentence_id": "DDI-DrugBank.d237.s8", "sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "arg1": {"span": [[95, 104]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e1"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s8.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s9-0", "sentence_id": "DDI-DrugBank.d237.s9", "sentence": "A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.", "arg1": {"span": [[82, 91]], "type": "drug", "id": "DDI-DrugBank.d237.s9.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-DrugBank.d237.s9.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-DrugBank.d237.s10-0", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-1", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-2", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-3", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[0, 23]], "type": "group", "id": "DDI-DrugBank.d237.s10.e0"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-4", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s10-5", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-6", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[25, 35]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e1"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-7", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "arg2": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-8", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[112, 121]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e2"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s10-9", "sentence_id": "DDI-DrugBank.d237.s10", "sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "arg1": {"span": [[145, 154]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e3"}, "arg2": {"span": [[197, 207]], "type": "drug", "id": "DDI-DrugBank.d237.s10.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s11-0", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e0"}, "arg2": {"span": [[50, 60]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s11-1", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[35, 45]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e0"}, "arg2": {"span": [[110, 119]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s11-2", "sentence_id": "DDI-DrugBank.d237.s11", "sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "arg1": {"span": [[50, 60]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e1"}, "arg2": {"span": [[110, 119]], "type": "drug", "id": "DDI-DrugBank.d237.s11.e2"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-0", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-1", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-2", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-3", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[0, 19]], "type": "group", "id": "DDI-DrugBank.d237.s12.e0"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-4", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-5", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-6", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e1"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-7", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "arg2": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-DrugBank.d237.s12-8", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[63, 72]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e2"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s12-9", "sentence_id": "DDI-DrugBank.d237.s12", "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "arg1": {"span": [[108, 117]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e3"}, "arg2": {"span": [[160, 169]], "type": "drug", "id": "DDI-DrugBank.d237.s12.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s13-0", "sentence_id": "DDI-DrugBank.d237.s13", "sentence": "Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.", "arg1": {"span": [[49, 58]], "type": "drug", "id": "DDI-DrugBank.d237.s13.e0"}, "arg2": {"span": [[92, 101]], "type": "drug", "id": "DDI-DrugBank.d237.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-0", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-1", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-2", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-3", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[0, 9]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e0"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 1, "ddi_type": "advise"}
{"id": "DDI-DrugBank.d237.s14-4", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-5", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-6", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[102, 117]], "type": "group", "id": "DDI-DrugBank.d237.s14.e1"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-7", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "arg2": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-8", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[156, 165]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e2"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s14-9", "sentence_id": "DDI-DrugBank.d237.s14", "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "arg1": {"span": [[170, 182]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e3"}, "arg2": {"span": [[207, 214]], "type": "drug", "id": "DDI-DrugBank.d237.s14.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s15-0", "sentence_id": "DDI-DrugBank.d237.s15", "sentence": "tricyclic antidepressants (such as amitriptyline);", "arg1": {"span": [[0, 25]], "type": "group", "id": "DDI-DrugBank.d237.s15.e0"}, "arg2": {"span": [[35, 48]], "type": "drug", "id": "DDI-DrugBank.d237.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s16-0", "sentence_id": "DDI-DrugBank.d237.s16", "sentence": "certain tetracyclic antidepressants (such as maprotiline);", "arg1": {"span": [[8, 35]], "type": "group", "id": "DDI-DrugBank.d237.s16.e0"}, "arg2": {"span": [[45, 56]], "type": "drug", "id": "DDI-DrugBank.d237.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s17-0", "sentence_id": "DDI-DrugBank.d237.s17", "sentence": "certain antipsychotic medications (such as sertindole);", "arg1": {"span": [[8, 33]], "type": "group", "id": "DDI-DrugBank.d237.s17.e0"}, "arg2": {"span": [[43, 53]], "type": "drug", "id": "DDI-DrugBank.d237.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-0", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-1", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-2", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e0"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-3", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "arg2": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-4", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[12, 20]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e1"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-DrugBank.d237.s18-5", "sentence_id": "DDI-DrugBank.d237.s18", "sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "arg1": {"span": [[22, 34]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e2"}, "arg2": {"span": [[40, 50]], "type": "drug", "id": "DDI-DrugBank.d237.s18.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s3-0", "sentence_id": "DDI-MedLine.d48.s3", "sentence": "Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. ", "arg1": {"span": [[0, 21]], "type": "drug_n", "id": "DDI-MedLine.d48.s3.e0"}, "arg2": {"span": [[94, 101]], "type": "drug_n", "id": "DDI-MedLine.d48.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s4-0", "sentence_id": "DDI-MedLine.d48.s4", "sentence": "Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. ", "arg1": {"span": [[16, 23]], "type": "drug_n", "id": "DDI-MedLine.d48.s4.e0"}, "arg2": {"span": [[29, 50]], "type": "drug_n", "id": "DDI-MedLine.d48.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s5-0", "sentence_id": "DDI-MedLine.d48.s5", "sentence": "Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. ", "arg1": {"span": [[13, 20]], "type": "drug_n", "id": "DDI-MedLine.d48.s5.e0"}, "arg2": {"span": [[34, 55]], "type": "drug_n", "id": "DDI-MedLine.d48.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s6-0", "sentence_id": "DDI-MedLine.d48.s6", "sentence": "The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. ", "arg1": {"span": [[15, 36]], "type": "drug_n", "id": "DDI-MedLine.d48.s6.e0"}, "arg2": {"span": [[58, 71]], "type": "drug_n", "id": "DDI-MedLine.d48.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-0", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-1", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-2", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[22, 29]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e0"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-3", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "arg2": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-4", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[48, 52]], "type": "drug", "id": "DDI-MedLine.d48.s11.e1"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d48.s11-5", "sentence_id": "DDI-MedLine.d48.s11", "sentence": "Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.", "arg1": {"span": [[150, 157]], "type": "drug_n", "id": "DDI-MedLine.d48.s11.e2"}, "arg2": {"span": [[164, 168]], "type": "drug", "id": "DDI-MedLine.d48.s11.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-0", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 11]], "type": "drug_n", "id": "DDI-MedLine.d95.s4.e0"}, "arg2": {"span": [[116, 129]], "type": "drug", "id": "DDI-MedLine.d95.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-1", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 11]], "type": "drug_n", "id": "DDI-MedLine.d95.s4.e0"}, "arg2": {"span": [[148, 151]], "type": "drug", "id": "DDI-MedLine.d95.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s4-2", "sentence_id": "DDI-MedLine.d95.s4", "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "arg1": {"span": [[116, 129]], "type": "drug", "id": "DDI-MedLine.d95.s4.e1"}, "arg2": {"span": [[148, 151]], "type": "drug", "id": "DDI-MedLine.d95.s4.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s6-0", "sentence_id": "DDI-MedLine.d95.s6", "sentence": "However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. ", "arg1": {"span": [[9, 15]], "type": "drug_n", "id": "DDI-MedLine.d95.s6.e0"}, "arg2": {"span": [[70, 82]], "type": "drug_n", "id": "DDI-MedLine.d95.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s7-0", "sentence_id": "DDI-MedLine.d95.s7", "sentence": "Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. ", "arg1": {"span": [[0, 12]], "type": "drug", "id": "DDI-MedLine.d95.s7.e0"}, "arg2": {"span": [[46, 57]], "type": "drug_n", "id": "DDI-MedLine.d95.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s8-0", "sentence_id": "DDI-MedLine.d95.s8", "sentence": "In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. ", "arg1": {"span": [[3, 16]], "type": "drug", "id": "DDI-MedLine.d95.s8.e0"}, "arg2": {"span": [[78, 89]], "type": "drug_n", "id": "DDI-MedLine.d95.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d95.s9-0", "sentence_id": "DDI-MedLine.d95.s9", "sentence": "This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.", "arg1": {"span": [[54, 65]], "type": "drug_n", "id": "DDI-MedLine.d95.s9.e0"}, "arg2": {"span": [[190, 201]], "type": "drug_n", "id": "DDI-MedLine.d95.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s0-0", "sentence_id": "DDI-MedLine.d112.s0", "sentence": "Effect of dofetillide on the pharmacokinetics of digoxin.\r\n", "arg1": {"span": [[10, 21]], "type": "drug", "id": "DDI-MedLine.d112.s0.e0"}, "arg2": {"span": [[49, 56]], "type": "drug", "id": "DDI-MedLine.d112.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s1-0", "sentence_id": "DDI-MedLine.d112.s1", "sentence": "The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. ", "arg1": {"span": [[14, 24]], "type": "drug", "id": "DDI-MedLine.d112.s1.e0"}, "arg2": {"span": [[65, 72]], "type": "drug", "id": "DDI-MedLine.d112.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s2-0", "sentence_id": "DDI-MedLine.d112.s2", "sentence": "Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d112.s2.e0"}, "arg2": {"span": [[105, 112]], "type": "drug", "id": "DDI-MedLine.d112.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d112.s3-0", "sentence_id": "DDI-MedLine.d112.s3", "sentence": "therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.", "arg1": {"span": [[22, 32]], "type": "drug", "id": "DDI-MedLine.d112.s3.e0"}, "arg2": {"span": [[71, 78]], "type": "drug", "id": "DDI-MedLine.d112.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s0-0", "sentence_id": "DDI-MedLine.d116.s0", "sentence": "Rifampin and warfarin: a drug interaction.\r\n", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-MedLine.d116.s0.e0"}, "arg2": {"span": [[13, 21]], "type": "drug", "id": "DDI-MedLine.d116.s0.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-MedLine.d116.s1-0", "sentence_id": "DDI-MedLine.d116.s1", "sentence": "The drug interaction between warfarin and rifampin is not well known. ", "arg1": {"span": [[29, 37]], "type": "drug", "id": "DDI-MedLine.d116.s1.e0"}, "arg2": {"span": [[42, 50]], "type": "drug", "id": "DDI-MedLine.d116.s1.e1"}, "ddi_label": 1, "ddi_type": "int"}
{"id": "DDI-MedLine.d116.s2-0", "sentence_id": "DDI-MedLine.d116.s2", "sentence": "Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ", "arg1": {"span": [[0, 8]], "type": "drug", "id": "DDI-MedLine.d116.s2.e0"}, "arg2": {"span": [[43, 51]], "type": "drug", "id": "DDI-MedLine.d116.s2.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s3-0", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[34, 42]], "type": "drug", "id": "DDI-MedLine.d116.s3.e0"}, "arg2": {"span": [[47, 55]], "type": "drug", "id": "DDI-MedLine.d116.s3.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s3-1", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[34, 42]], "type": "drug", "id": "DDI-MedLine.d116.s3.e0"}, "arg2": {"span": [[119, 127]], "type": "drug", "id": "DDI-MedLine.d116.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s3-2", "sentence_id": "DDI-MedLine.d116.s3", "sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "arg1": {"span": [[47, 55]], "type": "drug", "id": "DDI-MedLine.d116.s3.e1"}, "arg2": {"span": [[119, 127]], "type": "drug", "id": "DDI-MedLine.d116.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s4-0", "sentence_id": "DDI-MedLine.d116.s4", "sentence": "Withdrawal of rifampin decreased the warfarin requirement by 50%. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s4.e0"}, "arg2": {"span": [[37, 45]], "type": "drug", "id": "DDI-MedLine.d116.s4.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s5-0", "sentence_id": "DDI-MedLine.d116.s5", "sentence": "This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ", "arg1": {"span": [[46, 54]], "type": "drug", "id": "DDI-MedLine.d116.s5.e0"}, "arg2": {"span": [[113, 121]], "type": "drug", "id": "DDI-MedLine.d116.s5.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d116.s6-0", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d116.s6-1", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-2", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[14, 22]], "type": "drug", "id": "DDI-MedLine.d116.s6.e0"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-3", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "arg2": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-4", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[30, 38]], "type": "drug", "id": "DDI-MedLine.d116.s6.e1"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d116.s6-5", "sentence_id": "DDI-MedLine.d116.s6", "sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "arg1": {"span": [[125, 133]], "type": "drug", "id": "DDI-MedLine.d116.s6.e2"}, "arg2": {"span": [[178, 186]], "type": "drug", "id": "DDI-MedLine.d116.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-0", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-1", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-2", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[4, 22]], "type": "group", "id": "DDI-MedLine.d28.s7.e0"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-3", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "arg2": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-4", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[24, 37]], "type": "drug", "id": "DDI-MedLine.d28.s7.e1"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d28.s7-5", "sentence_id": "DDI-MedLine.d28.s7", "sentence": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" ", "arg1": {"span": [[42, 54]], "type": "drug", "id": "DDI-MedLine.d28.s7.e2"}, "arg2": {"span": [[77, 96]], "type": "group", "id": "DDI-MedLine.d28.s7.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-0", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[13, 22]], "type": "drug", "id": "DDI-MedLine.d102.s0.e0"}, "arg2": {"span": [[27, 39]], "type": "drug", "id": "DDI-MedLine.d102.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-1", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[13, 22]], "type": "drug", "id": "DDI-MedLine.d102.s0.e0"}, "arg2": {"span": [[84, 97]], "type": "drug", "id": "DDI-MedLine.d102.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s0-2", "sentence_id": "DDI-MedLine.d102.s0", "sentence": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "arg1": {"span": [[27, 39]], "type": "drug", "id": "DDI-MedLine.d102.s0.e1"}, "arg2": {"span": [[84, 97]], "type": "drug", "id": "DDI-MedLine.d102.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-0", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[78, 87]], "type": "drug", "id": "DDI-MedLine.d102.s1.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-1", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[78, 87]], "type": "drug", "id": "DDI-MedLine.d102.s1.e0"}, "arg2": {"span": [[128, 141]], "type": "drug", "id": "DDI-MedLine.d102.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s1-2", "sentence_id": "DDI-MedLine.d102.s1", "sentence": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "arg1": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s1.e1"}, "arg2": {"span": [[128, 141]], "type": "drug", "id": "DDI-MedLine.d102.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s3-0", "sentence_id": "DDI-MedLine.d102.s3", "sentence": "injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. ", "arg1": {"span": [[45, 54]], "type": "drug", "id": "DDI-MedLine.d102.s3.e0"}, "arg2": {"span": [[96, 108]], "type": "drug", "id": "DDI-MedLine.d102.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s5-0", "sentence_id": "DDI-MedLine.d102.s5", "sentence": "Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ", "arg1": {"span": [[70, 79]], "type": "drug", "id": "DDI-MedLine.d102.s5.e0"}, "arg2": {"span": [[109, 122]], "type": "drug", "id": "DDI-MedLine.d102.s5.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d102.s6-0", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d102.s6-1", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-2", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-3", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[42, 51]], "type": "drug", "id": "DDI-MedLine.d102.s6.e0"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-4", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-5", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-6", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[80, 93]], "type": "drug", "id": "DDI-MedLine.d102.s6.e1"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-7", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "arg2": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-8", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[121, 133]], "type": "drug", "id": "DDI-MedLine.d102.s6.e2"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d102.s6-9", "sentence_id": "DDI-MedLine.d102.s6", "sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "arg1": {"span": [[139, 151]], "type": "drug", "id": "DDI-MedLine.d102.s6.e3"}, "arg2": {"span": [[159, 168]], "type": "drug", "id": "DDI-MedLine.d102.s6.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-0", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s1.e0"}, "arg2": {"span": [[14, 45]], "type": "group", "id": "DDI-MedLine.d83.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-1", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s1.e0"}, "arg2": {"span": [[52, 100]], "type": "group", "id": "DDI-MedLine.d83.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s1-2", "sentence_id": "DDI-MedLine.d83.s1", "sentence": "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. ", "arg1": {"span": [[14, 45]], "type": "group", "id": "DDI-MedLine.d83.s1.e1"}, "arg2": {"span": [[52, 100]], "type": "group", "id": "DDI-MedLine.d83.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s3-0", "sentence_id": "DDI-MedLine.d83.s3", "sentence": "In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. ", "arg1": {"span": [[86, 96]], "type": "drug", "id": "DDI-MedLine.d83.s3.e0"}, "arg2": {"span": [[142, 153]], "type": "drug", "id": "DDI-MedLine.d83.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s4-0", "sentence_id": "DDI-MedLine.d83.s4", "sentence": "The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. ", "arg1": {"span": [[76, 86]], "type": "drug", "id": "DDI-MedLine.d83.s4.e0"}, "arg2": {"span": [[97, 108]], "type": "drug", "id": "DDI-MedLine.d83.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-0", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-1", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-2", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[57, 67]], "type": "drug", "id": "DDI-MedLine.d83.s5.e0"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-3", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "arg2": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-4", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[72, 83]], "type": "drug", "id": "DDI-MedLine.d83.s5.e1"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s5-5", "sentence_id": "DDI-MedLine.d83.s5", "sentence": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. ", "arg1": {"span": [[85, 95]], "type": "drug", "id": "DDI-MedLine.d83.s5.e2"}, "arg2": {"span": [[159, 170]], "type": "drug", "id": "DDI-MedLine.d83.s5.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s6-0", "sentence_id": "DDI-MedLine.d83.s6", "sentence": "In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. ", "arg1": {"span": [[75, 86]], "type": "drug", "id": "DDI-MedLine.d83.s6.e0"}, "arg2": {"span": [[117, 127]], "type": "drug", "id": "DDI-MedLine.d83.s6.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-0", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[53, 63]], "type": "drug", "id": "DDI-MedLine.d83.s7.e0"}, "arg2": {"span": [[204, 215]], "type": "drug", "id": "DDI-MedLine.d83.s7.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-1", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[53, 63]], "type": "drug", "id": "DDI-MedLine.d83.s7.e0"}, "arg2": {"span": [[219, 230]], "type": "drug", "id": "DDI-MedLine.d83.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s7-2", "sentence_id": "DDI-MedLine.d83.s7", "sentence": "Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. ", "arg1": {"span": [[204, 215]], "type": "drug", "id": "DDI-MedLine.d83.s7.e1"}, "arg2": {"span": [[219, 230]], "type": "drug", "id": "DDI-MedLine.d83.s7.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s8-0", "sentence_id": "DDI-MedLine.d83.s8", "sentence": "However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. ", "arg1": {"span": [[99, 109]], "type": "drug", "id": "DDI-MedLine.d83.s8.e0"}, "arg2": {"span": [[114, 125]], "type": "drug", "id": "DDI-MedLine.d83.s8.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s9-0", "sentence_id": "DDI-MedLine.d83.s9", "sentence": "Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. ", "arg1": {"span": [[30, 40]], "type": "drug", "id": "DDI-MedLine.d83.s9.e0"}, "arg2": {"span": [[158, 168]], "type": "drug", "id": "DDI-MedLine.d83.s9.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-0", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s10.e0"}, "arg2": {"span": [[79, 90]], "type": "drug", "id": "DDI-MedLine.d83.s10.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-1", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s10.e0"}, "arg2": {"span": [[95, 106]], "type": "drug", "id": "DDI-MedLine.d83.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s10-2", "sentence_id": "DDI-MedLine.d83.s10", "sentence": "Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. ", "arg1": {"span": [[79, 90]], "type": "drug", "id": "DDI-MedLine.d83.s10.e1"}, "arg2": {"span": [[95, 106]], "type": "drug", "id": "DDI-MedLine.d83.s10.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-0", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s11.e0"}, "arg2": {"span": [[86, 95]], "type": "drug", "id": "DDI-MedLine.d83.s11.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-1", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s11.e0"}, "arg2": {"span": [[155, 166]], "type": "drug", "id": "DDI-MedLine.d83.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s11-2", "sentence_id": "DDI-MedLine.d83.s11", "sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "arg1": {"span": [[86, 95]], "type": "drug", "id": "DDI-MedLine.d83.s11.e1"}, "arg2": {"span": [[155, 166]], "type": "drug", "id": "DDI-MedLine.d83.s11.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-0", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-1", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-2", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[19, 30]], "type": "drug", "id": "DDI-MedLine.d83.s13.e0"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-3", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "arg2": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-4", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[95, 105]], "type": "drug", "id": "DDI-MedLine.d83.s13.e1"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s13-5", "sentence_id": "DDI-MedLine.d83.s13", "sentence": "In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. ", "arg1": {"span": [[206, 217]], "type": "drug", "id": "DDI-MedLine.d83.s13.e2"}, "arg2": {"span": [[284, 294]], "type": "drug", "id": "DDI-MedLine.d83.s13.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s15-0", "sentence_id": "DDI-MedLine.d83.s15", "sentence": "Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. ", "arg1": {"span": [[40, 50]], "type": "drug", "id": "DDI-MedLine.d83.s15.e0"}, "arg2": {"span": [[174, 185]], "type": "drug", "id": "DDI-MedLine.d83.s15.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s16-0", "sentence_id": "DDI-MedLine.d83.s16", "sentence": "Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. ", "arg1": {"span": [[14, 25]], "type": "drug", "id": "DDI-MedLine.d83.s16.e0"}, "arg2": {"span": [[27, 37]], "type": "drug", "id": "DDI-MedLine.d83.s16.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-0", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s17.e0"}, "arg2": {"span": [[124, 135]], "type": "drug", "id": "DDI-MedLine.d83.s17.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-1", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[0, 10]], "type": "drug", "id": "DDI-MedLine.d83.s17.e0"}, "arg2": {"span": [[171, 182]], "type": "drug", "id": "DDI-MedLine.d83.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s17-2", "sentence_id": "DDI-MedLine.d83.s17", "sentence": "Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. ", "arg1": {"span": [[124, 135]], "type": "drug", "id": "DDI-MedLine.d83.s17.e1"}, "arg2": {"span": [[171, 182]], "type": "drug", "id": "DDI-MedLine.d83.s17.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s18-0", "sentence_id": "DDI-MedLine.d83.s18", "sentence": "CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. ", "arg1": {"span": [[13, 23]], "type": "drug", "id": "DDI-MedLine.d83.s18.e0"}, "arg2": {"span": [[83, 94]], "type": "drug", "id": "DDI-MedLine.d83.s18.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-0", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[77, 88]], "type": "drug", "id": "DDI-MedLine.d83.s19.e0"}, "arg2": {"span": [[93, 104]], "type": "drug", "id": "DDI-MedLine.d83.s19.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-1", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[77, 88]], "type": "drug", "id": "DDI-MedLine.d83.s19.e0"}, "arg2": {"span": [[180, 190]], "type": "drug", "id": "DDI-MedLine.d83.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d83.s19-2", "sentence_id": "DDI-MedLine.d83.s19", "sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "arg1": {"span": [[93, 104]], "type": "drug", "id": "DDI-MedLine.d83.s19.e1"}, "arg2": {"span": [[180, 190]], "type": "drug", "id": "DDI-MedLine.d83.s19.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s0-0", "sentence_id": "DDI-MedLine.d120.s0", "sentence": "Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.", "arg1": {"span": [[46, 60]], "type": "drug", "id": "DDI-MedLine.d120.s0.e0"}, "arg2": {"span": [[75, 82]], "type": "drug_n", "id": "DDI-MedLine.d120.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s1-0", "sentence_id": "DDI-MedLine.d120.s1", "sentence": "Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; ", "arg1": {"span": [[10, 29]], "type": "group", "id": "DDI-MedLine.d120.s1.e0"}, "arg2": {"span": [[42, 49]], "type": "drug_n", "id": "DDI-MedLine.d120.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-0", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[21, 28]], "type": "drug_n", "id": "DDI-MedLine.d120.s3.e0"}, "arg2": {"span": [[58, 72]], "type": "drug", "id": "DDI-MedLine.d120.s3.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-1", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[21, 28]], "type": "drug_n", "id": "DDI-MedLine.d120.s3.e0"}, "arg2": {"span": [[170, 189]], "type": "group", "id": "DDI-MedLine.d120.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s3-2", "sentence_id": "DDI-MedLine.d120.s3", "sentence": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "arg1": {"span": [[58, 72]], "type": "drug", "id": "DDI-MedLine.d120.s3.e1"}, "arg2": {"span": [[170, 189]], "type": "group", "id": "DDI-MedLine.d120.s3.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s4-0", "sentence_id": "DDI-MedLine.d120.s4", "sentence": "filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; ", "arg1": {"span": [[0, 7]], "type": "drug_n", "id": "DDI-MedLine.d120.s4.e0"}, "arg2": {"span": [[65, 79]], "type": "drug", "id": "DDI-MedLine.d120.s4.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d120.s5-0", "sentence_id": "DDI-MedLine.d120.s5", "sentence": "and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. ", "arg1": {"span": [[24, 31]], "type": "drug_n", "id": "DDI-MedLine.d120.s5.e0"}, "arg2": {"span": [[151, 165]], "type": "drug", "id": "DDI-MedLine.d120.s5.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s0-0", "sentence_id": "DDI-MedLine.d85.s0", "sentence": "Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.\r\n", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s0.e0"}, "arg2": {"span": [[80, 84]], "type": "drug", "id": "DDI-MedLine.d85.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d85.s1-0", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-1", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-2", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[12, 23]], "type": "group", "id": "DDI-MedLine.d85.s1.e0"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-3", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "arg2": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-4", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[24, 28]], "type": "drug", "id": "DDI-MedLine.d85.s1.e1"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s1-5", "sentence_id": "DDI-MedLine.d85.s1", "sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "arg1": {"span": [[184, 188]], "type": "drug", "id": "DDI-MedLine.d85.s1.e2"}, "arg2": {"span": [[246, 258]], "type": "drug_n", "id": "DDI-MedLine.d85.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d85.s7-0", "sentence_id": "DDI-MedLine.d85.s7", "sentence": "Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s7.e0"}, "arg2": {"span": [[53, 57]], "type": "drug", "id": "DDI-MedLine.d85.s7.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d85.s9-0", "sentence_id": "DDI-MedLine.d85.s9", "sentence": "Misonidazole has a complex effect on oral CCNU pharmacokinetics. ", "arg1": {"span": [[0, 12]], "type": "drug_n", "id": "DDI-MedLine.d85.s9.e0"}, "arg2": {"span": [[42, 46]], "type": "drug", "id": "DDI-MedLine.d85.s9.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d85.s14-0", "sentence_id": "DDI-MedLine.d85.s14", "sentence": "We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ", "arg1": {"span": [[98, 102]], "type": "drug", "id": "DDI-MedLine.d85.s14.e0"}, "arg2": {"span": [[119, 131]], "type": "drug_n", "id": "DDI-MedLine.d85.s14.e1"}, "ddi_label": 1, "ddi_type": "mechanism"}
{"id": "DDI-MedLine.d55.s0-0", "sentence_id": "DDI-MedLine.d55.s0", "sentence": "Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.", "arg1": {"span": [[28, 41]], "type": "drug", "id": "DDI-MedLine.d55.s0.e0"}, "arg2": {"span": [[75, 83]], "type": "drug", "id": "DDI-MedLine.d55.s0.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d55.s1-0", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-1", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-2", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[6, 14]], "type": "drug", "id": "DDI-MedLine.d55.s1.e0"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-3", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "arg2": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-4", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[50, 63]], "type": "drug", "id": "DDI-MedLine.d55.s1.e1"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s1-5", "sentence_id": "DDI-MedLine.d55.s1", "sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "arg1": {"span": [[115, 123]], "type": "drug", "id": "DDI-MedLine.d55.s1.e2"}, "arg2": {"span": [[149, 162]], "type": "drug", "id": "DDI-MedLine.d55.s1.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d55.s4-0", "sentence_id": "DDI-MedLine.d55.s4", "sentence": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "arg1": {"span": [[58, 71]], "type": "drug", "id": "DDI-MedLine.d55.s4.e0"}, "arg2": {"span": [[91, 99]], "type": "drug", "id": "DDI-MedLine.d55.s4.e1"}, "ddi_label": 1, "ddi_type": "effect"}
{"id": "DDI-MedLine.d4.s0-0", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[15, 25]], "type": "brand", "id": "DDI-MedLine.d4.s0.e0"}, "arg2": {"span": [[118, 134]], "type": "group", "id": "DDI-MedLine.d4.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d4.s0-1", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[15, 25]], "type": "brand", "id": "DDI-MedLine.d4.s0.e0"}, "arg2": {"span": [[145, 155]], "type": "brand", "id": "DDI-MedLine.d4.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d4.s0-2", "sentence_id": "DDI-MedLine.d4.s0", "sentence": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "arg1": {"span": [[118, 134]], "type": "group", "id": "DDI-MedLine.d4.s0.e1"}, "arg2": {"span": [[145, 155]], "type": "brand", "id": "DDI-MedLine.d4.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-0", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-1", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-2", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-3", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[45, 56]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e0"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-4", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-5", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-6", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[183, 196]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e1"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-7", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "arg2": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-8", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[201, 214]], "type": "drug_n", "id": "DDI-MedLine.d14.s0.e2"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s0-9", "sentence_id": "DDI-MedLine.d14.s0", "sentence": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "arg1": {"span": [[218, 230]], "type": "drug", "id": "DDI-MedLine.d14.s0.e3"}, "arg2": {"span": [[236, 245]], "type": "drug", "id": "DDI-MedLine.d14.s0.e4"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s1-0", "sentence_id": "DDI-MedLine.d14.s1", "sentence": "It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. ", "arg1": {"span": [[89, 101]], "type": "drug", "id": "DDI-MedLine.d14.s1.e0"}, "arg2": {"span": [[113, 122]], "type": "drug", "id": "DDI-MedLine.d14.s1.e1"}, "ddi_label": 0, "ddi_type": ""}
{"id": "DDI-MedLine.d14.s2-0", "sentence_id": "DDI-MedLine.d14.s2", "sentence": "Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.", "arg1": {"span": [[127, 139]], "type": "drug_n", "id": "DDI-MedLine.d14.s2.e0"}, "arg2": {"span": [[167, 178]], "type": "drug_n", "id": "DDI-MedLine.d14.s2.e1"}, "ddi_label": 0, "ddi_type": ""}
